AU2007202554A1 - Receptor Ligand VEGF-C - Google Patents

Description

01/06 2007 16:55 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 11004

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicants LUDWIG INSTITUTE FOR CANCER RESEARCH and HELSINKI UNIVERSITY LICENSING LTD.OY Invention Title: RECEPTOR LIGAND VEGF-C The following statement is a full description of this invention, including the best method for performing it known to us: COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:55 FAX 61 3 92438333 GRIFFITH HACK -IPAUSTRALIA mo la CK RECEPTOR LIGAND VEGF-C i Field of the Invention 0 The present invention generally relates to the field of genetic engineering and more particularly to growth l/ factors for endothelial cells and growth factor genes.

In The entire disclosure in the complete specification o of our Australian Patent Application No. 2003201371 is by 10 this cross-reference incorporated into the present O specification.

Background of the Invention Developmental growth, the remodelling and regeneration of adult tissues, as well as solid tumor growth, can only occur when accompanied by blood vessel formation. Angioblasts and hematopoietic precursor cells differentiate from the mesoderm and form the blood islands of the yolk sac and the primary vascular system of the embryo. The development of blood vessels from these early (in situ) differentiating endothelial cells is termed vasculogenesis. Major embryonic blood vessels are believed to arise vis vasculogenesis, whereas the formation of the rest of the vascular tree is though to occur as a result of vascular sprouting from pre-existing vessels, a process called angiogenesis, Risau et al., .Devel. Biol., 125:441-450 (1988).

Endothelial cells give rise to several types of functionally and morphologically distinct vessels. When N.lMA lounc\CaPe6200042a9P6292 57.U I.Specci\PG22.A. Specficadion oo7-l doc IO607 COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:55 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1006 0 -2- SOrgans differentiate and begin to perform their specific functions, the phenotypic heterogeneity of endothelial cells increases. Upon angiogenic stimulation, endothelial cells may re-enter the cell cycle, migrate, Withdraw from the cell cycle and subsequently differentiate again to form new vessels that are functionally adapted to their tissue environment.

O Endothelial cells undergoing angiogenesis degrade the nderlying basement membrane and migrate, forming 1 capillary sprouts that project into the perivascular Sstroma. Ausprunk et al-, Microvasc- Rev-, 14:51-65.

(1977). Angiogenesis during tissue development and regeneratioh depends on the tightly controlled processes of endothelial cell proliferation, migration, differentiation, and survival. Dysfunction of the edothelial cell regulatory system is a key feature of many diseases Most significantly, tumor growth and metastasis have been shown to be angiogenesis dependent.

F2olkman et al., J. Biol. Chem., 267:10931-10934 (1992).

Key signals regulating cell growth and differentiation are mediated by polypeptide growth factors and their transmembrana receptors, many of which are tyrosine kinases. AUtophosphorylated peptides within the tyrosine kinase insert and carboxyl-terminal sequences of activated receptors are commonly recognized by kinase substrates involved in signal transduction for

J

the readjustment of gene expression in responding cells.

Several families of receptor tyrosine kinases have been characterized. Van der Geer et al., Ann. Rev. Cell Biol., 10:251-337 (.1994). The major growth factors and receptors transducing angiogenic stimuli are schematically shown in Fig. i.

Fibroblast growth factors are also known to be involved in the regulation of angiogenesis. They hg-e been shown to be mitogenic and chemotactic for cultured endothelial cells. Fibroblast growth factors also stimulate the production of proteases, such as COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:56 FAX 61 3 92438333 GRIFFITH HACK 4, IPAUSTRALIA 007 03 Scollagenases and plasminogen activators, and induce tube ;Z formation by endothelial cells, Saksela et al., Ann.

Rev. Cell Biol., 4:93-126 (1988). There are two general classes of fibroblast growth factors, FGF-1 and FGF-2, both of which lack conventional signal peptides. Both types have an affinity for heparin and FGF-2 is bound to l heparin sulfate proteoglycans in the subendothelial O extracellular matrix from which it may be released after Ci injury. Heparin potentiates the stimulation of endothelial cell proliferation by angiogenic FGFs, both 0 by protecting against denaturation and degradation and dimerizing the FGFs. Cultured endothelial cells express 7 S- the FGF-1 receptor but no significant levels of other high-affinity fibroblast growth factor receptors.

Among other ligands for receptor tyrosine kinases, the platelet derived growth factor, PDGP-BB, has been shown to be weakly angiogenic in the chick chorioallantoic membrane: Risau et al., Growth Factors, 7:261-266 (1992). Transforming growth factor a (TGFa) is an angiogenic factor secreted by several tumor cell types and by macrophages. Hepatocyte growth factor (HGF), the ligand of the c-met proto-oncogene-encoded receptor, also is strongly angiogenic.

Recent evidence shows that there are endothelial cell specific growth factors and receptors that may be primarily responsible for the stimulation of endothelial cell growth, differentiation and certain differentiated functions. The best studied of these is vascular endothelial growth factor (VEGF), a member of the PDGF family. Vascular endothelial growth factor is a dimeric glycoprotein of disulfide-linked 23 kD subunits.

Other reported effects of VEGF include the mobilization of intracellular calcium, the induction of plasminogen activator and plasminogen activator inhibitor-i 35 synthesis, stimulation of hexose transport in endothelial Scells, and promotion of monocyte migration in vitro.

Four VEGF isoforms, encoded by distinct mRNA splice COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:56 FAX 61 3 92438333 GRIFFITH HACK -IPAUSTRALIA [1008 C -4 variants, appear to be equally capable of stimulating mitogenesis in endothelial cells. However, each isoform has a different affinity for cell surface proteoglycans, which behave as low affinity receptors for VEGF. The 121 and 165 amino acid isoforms of VEGF (VEGFl21 and VEGF165) are secreted in a soluble form, whereas the isoforms of 189 and 206 amino acid residues remain cell surface- Cassociated and have a strong affinity for heparin.

VEGF

0' was originally purified from several sources on the basis of its mitogenic activity toward endothelial cells, and D also by its ability to induce microvascular permeability, hence it is also called vascular permeability factor The pattern of VEGF expression suggests its involvement in the development and maintenance of the normal vascular system and in tumor angiogenesjis During murine development, the entire 7.5 day post-coital endoderm expresses VEGF and the ventricular neuroectoderm produces VEGF at the capillary ingrowth stage. see Breier et al., Development, 114:521-523 (1992). On day two of quail development, the vascularized area of the yolk sac as well as the whole embryo show expression of VEGF. In addition, epithelial cells next to fenestrated endothelia in adult mice show persistent VEGF expression, suggesting a role in the maintenance of this specific endothelial phenotype and function.

Two high affinity receptors for VEGF have been characterized. These are VEGFR-1/FIt- 1 (fms-like tyrosine kinase-1) and VEGFR-2/Kdr/Flk-1 (kinase insert domain containing receptor/fetal liver kinase-1)- Those receptors are classified in the PDGF-receptor family, but they have seven rather than five immunoglobulin-like loops in their extracellular domain (see Fig. 1) and they possess a longer kinase insert than normally observe( in this family. The expression of VEGF receptors occurs, mainly in vascular endothelial cells, although some may be present on hematopoe i tic progenitor cells, monocytes, COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:56 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1009 0 Cl Sand melanoma cells. Only endothelial cells have been reported to proliferate in response to VEGF, and endothelial cells from different sources show different responses. Thus, the signals mediated through VEGFR-1 and VEGFR-2 appear to be cell type specific. The VEGF- Srelated placenta growth factor (P1GF) was recently shown Sto bind to VEGFR-1 with high affinity. PJGF was able to o enhance the growth factor activity of VEGF,. but it did l not stimulate endothelial cells on its own. Naturally occurring VEGF/P1GF heterodimers were nearly as potent omitogens as VEGF homodimers for endothelial cells. Cao et al., J. Biol. Chem., 271:3154-62 (1996).

The Flt4 receptor tyrosine kinase (VEGFR-3) is closely related in structure to the products of the VEGFR-1 and VEGFR-2 genes. Despite this similarity, the mature form of Flt4 differs from the VEGF receptors in that it is proteolytically cleaved in the extracellular domain into two disulfide-linked polypeptides. Pajusola et al., Cancer Res., 52:5738-5743 (1992). The 4.5 and 5.8 kb Flt4 mRNAs encode polypeptides which differ in their c-termini due to the use of alternative 3' exons.

Isoforms of VEGF or PlGF do not show specific binding to Flt4 or induce its autophosphorylation.

Expression of Flt4 appears to be more restricted than the expression of VEGFR-1 or VEGFR-2.

The expression of Flt4 first becomes detectable by in situ hybridization in the angioblasts of head mesenchyme, the cardinal vein, and extrapsibryonically in the allantois of 8.5 day p.c. mouse embryos. In 12.5 day p.c. embryos, the Flt4 signal is observed in developing venous and presumptive lymphatic endothelia, but arterial endothelia appear negative. During later stages of development, Flt4 mRNA becomes restricted to developing lymphatic vessels. The lymphatic endothelia and some high enduthelial venules express Flt4 mRNA in adult human tissues and increased expression occurs in lymphatic sinuses in metastatic lymph nodes and in lymphangioma.

"I

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:57 FAX 61 3 92438333 GRIFFITH HACK -*IPAUSTRALIA Thesh results support the theory of the venous origin of lymphatic vessels.

Five endothelial cell specific receptor O tyrosine kinases, Flt- 1 (VEGFR-1), KDR/Flk-l (VEGFR-2), Flt4 (VEGFR-3), Tie, and Tek/Tie-2 have so far been described, which possess the intrinsic tyrosine kinase Sactivity essential for signal transduction. Targeted mutations inactivating Flt-1, Flk-1, Tie, and Tek in C 1 ouse embryos have indicated their essential and specific roles in vasculogenesis and angiogenesis at the molecular level- VEGFR-1 and VEGFR-2 bind VEGF with high affinity C(Kd 16 pM and 760 pM, respectively) and VEGFR-1 also binds the related placenta growth factor (PIGF; KY about 200 pM). A ligand for Tek is reported in PCT patent publication Wo 96/11269.

SUMMARY OF THE INVENTION The present invention provides a ligand, designated VEGF-C, for the Flt4 receptor tyrosine kinase (VEGFR-3). Thus, the invention provides a purified and isolated polypeptide which is capable of binding to the Flt4 receptor tyrosine kinase. Preferably, an Flt4 ligand of the invention is capable of stimulating tyrosine phosphorylation of Flt4 receptor tyrosine kinase in a host cell expressing the Flt4 receptor tyrosine kinase. Preferred ligands of the invention are mammalian Polypeptides. Highly preferred ligands are human polypeptides. As explained in detail below, dimers and multimers comprising polypeptides of the invention linked to each other or to. other polypeptides are specifically contemplated as ligands of the invention.

In one embodiment, an FLT4 ligand polypeptide has a molecular weight of approximately 23 kD as determined by SDS-PACE under reducing conditions. Fr example, the invention includes a ligand composed of one or more polypeptides of approximately 23 kD which is Purifyable from conditioned media from a PC-3 prostatic COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:57 FAX 61 3 92438333 GRIFFITH HACK 4IPAUTSTRALIA laoll 1-.

Sadenocarcinoma cell line, the cell line having ATCC Ace.

No. CRL 1435. Amino acid sequencing of this PC-3 cell derived ligand polypeptide revealed that the ligand o olypeptide comprises an amino terminal amino acid sequence set forth in SEQ.ID NO: 13. A conditioned medium comprising an Flt4 ligand is itself an aspect of the invention. The present invention also provides a new use for the PC-3 Prostatic adenocarcinoma cell line which Sroduces an Flt4 ligan d In a preferred embodiment, the ligand may be purified and isolated directly from the PC- O 3 cell culture medium.

C In a highly preferred embodiment, the ligand polypeptide comprises a fragment. of the amino acid sequence shown in SEQ ID No: 33 which specifically binds.

to the human Flt4 receptor tyrosine kinase. Exemplary fragments include: a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 33 from about residue 112 to about residue 213; a .polypeptide comprising an amino acid sequence from about residue 104 to about residue 227 of SEQ ID NO: 33; and a polypeptide comprising an amino acid sequence from about residue 112 to about residue 227 of SEQ ID NO: 33- Other exemplary fragments include polypeptides comprising amino acid sequences of SEQ ID NO: 33 that span, approximately, the following residues: 31-213, 31-227, 32-227, 103-217, 103-225, 104-213, 113-213, 103-227, 113-227, 131-211, 161-211, 103-225, 227-419, 228-419, 31-419, and 1-419, as described in greater detail below.

The present invention also provides one or more polypeptide precursors of an Flt4 ligand, wherein one such precursor (designated "prepro-VEGF-C") comprises the complete amino acid sequence (amino acid residues 1 to 419) shown in SEQ ID NO: 33. Thus, the invention includes a purified and isolated polypeptide having the amino acid sequence of residues 1 to 419 shown in SEQ ID NO: 33. Ligand precursors according to the invention, when expressed in an appropriate host cell, produce, via COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:57 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 012 1-s Scleavage, a polypeptide which binds specifically to the c. Flt4 receptor tyrosine kinase. A putative 102 amino acid leader (prepro) PtPtide has been identified in the amino Sacid sequence shown in SEQ ID NO-: 33. Thus, in a s related aspect, the invention includes a purified and isolated.olypeptide having the amino acids sequence of residues 103-419 shown in SEQ ID NO: 33, In one embodiment, an expressed Fit4 ligand Spolypeptide precursor is proteolytically cleaved upon expression to produce an approximately 23 kD Flt4 ligand molecular weight of aPProximately 23 kD under reducing conditions.

A putative VEGF-C precursor or splice variant, consisting of polypeptides with molecular weights of about 29 and 32 kD, also is considered an aspect of the invention.

20 In another embodiment, an expressed Flt4 ligand olypeptide precursor is proteolytically cleaved upon expression to produce an approximately 21 kD VEGF-C polypeptide. Sequence analysis has indicated that an observed 21 kD form has an amino terminus approximately 9 amino acids downstream from the amino terminus of the 23 kD form, suggesting that alternative cleavage sites exist.

From the foregoing, it will be apparent that an aspect of the invention includes a fragment of the Purified and isolated polypeptide having the amino acid sequence of residues 1 to 419 shown in SEQ ID NO: 33, the fragment being capable of specifically binding to Flt4 receptor tyrosine kinase. Preferred embodiments include fragments having an apparent molecular weight of approximately 21/23 kD and 29/32 kD as assessed by SDS.

PAGE under reducing conditions.

Evidence suggests that the amino acids COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:58 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA [013 1^- 0 0 essential for retaiing Flt4 ligand activity are contained within approximately amino acids 103/112- 2 226/227 of SEQ ID NO: 33, and that a carboxy-terminal proteolytic cleavage to produce a mature, naturally- S ccurr Flt4 and occurs at the approximate position of amino acids 226-227 of SEQ ID NO: 33. Accordingly preferred Flt4 ligand comprises approximately amino acids 103-227 of SEQ ID NO: 33.

VEGF-C mutational analysis described herein i0 indicates that a naturally occurring VEGp-C polypeptide spanning amino acids 103-227 of SEQ ID NO: 33, produced cby a natural processing clavage that defines the C- 1 terminus, exists and is biologically active as an Flt4 ligand. A polypeptide fragment consisting of residues 104-213 of SEQ ID NO: 33 has been shown to retain

VEGF-C

biological activity. Additional mutational analyses indicate that a polypeptide spanning only amino acids 113-213 of SEQ ID NO: 33 retains Flt4 ligand activity.

Accordingly, preferred polypeptides comprise sequences spanning, approximately, amino acid residues 103-227, 104-213, or 113-213, of SEQ ID NO: 33.

Moreover, sequence comparisons of members of the VEGP family of polypeptides provide an indication that still smaller fragments will retain biological activity, and such smaller fragments are intended as aspects of the invention. In particular, eight highly conserved cysteine residues of the VEGF family of polypaptides define a region from residue 131 to residue 211 of SEQ ID No: 33 (see Figures 1 0 31); therefore, a polypeptide spanning from about residue 131 to about residue 211 is expected to retain VEGF-C biological activity. In fact, .a polypeptide comprising approximately residues 161-211, which retains an evolutionarily-conserved RCXXCC motif, is postulaCed to retain VEGF-C activity, and therefore is intended a. an aspect of the invention. Some of the conserved cysteine residues in VEGF-C participate in interchain disulfide COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:58 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1014 010 (N io bonding to make ho- and heterodimers of the various naturally occurring VEGF-C polypeptides. Beyond the Sprecding considerati ey o n d on 5 preceding considerations, evidence exists that

VEGF-C

o POlypeti de s lacking interchain disulfide bonds retain SVand mehodlo al activity. Consequently, the materials had eth of the invention include all VEGF-C fragments that retain at least one biological activity of VEGF-c, regardless of the resence or absence of interchain 0 disunfid bonds. The invention also includes m l timers 1 (including dimers) comprising such fragments linked to O each other or to other polypeptides. Fragment linkage may be by way of covalent bonding disulfide bonding) or non-covalent bonding of polypoptide chains hydrogen bonding, bonding due to stable or induced dipole-dipole interactions, bonding ue to hydrophobic or hydrophilic interactions, combinations of these bonding mechanisms, and the like).

In yet another related aspect, the invention includes variants and analogs of the aforementioned Polypeptides, including VEGF-C, precursors of VEGF-C, and fragments of VEGF-C. The variants contemplated by the invention include purified and isolated polypeptides having aino acid sequences that differ from the. amino acid sequences of VEGP-c, VEGF-C precursors and VEGF-C fragments by conservative substitutions, as recognized by those of skill in the art, or by additions or deletions of amino acid residues that are compatible with the retention of at least one biological activity of VEGF-C.

Analogs contemplated by the invention include Polypeptides having modifications to one or more aino acid residues that differ from the modifications found in VEGF-C, VEGF-C precursors, or VEGF-C fragments, -but are compatible with the retention of at least one biological activity of VEGP-c, VEGF-c precursors, or VEGF-C fragments. For example, analogs within the scope of the invention include glycosylation variants and conjugants (attachment of the aforemetioned polypeptides to COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:58 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA R015 0 11 compounds such as labels, toxins, etc.) c- The present invention also provides purified and isolated polynucleotides nucleic acids) encoding polypeptides of the invention, for example a cDNA or corresponding genomic DNA encoding a VEGF-C Sprecursor, VEGF-C, or biologically active fragments or VC variants thereof. A preferred nucleic acid of the Cl o invention comprises a DNA encoding amino acid residues 1 C to 419 of SEQ ID NO: 33 or one of the aforementioned o 10 fragments thereof. Due to the degeneracy of the genetic o code, numerous such coding sequences are possible, each having in common the coding of the amino acid sequence shown in SEQ ID NO: 33 or fragment thereof. The invention also comprehends analogs of these polynucleotides, or derivatives of any one of these polynucleotides that encodes a polypaptide which retains at least one biological activity of VEGF-C. DNA polynucleotides according to the invention include genomic DNAs, cDNAs, and oligonucleotides comprising the coding sequence for a fragment of VEGF-C, or an analog of a VEGF-C fragment that retains at least one of the biological activities of VEGF-C. Distinct polynucleotides encoding a polypeptide of the invention by virtue of the degeneracy of the genetic code are within the scope of the invention. In one embodiment, the invention contemplates polynucleotides having sequences that differ from polynucleotides encoding a VEGF-C fragment in a manner that results in conservative amino acid differences between the encoded polypeptides, as understood by those of skill in the art.

A preferred polynucleotide according to the invention comprises the human VEGF-C cDNA sequence set forth in SEQ ID NO: 32 from nucleotide 352 to 1611.

Other polynucleotides according to the invention-encode a VEGF-C polypeptide from, mammals other than humans, birds avian quails), and others. Still other polynucleotides of the invention comprise a coding COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:58 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1016 N 12 Ssequence for a VEGF-C fragment, and allelic variants of those DNAs encoding part or all of VEGF-C.

Ttht h e eion further comprises polynucleotides that hybridize to the aforementioned polynucleotides uder standard stringent hybridization conditions..

Exemplary tringent hybridization conditions are as follows: hybridization at 42'C in 50% forjn de ssi mM Na Po i 50% formaide, 5X SSC C0 m 68 and washing in 0.2X SSC at 55c.' It Sis understood by those of skill in the art-that variation 0 in these conditions ccurs based on the length and GC nUcleotie cntnt of the sequences to be hybridized. Formulas standard in the art are appropriate for deteiani n appropriate for deteriuning appropriate hybridization conditions- See Sambrook et al., Molecular Cloning: A Laboratory Manual (Second ed., Cold Spring Harbor Laboratory Press 1989)

SB

9t7-9.51o These polynucleotides, capable of hybridizing to plynucleotides encoding VEGF-C, VEGF-C fragments, or VEGF-C aalogs, are useful as nucleic acid probes for identifying, purifying and isolating polynucleotides encoding other (non-human) mammalian forms of VEGF-C.

Additionally, these polynucleotides are useful in screening methods of the invention, as described below.

cop r eferred nucleic acid probes of the invention comprise nucleic acid sequences of at least about 16 continuous nucleotdes of SEQ lD NO: 32. More referabl these nucleic acidprobes would have at least about 20 nucleotides found in a subsequence of SEQ ID NO: 32. In using these nucleic acids as probes, it is preferred that the nucleic acids specifically hybridize to a portion of the-sequence set forth in SEQ ID NO: 32.

Specific hybridization is herein defined as hybridization under standard stringent hybridization conditions. To identify and isolate other mammalian VEGF-C genes specifically, nucleic acid probes preferably are selected such that they fail to hybridize to genes related to VEGF-C fail to hybridize to human VEGF or to human VEGF-B genes) COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:59 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 017 0 13- SThus, the invention comprehends polynucleotides c' comprising at least about 16 nucleotides wherein the polynucleoti.des are capable of specifically hybridizing to a gene encoding VEGF-C, a human gene. The specificity of hybridization ensures that a n polynucleotide of the invention is able to hybridize to a n nucleic acid encoding a VEGF-C under hybridization o conditions that do not support hybridization of the polynucleotide to nucleic acids encoding, VEGF or o 10 VEGF-B. In one embodiment, polynucleotides of at least about 16 nucleotides, and preferably at least about nucleotides, are selected as continuous nucleotide sequences found in SEQ ID NO: 32 or the complement of the nucleotide sequence set forth in SEQ ID NO: 32.

Additional aspects of the invention include vectors which comprise nucleic acids of the invention; and host cells transformed or transfected with nucleic acids or vectors of the invention. Preferred vectors of the invention are expression vectors wherein nucleic acids of the invention are operatively connected to appropriate promoters and other control sequences, such that appropriate host cells transformed or transfected with the vectors are capable of expressing the Flt4 ligand. A preferred vector of the invention is plasmid pFLT4-L, having ATCC accession no. 97231. Such vectors and host cells are useful for recombinantly producing VEGF-C polypeptides.

The invention further includes a method of making polypeptides of the invention. In a preferred method, a nucleic acid or vector of the invention is expressed in a host cell, and a polypeptide of the invention is purified from the host cell or the host cell's growth medium.

In a related embodiment, the invention-includes a method of making a polypeptide capable of specifically binding to Flt4 receptor tyrosine kinase, comprising the steps of: transforming or transfecting a host cell COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:59 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 018 c -14 Swith a nucleic acid of the invention cultivating the Shost cell to express the nucleic acid; and purifying Spolypeptide capable of specifically binding to Flt4 receptor tyrosine kinase from the host cell or from the host cell.s growth media.

T he invention also is intended to include purified and isolated polypeptide ligands of Flt4 Sproduced by methods of the invention. In one preferred embodiment, the invention includes a human

VEGF-C

polypeptide or biologically active fragment thereof that is substantially free of other human polypeptides.

In another aspect, the invention includes an antibody which is specifically reactive with polypeptides Of the invention, or with polypeptides multimers of the invention. Antibodies, both monoclonal and polyclonal, may be made against a polypeptide of the invention according to standard techniques in the art. Such antibodies may be used in diagnostic applications to monitor angiogenesis, vascularization, lymphatic vessels and their disease states, wound healing, or certain tumor cells, hematopoietic, or leukemia cells. The antibodies also may be used to block the ligand from activating the Plt4 receptor.

Ligands according to the invention may be labeled with a detectable label and used to identify their corresponding receptors in situ. Labeled Flt4 ligand and anti-Flt4 ligand antibodies may be used as imaging agents in the detection of lymphatic vessels, high endothelial venules and their disease states, and Flt4 receptors expressed in histochemical tissue sections, The ligand or antibody may be covalently or non-covalently coupled to a suitable supermagnetic, paramagnetic, electron dense, echogenic, or radioactive agent for imaging. Other, non-radioactive labels, such as biotin and avidin, may also be used.

A related aspect of the invention is a method for the detection of specific cells, endothelial COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 16:59 FAX 61 3 92438333 GRIFFITH HACK 4 IPATSTRALIA 1@019 C0 Scells. These cells may be found in vivo, or in ex vivo biological tissue samples. The method of detection comprises the steps of exposing a biological tissue comprising, endothelial cells, to a polypeptide according to the invention which is capable of binding to Flt4 receptor tyrosine kinase, under conditions wherein Sthe polypeptide binds to the cells, optionally washing the biological tissue, and detecting the polypeptide c bound to the cells in the biological tissue, thereby detecting the cells.

o The present invention also provides diagnostic and clinical applications for claimed ligands. In a preferred embodiment, Flt4 ligands or precursors are used to accelerate angiogenesis, during wound healing, or to promote the endothelial functions of lymphatic vessels. A utility for VEGF-C is suggested as an inducer of angiogenesis also in tissue transplantation, in eye diseases, in the formation of collateral vessels around arterial stenoses and into injured tissues after infarction. Polypeptides according to the invention may be administered in any suitable manner using an appropriate pharmaceutically-acceptable vehicle, a pharmaceutically-acceptable diluent, adjuvant, excipient or carrier. VEGF-C polypeptides also may be used to quantify future metastatic risk by assaying biopsy material for the presence of active receptors or ligands in a binding assay or kit using detestably-labeled

VEGF-

C. An Flt4 ligand according to the invention also may be used to promote re-growth or permeability of lymphatic vessels in, for example, organ transplant patients. In addition, an Flt4 ligand may be used to mitigate the loss of axillary lymphatic vessels following surgical interventions in the treatment of cancer breast cancer). Ligands according to the invention alsotmay be used to treat or prevent inflammation, edema, aplasia of the lymphatic vessels, lymphatic obstruction, elephantiasis, and Milroy's disease. Finally, Flt4 COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:00 FAX 61 3 92438333 GRIFFITH HACK -4IPAUSTRALIA 020 S-16 ligands may be used to stimulate lymphocyte production and maturation, and to promote or inhibit trafficking of leukocytes between tissues and lymphatic vessels or to O affect migration in and out of the thymus.

The invention includes a method of screening for an endothelial cell disorder in a maalian ubject The method comprises providing a sample of endothelial Scells from the subject, contacting the sample of o endothelial cells with a polypeptide according to claim 1 0 4, determining the growth rate of the cells, and correlating the growth rate with a disorder. In a Spreferred embodiment, the endothelial cells are lymphatic endothelial cells. In another preferred embodiment, th mammalian subject is a human being and the endothelial cells are human cells. In yet another preferred embodient the disorder is a vessel disorder, a lymphatic vessel disorder, such as the loss of lymphatic vessels through surgery or the reduction in function of existing lymphatic vessels due to blockages. In another embodiment, the endothelial cells are contacted with the polypeptide in vitro. The growth rate determined in the method is the rate of cell division per unit time, detrmined by any one of a number of techniques known in the art. The correlation of the growth rate with a disorder can involve a positive or negative correlation, whether the polypeptide has Flt4 ligand activity or is an inhibitor of such activity, as described below.

Inhibitors of the Flt4 ligand may be used to control endothelial cell proliferation, lymphangiomas, and metastatic cancer. For example, such inhibitors may be used to arrest metastatic growth or spread, or to control other aspects of endothelial cell expression and growth Inhibitors include antibodies, antisense oligonucleotides, and polypeptides which block the Plt4 receptor, all of which are intended as aspects of the invention.

In another embodiment, the invention provides a COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:00 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA Z021 17 0- 17 Smethod for modulating the growth of endothelial cells in a mammalian subject comprising the steps of exposing mammalian endothelial cells to a polypeptide according to the invention in an amount effective to modulate the growth of the mammalian endothelial cells. In one embodiment, the modulation of growth is effected by using a polypeptide capable of stimulating tyrosine phosphorylation of Flt4 receptor tyrosine kinase in a 0c host cell expressing the Flt4 receptor tyrosine kinase.

S 10 In modulating the growth of endothelial cells, the 0 invention contemplates the modulation of endothelial cell-related disorders. Endothelial cell disorders contemplated by the invention include, but are not limited to, physical loss of lymphatic vessels surgical removal of axillary lymph tissue), lymphatic vessel occlusion elephantiasis), and lymphangiomas. In a preferred embodiment, the subject, and endothelial cells, are human. The endothelial cells may be provided in vitro or in vivo, and they may be contained in a tissue graft. An effective amount of a polypeptide is defined herein as that amount of polypeptide empirically determined to be necessary to achieve a reproducible change in cell growth rate (as determined by microscopic or macroscopic visualization and estimation of cell doubling time, or nucleic acid .j synthesis assays), as would be understood by one of ordinary skill in the art.

The present invention also provides methods for using the claimed nucleic acids polynucleotides) in screening for endothelial cell disorders. In a preferred embodiment, the invention provides a method for screening an endothelial cell disorder in a mammalian subject comprising the steps of providing a sample of Sendothelial cell nucleic acids from the subject,contacting the sample of endothelial cell nucleic acids with a polynucleotide of the invention which is capable of hybridizing to a gene encoding VEGF-C (and preferably COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:00 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 0022 CN 18capable of hybridizing to VEGF-C RNA), determining the level of hybridization between the endothelial cell nucleic acids and the polynucleotide, and correlating the O level of hybridization with a disorder. A preferred mammalian subject, and source of endothelial cell nucleic acids, is a human. The disorders contemplated by the Smethod of screening with polynucleotides include, but are O not limited to, vessel disorders such as the aforementioned lymphatic vessel disorders, and hypoxia.

0 Purified and isolated polynucleotides encoding o other (non-human) VEGF-C forms also are aspects of the invention, as are the polypeptides encoded thereby, and antibodies that are specifically immunoreactive with the non-human VEGF-C variants. Preferred non-human forms of VEGF-C are forms derived from other vertebrate species, including avian and mammalian species. Mammalian forms are highly preferred. Thus, the invention includes a purified and isolated mammalian VEGP-C polypeptide, and also a purified and isolated polynucleotide encoding such a polypeptide.

In one embodiment, the invention includes a purified and isolated polypeptide having the amino acid sequence of residues 1 to 415 of SEQ ID NO: 41, which sequence corresponds to a putative mouse

VEGF-C

precursor. The putative mouse VEGF-C precursor is believed to be processed into a mature mouse VEGF-C in a manner analogous to the processing of the human prepropolypeptide. Thus, in a related aspect, the invention includes a purified and isolated polypeptide capable of specifically binding to an Flt4 receptor tyrosine kinase a human or mouse Flt-4 receptor tyrosine kinase), the polypeptide comprising a fragment of the purified and isolated polypeptide having the amino acid sequence of residues 1 to 415 of SEQ ID NO; 41, the fragment being capable of specifically binding to the Flt4 receptor, tyrosine kinase. The invention further includes multimers of the foregoing polypeptides and purified and COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:01 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA Uj023 C 19- Sisolated nucleic acids encoding the foregoing polypeptides, such as a nucleic acid comprising all or a portion of the sequence shown in SEQ ID NO: In another embodiment, the invention includes a purified and isolated quail VEGF-C polypeptide, biologically active fragments and multimers thereof, and polynucleotides encoding the foregoing polypeptides.

SIn yet another embodiment, the invention includes a DNA comprising a VEGF-C promoter, that is capable of promoting expression of a VEGF-C gene or another operatively-linked, protein-encoding gene in native host cells, under conditions wherein VEGF-C is t expressed in such cells.

BRIEF DESCRIPTION OF THE DRAWING Figure 1 schematically depicts major endothelial cell receptor tyrosine kinases and growth factors involved in vasculogenesis and angiogenesis.

Major structural domains are depicted, including immunoglobulin-like domains (IGH), epidermal growth factor homology domains (EGPH), fibronectin type III domains (FNIII), transmembrane (TM) and juxtamembrane (JM) domains, tyrosine kinase (TKl, TK2) domains, kinase insert domains and carboxy-terminal domains

(CT).

Figure 2 schematically depicts the construction 25 of the pLTRFlt41 expression vector.

Figure 3 schematically depicts the construction of the baculovirus vector encoding a secreted soluble Flt4 extracellular domain (Flt4EC).

Figure 4 shows results of stimulation of Flt4 autophosphorylation by conditioned medium from PC-3 cell cultures.

Figures 5A, 5B, and 5C show that the major tyrosyl phosphorylated polypeptide of Flt4-transf4ted cells stimulated with PC-3 conditioned medium is the 125 kD Flt4 polypeptide (VEGFR-3), and also that the Flt4 stimulating activity is not adsorbed to heparin- COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/08 2007 17:01 FAX 61 3 92438333 GRIFFITH BACK IPAUSTRALIA 1024 0 0 C 20 g sepharose.

of t Figure 6 shows Western immunoblotting analysis of the Flt4 ligand activity isolated from PC-3 O conditioned medium.

.Figure 7 shows results of gel elJectrophoresis of chromatographic fractions from the affinity I purification of Flt4- ligand (VEGF~C) isolated from concentrated PC-3 conditioned edium.

Cq Figure 8 depicts the amino acid sequences of 10 human, urine, and quail VEGF-C polypeptides, aligned to show similarity. Residues conserved in all three species are depicted in bold, Figure 9 schematically depicts the cloning and Structure of the Flt4 ligand, VEGF-C. The VEGF homologous region (dark shaded box) and amino and carboxyl terminal propeptides (light shaded and unshaded boxes, respectively) as well as putative signal sequence are depicted between 5' and 3' untranslated (ut) nucleic acid regions. The cleavage sites for the signal sequence and the amino and carboxyl terminal propeptides are indicated with triangles.

Figure 10 shows a comparison of the deduced amino acid sequences of PDGF-A, PIGF-1,

VEGF-B

1 8 6 7 and Flt4 ligand

(VEGF-C).

Figure 1I depicts the exon-intron organization of the human VEG-C gene- Seven exons are depicted as open boxes, with axon size depicted in base pairs.

Introns are depicted as lines, with intron size (base pairs) depicted above the lines. 5' and 3' untranslated sequences of a p utative 2.4 kb mature mRNA are depicted as shaded boxes. The location of genomic clones used to characterize the VEGF-C gene are depicted belo the map of the gene.

Figure 12 shows Northern blotting analysis-of the genes encoding VEGF, VEGF-B, AND VE

G

P-C (indicated,by "FLT4-L") in two human tumor cell lines and in brain tissue.

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:01 FAX 61 3 92438333 GRIFFITH HACK -)IPATSTRALIA [025 (N 21- Figure 13A is an autoradiograph showing c, recombinant VEGF-C isolated following a pulse-chase o experiment and electrophoresed via SDS-PAGE under reducing conditions.

,Figure 13B is a photograph of polyacrylamide n gel showing that recombinant VEGF-C forms are disulfidel linked in nonreducing conditions.

o Figure 14A and 14B depict Western blots showing that VEGF-C stimulates autophosphorylation of VEGFR-2 O 10 (KDR) but has no effect on PDGFR-f phosphorylation.

C Figure 15A shows that VEGF-C stimulates endothelial cell migration in a three-dimensional collagen gel assay.

Figure 16A shows the expression of VEGF-C muRNA in human adult tissues.

Figure 16B shows the expression of VEGF, VEGF- B, and VEGF-C in selected human fetal tissues.

Figure 17 depicts the genomic structure of the human and murine VEGF-C genes. Sequences of exon-intron junctions are depicted together with exon and intron lengths. Intron sequences are depicted in lower case letters. Nucleotides of the open reading frame observed in VEGF-C cDNAs are indicated as upper case letters in triplets (corresponding to the codons 'encoded at the junctions).

Figure 18 presents a schematic illustration of VEGF-C processing, including the major forms of VEGF-C.

Figure 19 depicts autoradiograms from a pulsechase immunoprecipitation experiment wherein cells transfected with a VEGF-C expression vector (VEGF-C) and mock transfected cells were pulse-labeled with radioactive amino acids and chased for varying lengths of time.

Figure 20 is a schematic map of the KlC4VEGF-C vector construct.

Figures 21A-C depict electrophoretic fractionations of the various forms of recombinant VEGF-C COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:02 FAX 61 3 924383S3 G I F~ A KIAJTAI 2 GRIFFITH HACK IPAUSTRALIA 1a026 22 Produced by transfeoted 293 E8NA cel.Figu~re 21B depict-S the e-lectrophoretic fractionation, un-der non- reducing condition., of POlYpeptiass produced fraom mock (M4) transfected. cells, cell1s transfected with wild type (w t) VRGF.7C cDNA, and cells transr6Oted with a CDNA variant encoding VEGp-c....o2s. Each Of the bands identified in Figure 218 was excise4 and.

electroPhoreticalaY fractionated in a separate lane under reducing, conditions. Fractionation of bands, Co-rresponding to wt VI(sp-c are depicted in Fig-ure 21AF fractionation of bands corresponding to the'RXO2S variant are depicted ina Figure 210.

Figures 22A-B depict the forms and sizes of wild type and mutant recombinant VEGF-Cs, as revealed by non-reducing gel electrophoresis- Figure 22A shows the VEOP-C for-- secreted into the media; Figure 22B shois the VEGr-c forms retained by the cells. Nockc (mJ transfected cells set-vdd as a control- Figilt-es 23A-13 -present a comparison of the pattern ofE immnnopredipitated, labelled VIEGF--c forms Using antisera 882 and antisera 905. Adjacent lanes contain imnUnopreCiPitates that were (lanes marked or Were not (lanes marked subjected to reduction and alkylation.

Figure~s 24A-B present Northern blots of total RNA Isolated frox cells grown in the presence or absence of -interleukn..

1 (IL-i) and/or deaietbason. (flEX) for the indicated times. For Figure 24B, the Northerni blot Was probed with radiolabeled DNA from a VEGP 581 bp cDNA COering bps 57-638 (GeribaJ Aco. No. XIS99Y), and a human VEGF-B6 7 eDMA fragment (nucleotides 11382,, Genbank Ace. No. 1148800- For Figure 24Ar the Northern blot was probed with radiolaae DNA from a human full-length VECPF-C cDNA (Genbank Ace. No. X94216). 18$ and 28$- rlilA markers, Figure 25 shows

VEGF-

0 expression in .p, past Ois cultures transfected with. a VEGF-C cDNA, with $3

L)

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:02 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1027 t( 23 ;vector alone, or mock- transfected, following induction with methanol for various periods of time as Sindicated. About 10 Pl of medium was analyzed by gel electrophoresis followed by Western blotting and detection with anti-VEGF-c antiserum.

SFigure 26 depicts the results of a Western blot In1 wherein NIH 3T3 cells expressing VEGFR-3 (Flt4), and PAE Scells expressing VEGFR-2 were stimulated with concentrated medium from Pichia yeast transfected with a o 10 VEGF-C cDNA-containing vector with a vector lacking c an insert or stimulated with the positive control Svanadate. The stimulated cells were lysed and immunoprecipitated with VEGFR-specific antibodies, and the immunoprecipitates were blotted and probed with antiphosphotyrosine antibodies.

Figures 27A-B present gel electrophoretograms of human VEGF-C (wt) and VEGF-C variants secreted (Figure 27A) or retained (Figure 27B) by the host 293 EBNA cells.

Mock transfected cells served as a control.

Molecular weight markers are indicated on the left in kilodaltons (kD).

Figures 28A-B show Western blots of VEGFRs that were stimulated to autophosphorylate by wild type (wt) VEGF-C, as well as three VEGF-C polypeptide variants.

25 Cell lysates (NIH 3T3 for VEGFR-3 and PAE for VEGFR-2) were subjected to receptor-specific antisera and the receptors were immunoprecipitated. Immunoprecipitates were then gel-fractionated and blotted for Western analyses. Western blots were probed with antiphosphotyrosine antibodies.

Figures 29A-D are photomicrographs of hematoxylin-eosin stained sections of K14-VEGF-C transgenic and control mouse littermate tissues. Areas shown are from the dorsal skin and snout, as indicated.

The white arrows show the endothelium-lined margin of the lacunae devoid of red cells.

.Figure 30 presents a Northern blot of COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:02 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA U028 0 T- 24 olyadenylted NA from the indicated tissues, with a pool of VEGF, VEGF- and VEGF-C robes.

Estimated transcript sizes are shown on the right in O kilobases (kb).

and m Figure 31 paesents a comparison of the human nd mouse VEGF-C amino acid sequences. The amino acid ffereces i thouse F- is presented on the top line and difeences in the human sequence are marked belo it 0 The sequences have been labeled to depict the regions shown in Figure 9. The arrow indicates the putative 8le~vagh put at ith v e Cle avage site for the signal peptidase; BR3P motifs, as well as a CRSC motif, are boxed; and conserved cysteine residues are marked in bold above the sequence. Arginine residue 158 is also arked in bold. The numbering refers to Mouse VEGF-C residues.

Figure 32 presents SDS-PAGE-fractionated samples immunoprecipitated or affinty-purfied from various "S-labeled media. In the left panel, control mediium from Bosc23 cells containing vector only, medium expressing mouse VEGF-c were independently precipitated with human VEGFR-3-Extracellular Domain coupled to epharose. In the right panel, similar conditioned media were subjected to precipitation with anti-VEGF-C an tibodies, m molecular weight markers; m- mouse; hhuman; a- anti.

Figure 33 shows Western blots of gelfractionated immunoprecipitates from lysates made from NIH 3T3 cells expressing VEGFR-3 or VEGFR-2 as indicated, that had been stimulated by contact with

VEGF-

C-containing lysates (or a vector control), as a measure of VEGF-cndued receptor autophosphorylation Western blots were probed with anti-phosphotyrosine (a-PTyr) or anti-receptor antisera (anti-VEGFR-3 and anti-VEGFR-2), as dicated As a control, receptor autophosphorylation was induced by pervanadate treatment (Vo 4 The arrows and numbers refer to the apparent molecular weights of COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:02 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 1029 25 the tyrosyl phosphorylated receptor polypeptide bands.

bVEGF: human baculoviral VEGF-C protein; C-FGEVm: lysate from cells harboring a mouse VEGF-C cDNA cloned into the vector in an untisense orientation.

Figures 34A-D depict photomicrographs of in situ hybridizations revealing the expression of VEGF-C and VEGF-B mRNAs in a parasagittal section of a 12.5 day mouse embryo. Figure 34A: VEGF-C probe; j- jugular veins, mn- metanephros, m- mesenterium (arrowheads), vcintervertebral vessels, lu- lung (arrowheads). Figure 34B: VEGF-B probe; h- heart, nasopharyngeal area (arrowheads). Figure 34C: VEGF-C sense strand probe serving as a control. Figure 34D: bright-field photomicrograph of the same field shown in Figure 34C.

Figures 35A-H depict sections of mouse embryos providing comparisons of VEGF-C and VEGFR-3 expression in the jugular vessels and the mesenteric area. Figures and 35C show expression of VEGF-C-transcripts in the mesenchyme around the large sac-like structures in the jugular area (arrowheads). Figures 35B and 35D show expression of VEGFR-3 transcripts in the jugular venous sacs. Figures 35E and 35G show VEGF-C mRNA distribution in the mesenteric region of a 14.5 day p.c. embryo, as well as around the gut. Figures 35F and 35H show VEGFR-3 mRNA in the mesenteric region of a 14.5 day embryo, as well as the gut area, developing lymphatic vessels, and venules.

Figures 36A-D depict photomicrographs showing FLT4 and VEGF-C in situ hybridization of the cephalic region of a 16-day p.c. mouse embryo. A section of the cephalic region hybridized with the Flt4 probe (Figure 36A) shows the developing snout, nasal structures and eyes. A more caudally located section shows hybridization with the VEGF-C probe (Figure 36B). The round structures an both sides in the upper part represent the developing molars.

In the upper (dorsal) part on both sides of the midline, the caudal portion of the developing conchae are seen.

1)3 1 COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:03 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0030 C 26 These structures also are shown in higher magnification Sdarkfield (Figure 36C) and lightfield (Figure 36D) microscopy, DETAILED DESCRIPTION OF THE INVENTION Described herein is the isolation of a novel vascular endothelial growth factor and the cloning of a SDNA encoding this novel growth factor from a cDNA library Cp repared from the human prostatic adenocarcinoma cell S0 line Pc-3. The isolated cDNA encodes a protein which is 8 10 proteolytically processed and secreted to cell culture medium. The secreted protein, designated VEGP-C, binds. to the extracellular domain of Flt4 and induces tyrosine autophosphorylation of Flt4 and VEGFR-2. VEGF-C also 15 timulates the migration of endothelial cells in collagen gel.

Data reported herein indicates that VEGF-C is expressed as a larger precursor which is cleaved to produce the ligand. A coexpressed region in some cases results from alternative splicing of RNA of the ligand gene. Such a co-expressed region may be a function of the particular expression system used to obtain the ligand. The skilled artisan understands that in recombinant production of proteins, additional sequence may be expressed along with a functional polypeptide depending upon the particular recombinant construct used to express the protein, and subsequently removed to obtain the desired ligand. In some cases the recombinant ligand can be made lacking certain residues of the endogenous/natural ligand. Moreover, it is well-known in that conservative replacements may be made in a protein which do not alter the function of the protein.

Accordingly, it is anticipated that such alterations are within the scope of the invention. Moreover, it is anticipated that one or more VEGP-C precursors (the largest putative native secreted VEGF-C precursor having the complete amino acid sequence from residue 32 to COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:03 FAX 61 3 92438333 GRIFFITH HACK i IPAUSTRALIA 1@t031 S- 27 residue 419 of SEQ ID No: 33) is capable of stimulating Sthe Flt4 ligand without any further processing, in a Smanner similar to that in which VEGF stimulates its receptor in its unprocessed form after the secretion and concomitant release of the signal sequence.

4 *Results reported herein show that Flt4 (VEGCR- 3) transmits signals for VEGF-C. This conclusion is o based on the specific binding of VEGF-C to recombinant Flt4Ec (Flt4 extracellular domain) protein and the induction of VEGFR-3 autophosphorylation by medium from 0 VEGF-C transfected cells. In contrast, neither VEGF nor P1GF showed specific binding to VEGFR-3 or induced its autophosphorylation.

As set forth in greater detail below, the putative prepro-VEGF-C has a deduced molecular mass of 46,883; a putative prepro-VEGF-c processing intermediate has an observed molecular weight of about 32 kD; and mature VEGF-C isolated form conditioned media has a molecular weight of about 23 kD as assessed by SDS-PAGE under reducing conditions. A major part of the difference in the observed molecular mass of the purified and recombinant VEGF-C and the deduced molecular mass of the prepro-VEGF-C encoded by the VEGF-C open reading frame (ORF) is attributable to proteolytic removal of sequences at the amino-terminal and carboxyl-terminal regions of the prepro-VEGF-C polypeptide. However, proteolytic cleavage of the putative 102 amino acid leader sequence is not believed to account for the entire difference between.the deduced molecular mass of 46,883 and the observed mass of about 23 kD, because the deduced molecular weight of a polypeptide consisting of- amino acids 103-419 of SEQ ID NO: 33 is 35,881 kD. Evidence indicates that a portion of the observed difference in molecular weights is attributable to proteolytic removal of amino acid residues in both the amino and carboxyl terminal regions of the VEGF-C precursor. Extrapolation from studies of the structure of PDGF (Heldin et al., COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:03 FAX 61 3 92438333 GRIFFITh HACK IPAUSTRALIA [~]032 01/06 2007 17:03 FAX 61 3 92438333 GRIFFITH HACK 4IPAUSTRALIA 0032n C 28 Growth Factors, 8:245--52 (1993)) suggests that the region critical for receptor bindin and activation by VEGF-C is contained within mino acids residues 0 ,by VEGwich found in th. r::::104- 2 1 3, w h i c h are 0 found in the secreted form of the VEGF-C protein the form lacking the putative prepro leader sequence and some carboXyterminal sequences) The 23 pte bihing VEeR3 ie 23 kD polypeptide Cbinding VEGFR3 is likely to represent the VEGF- SC polypo domain, After biosynthesis, the nascent VEGF- C polypeptide may be glycosylate d at three putative

N-

linked glycosylation site identified ih the deduced s identified in the deduced o VEGFC amino acid s equence. Polypeptides containing Smodifications, such as N-linked glycosylations, are intended as aspects of the invention.

The carboxyl terminal amino acid sequences, which increase the length of the VEGF-C polypeptide in comparison with Other ligands of this family, show a pattern of spacing of cysteine residues reminiscent of the Balbiani ring 3 protein (BR3P) sequence (Dignam et al2, Gene, 88:133-40 (1990); Paulsson et al., J. fol.

B eil., 211:331-49 (1990)). This novel C-terminal silk protein-like structural motif of VEGF-C may fold into an independent domain, hich, on the basis of the considerations above, is at least partially cleaved off after biosynthesis Interestingly, at least one cysteine motif of the BR3P type is also found in the carboxyl ;4 e usof VEG. In our experiments both the putative.

precursor and cleaved ligand were detected in the cell culture media, suggesting cleavage by cellular proteases.

The determination of anino-terminal and carboxy-terminal sequences of VEGF-- "iolates allows the identificaion of the proteolytic processing sites. The generation of antibodies against different parts of the pro-VEGF-C molecule allows the exact determination of the precursorproduct relationship and ratio, their cellular distribution, and the kinetics of processing and secretio n VEGF-C has a conserved pattern of eight COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:04 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0033 CN 29 Scysteine residues, which may participate in the formation Sof intra- and interchain disulfide bonds, creating an antiparallel dimeric biologically active molecule, similar to PDGF. Mutational analysis of the cysteine residues involved in the interchain disulfide bridges has shown that, in contrast to PDGF, VEGF dimers need to be Sheld together by these covalent interactions in order to q maintain biological activity.. Disulfide linking of the (c VEGF-C polypeptide chains was evident in the analysis of o 10 VEGF-C in nonreducing conditions, although recombinant o protein also contained ligand-active VEGF-C forms which iC lacked disulfide bonds between the polypeptides.

VEGFR-3, which distinguishes between VEGF and VEGF-C, is closely related in structure to VEGFR-1 and VEGFR-2. Finnerty et al., Oncogene, 8:2293-98 (1993); Galland et al., Oncogene, 8:1233-40 (1993); Pajusola et al., Cancer Res., 52:5738-43 (1992). Besides VEGFR-3, VEGFR-2 tyrosine kinase also is activated in response to VEGF-C. VEGFR-2 mediated signals cause striking changes in the morphology, actin reorganization and membrane ruffling of porcine aortic endothelial cells overexpressing this receptor. In these cells, VEGFR-2 also mediated ligand-induced chemotaxis and mitogenicity.

Waltenberger et al., J. Biol. Chem., 269:26988-95 (1994).

Similarly, the receptor chimera CSF-1R/VEGFR-3 was mitogenic when ectopically expressed in NIH 3T3 fibroblastic cells, but not in porcine aortic endothelial cells (Pajusola et al., 1994). Consistent with such results, the bovine capillary endothelial (BCE) cells, which express VEGFR-2 mRNA but very little or no VEGFR-1 or VEGFR-3 mRNAs, showed enhanced migration when stimulated with VEGF-C. Light microscopy of the BCE cell cultures in collagen gel also suggested that VEGF-C stimulated the proliferation of these cells. The'data thus indicate that the VEGF ligands and receptors show a great specificity in their signalling, which may be celltype-dependent.

A'

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:04 FAX 61 3 92438333 GRIFFITH HACK -)IPAUSTRALIA Z034a 0 C 30 The expression pattern of the VEGR-3 S(Kaipaien et al., Proc. Natl. Aca d Sci. (USA), 92;:566- (1995)) suggests that VEGF-C may function in the formation of the venous and lymphatic vascular systems during embryogenesis- Constitutive expression of VEGF-c in adult tissues shown herein further suggests that this Sgene product also is involved in the maintenance of the differentiated functions of the lymphatic and certain 0 venous endothelia Where VEGFR-3 is expressed (Kaipainen et al., 1995). Lymphatic capillaries do not have wellformed basal laminae and an interesting possibility C remains that the silk-like BR3P motif is involved in producing a supramolecular structure which could regulate the availability of VEGF-C in tissues. However, as shown here, VEGF-c also activates VEGFR-2, which is abundant in proliferating endothelial cells of vascular sprouts and branching vessels of embryonic tissues, but not so abundant in adult tissues. Millauer et al., Nature, 367:576-78 (1993). These data have suggested that VEGFR-2 is a major regulator of vasculogenesis and angiogenesis. VEGP-c may thus have a unique effect on lymphatic endothelium and a more redundant function, shared with VEGF, in angiogenesis and possibly in regulating the permeability of several types of endothelia- Because VEGF-C stimulates VEGFR-2 and promotes endothelial migration, VEGF-C may be useful as an inducer of angiogenesis of blood and lymphatic vessels n. wound healing, in tissue transplantation, in eye diseases, and in the formation of collateral vessels around arterial stenoses and into injured tissues after infarction.

Taken together, these results show an increased complexity of signalling in the vascular endothelium.

They reinforce the concept that when organs differentiate 3 and begin to perform their specific functions, the phenotypic heterogeneity of endothelial cells increases in several types of functionally and morphologically COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:04 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0035 31 Sdistinct Vessels. However, upon stimulation by suitable angiogenic stimuli, endothelial cells can re-enter the O cell cycle, migrate, withdraw from the cell cycle and subsequently differentiate again to form new vessels that are functionally adapted to their tissue environment.

nThis process of angiogenesis, concurrent with tissue Nq development and regeneration, depends on the tightly o controlled balance between positive and negative signals c for endothelial cell proliferation, migration, o 10 differentiation and survival.

Previously-identified growth factors promoting angiogenesis include the fibroblast growth factors, hepatocyte growth factor/scatter factor, PDGF and TGF-a.

(See Folkman, Nature Med., 1:27-31 (1995); Friesel et al., FASEB 9:919-25 (1995); Mustonen et al., J.

Cell. Biol., 129:895-98 (1995). However, VEGF has been the only growth factor relatively specific for endothelial cells. The newly identified factors

VEGF-B

[Olofsson et al., Proc. Natl. Acad. Sci., 93:2578-81 (1996)] and VEGF-C thus increase our understanding of the complexity of the specific and redundant positive signals for endothelial cells involved in vasculogenesis, angiogenesis, permeability, and perhaps also other endothelial functions. Expression studies using Northern blotting show abundant VEGF-C expression in heart and skeletal muscle; other tissues, such as placenta, ovary, small intestine, thyroid gland, kidney, prostate, spleen, testis and large intestine also express this gene.

Whereas PlGF is predominantly expressed in the placenta, the expression patterns of VEGF, VEGP-B and VEGF-C overlap in many tissues, which suggests that members of the VEGF family may form heterodimers and interact to exert their physiological functions.

Targeted mutagenesis leading to inactivation of the VEGF receptor loci in the mouse genome has shown that VEGFR-1 is necessary for the proper organization of endothelial cells forming the vascular endothelium while COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/Oft 2007 17:05 FAX 61 3 92438333 GIF~ AK4IAITAI GRIFFITH HACK 4 IPAITSTRALIA a 036 0 -32ci VEQFR-2 is necessary for the generation of both ;Zendotleael and hematopoietic call, Thssuggest that the tour gen 'es of the VEOF family can be targets for muaions ledn ovascular malforimations or cardiovascular diseases.

The following E xainples ilustrate preferred *2bodimnts; of the -invention, wherein the isoaton characterizatio charcteizatonand function of Flt4 ligaada and lignd-ncoingnucleic acids according to the invention are showni.

0 EX W.LE 1 Production of pLrlwlt 4 i Gxpressjou Vector Construction of the. LTR.-plt41 vector, encoding the long form of Flt4 r~ceptor tyrosine kinase, is schematicaliy shown in Fig. 2. The full-ilentpjt 45 (Flt4 short form) ODNAk (Cenbank Accession No. X68203, SEQ ID-NO: 36) was assembled by first suboloning the fragment, -reported in PajUsola et al., Cancer- Res., 52:5738..9743 (1992), incorporated by reference herein, cntaiingbase pairs 56-2534 of the Plt4 5 into the LEoRt site of the PSP73 vector (Promega, Madison,

WI).

Since eDNA libraries used for screening of Flt4 ODNAs did not contain the extreme 5' protein-coding squences inverse PeR was used for the amplification of 259 the S' end of Plt4 corresponding to the first 12 amino acid residues (mR~,LLL) Poly

(A)

4 RNA was isolated fromu human EEL erythroleukemia cells and double-stranded ODRA&, were synlthesized using an Amershamn CONA synthesis SYstem Plus kit (Amersham Corp., BUckinghamshije,

U.K.)

and a gene-specific primer:- 'TTCCCTTCTTT3 (SEQ ID NO: which was located 195 bp downstream of the 5f end of clone 32.5. Double-stranded cDNA was treated with T4 DNA polymnerase to blunt the ends and-hDNA Was Purified by filtration with Centricox 100 filters- (Amicon Inc., Beverly, HA)_ Circularization of the blwnt-en4Qd CDNA was pertormed by ligation in a total COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:05 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 10037 3volume of 150 microliters The reaction mixture DTT ained a Standard ligation buffer, 5% PEG-8000, 1 mN and a U Of T4 DNA ligase (New England Biolabs, Beverly, Ligation was carried out at 16'C for 16 hours. Fifteen microliters of this reaction mix Were 7tused in a standard PCR reaction V) (100 Al total voluxe) containing 100 ng of Ylt4-specific primers introducing al and PstI restriction sites, and 1 unit of Taq DNA 000e (Perkin Elmer Ctus). Two rounds of PCR were performed using 33 cycles per round (denaturation at 9 *c for 1 minute, annealing at 55C for 2 minutes, and elongatioA at 72 C for 4 minutes). The Pca mixture was treated sequentially with the Sadl and PstI restriction enzymes, and after purification with lagicPCR Preps romga), DNA fragments were subcloned into the PGEM3ZE(+) vector for sequencing (Promega). The sequence corresponded to the 5' end of the Flt4s cDNA clone deposited in the Genbank Database as Accession No.

X68203.

The sequence encoding the first 12 amino acid residues was added to the expression construct by ligating an SphI-digested PCR fragment amplified using rverse transcription-PCR of poly(A)+ RNA isolated from the HEL cells. The forward primer had the following seqenc_ 5'-ACAT(G C CACCAGCAG CGGGGCGCCG

CGCTGTGCCT

GCG-ACTGG CTCTGCTGG GACTCCTGGA.-3' (SEQ ID NO: 2) (Sphl site underlined, translational start codon marked in bold)- The translation start codon is immediately dowrstream from an optimized Rozak consensus sequence.

(Rozak, Nucl. Acid 'Res., 15: 8125-8148 (1987).) The reverse primer, 5'-ACATg ATGG CCGCCCGT CATCC-3' (SEQ

D

ITO: 3) (SphI site underlined), to the 5' end of the 82.5 fragment, thus replacing the unique Sphl fragment of the plasmid. The resulting vector was digested with LcocRI and Clal and ligated to a 138 bp PCR fragment amplified from the 0.6 kb RoR fragment (base pairs 3789 .to 4416 in the Genbank X68203 sequence) which encodes the COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/00 2007 17:05 FAX 61 3 92438333GR F I h H C- I AU R L A I03 GRIFFITH HACK IPAUSTRALIA 0038 3f end of Flt4s shown in Figure I of Pajnsoaa et a.

-ace Res, 52-:5738-5743 (1992), using the o OLgonuleot ides s'-CGAAnccc CATGACCCCA AC-3' (SEQ

:ED

XO: 4) (forward primer, ECoRI site underlined) and

S'-

CCAT-Ct-ArG ATCCTACCTQ AAGCCGCnTT CrT-3' (SEQ ID NVO. -9 (reverse primer, Clal site underlined)- Thie coding domain was comnpleted. by ligation of the 1.2 kb EcoRI Cl fragment (base Pairs 2535-3769 of the sequence found in 0 Gen Bank Ac. No. X68203) into the above construct. The 1o Comlipete eDNA was suboloned as dafnIICa butd 0 fragment (this C1az site was also included in the 3' Cl primer used to conlstruct the 3' end of the coding sequence) to the PLTRnpoly expression vector reported in Haicem et al., Gene, 118: 293-294 (1992) (Genbapic accession number X60280, SEQ ID HO: 37), incorporated by reference herein, Using its HIxxdlxIll-c(blunted) res triction sites The long formr of Flt4 (Flt41) was produced by replacing the 31 -end of the short form as follows: The 3' -region of the Flt4l eDNA Was VCR-amplified using a gene- S'Pecifjc Oligonucleotide (SEQ ID NO: 7, see below) and a pQEM JZ.vctor..specifc (SPE promoter) oliqonucleotjde S'-ATTTAGQTGA~cATATA- 3 (SEQ ID NO: 6) as reverse and.

forward Primers, respectively- The template for PC2R was an Ftlt41 cDNA clone containing a 495 bp LEolI fragment extending downstream of the LeeRs site at nucleotide. 37S9 Of the Geubanc X68203 sequence (the sequence downstream Of this teaks site is deposited as the Flt4 long form 3' sequence having Cenbanc accession number S66407 (SEQ ID NO.* The 9ene-speciric Oltgonucleotiae contains a BaofI restriction site located right after the end of the coding region and has the folhlowing sequence! cCATCGATGGATCCGATGcrT;CT~&AGTT3 (SEQ 11D NO: 74L CBaMwr site is underlined). The PCR product was digested with EcoRi and Eamn and transferred in frame to the LTR-Flt4w vector fragment from which the coding sequencesa downstream of the Econs site at base pair 2535 (sea, COMB ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:06 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA lao3m SN- 35 sequence X68203) had been removed by EcoRI-BamHI digestion. The resulting clone was designated pLTRFlt41. Again, the coding domain was completed by ligation of the 1.2 kb EcoRI fragment (base pairs 2535- 3789 of sequence X68203) back into the resulting S" construct.

in EXAHMPLE 2 Production and analysis of iPt41 transfected cells 0 NIH 3T3 cells (60 confluent) were co- O 10 transfected with 5 micrograms of the pLTRFlt41 construct and 0.25 micrograms of the pSV2neo vector containing the neomycin phosphotransferase gene (Southern et al., J.

Mol. Appl. Genet., 1:327 (1982)), using the DOTAP liposome-based transfection reagents (Boehringer- Mannheim, Mannheim, Germany). One day after transfection, the cells were transferred into selection media containing 0.5 mg/ml geneticin (GIBCO, Grand Island, Colonies of geneticin-resistant cells were isolated and analyzed for expression of the Flt4 proteins. Cells were lysed in boiling lysis buffer containing 3.3% SDS 125 mM Tris, pH 6-.8 Protein concentrations of the samples were measured by the BCA method (Pierce, Rockford, IL). About 50 micrograms of protein from each lysate were analyzed for the presence of Flt4 by 6% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting using antisera against the carboxyl terminus of Flt4. Signals on Western blots were revealed using the ECL method (Amersham).

For production of anti-Flt4 antiserum, the Flt4 cDNA fragment encoding the 40 carboxy-terminal. amino acid residues of the short form: NH2-PMTPTTYKG

SVDNQTDSGM

VLASEEFEQI ESRHRQESGFR-COOH (SEQ ID NO: 8) was cloned as a 657 bp EcoRI-fragment into the pGEX-IXT bacterial expression vector (Pharmacia-LKB, Inc., Uppsala, Sweden) in frame with the glutathione-S-transferase coding region. The resultant GST-F1t4S fusion protein was COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:06 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA R1040 0 0 (C 36 gproduced in E. coli and purified by affinity chromatography using a glutathione-Sepharose 4B column.

The purified protein was lyophilized, dissolved in phosphate-buffered saline (PBS), mixed with Freundrs adjuvant and used for immunization of rabbits at biweekly intervals using methods standard in the art (Harlow et al., Antibodies; A Laboratory Manual (Cold o Spring Harbor Laboratory Press, 1988)). Antisera were 1 used, after the fourth booster immunization, for imunoprecipitation of Flt4 from transfected cells. cell o clones expressing Flt4 were also used for ligand stimulation analysis.

EXAMPLE 3 Construction of a Flt4 EC baoulovirus vector and expression and purification of its product The construction of an Flt4 extracellular domain (EC) baculovirus vector is schematically depicted in Fig. 3. The Flt4-encoding ODNA was prepared in both a long form and a short form, each being incorporated in a vector under control of the Moloney murine leuKemia virus LTR promoter. The nucleotide sequence of the short form of the Flt4 receptor is available from the Genbank database as Accession No. X68203 and the specific 3' segment of the long form CDNA is available under GenBank Accession No. 566407.

The ends of a eDNA segment encoding the Flt4 extracellular domain (EC) were modified as follows: The 3' end of the Flt4 cDNA (Genbank Accession Number X68203) extracellular domain sequence was amplified using primer 1116 (5'-CTGGAGTC!ACTTGGCGGACT-3'; SEQ ID NO: 9, Sall site underlined) and primer 1315

CGCGAZCCCTAGTGATGGTGATGGTGATGTCTACCTTCGATCATGCTGCCCTTAT

CCTC-3'; (SEQ ID NO: 10, BamHI site underlined). The sequence at the 5' end of primer 1315 is not complementary to the Flt4 coding region. Inspection of the sequence that is complementary to this region of COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:06 FAX 61 3 92438333 GRIFFITH HACK 4, IPAUSTRALIA 041 0 C, 37 primer 1315 reveals in a 5' to 3' order, a stop codon, six contiguous histidine codons (for subsequent chromatographic purification of the encoded polypeptide using a Ni-NTA column; Qiagen, Hilden, Germany), and an added BaamH site. The amplified fragment was digested Swith Sal and BamHI and used to replace a unique SalI- I BanHI fragment in the LTRFlt4 vector shown in Fig. 3.

The Sall-BamRI fragment that was replaced encodes the Flt4 transmembrane and cytoplasmic domains. The result was a modified LTRFlt4 vector.

0 The 5' end without the Flt4 signal sequence encoding region was amplified by PCR using the primer 1335 (S'-CCCAAGTCGA-ZCAAGTGGCTACTCCATGACC-3'; (SEQ ID NO: 11) the primer contains added HindlII (AAGCTT) and BamHI (GGATCC) restriction sites, which are underlined).

The second primer used to amplify the region encoding the Flt4 signal sequence was primer 1332 GTTGCCTGTGATGTGCACCA-3'; SEQ ID NO: 12). The amplified fragment was digested with findlI and SphI (the HindIII site (AAGCTT) is underlined in primer 1335 and the SphI site is within the amplified region of the Flt4 cDNA).

The resultant HindIII-SphI fragment was used to replace a HindII-sphI fragment in the modified LTRFlt4 vector described immediately above (the HindIII site is in the 5' junction of the Flt4 insert with the pLTRpoly portion of the vector, the Sphl site is in the Flt4 cDNA). The resultant Flt4EC insert was then ligated as a BamHI fragment into the BamHI site in the pVTBac plasmid described in Tessier et al., Gene 98:177-183 (1991), incorporated herein by reference. The relative orientation of the insert was confirmed by partial sequencing so that the open reading frame of the signal sequence-encoding portion of the vector was adjacent to, and in frame with, the Flt4 coding region sequence. The F1t4EC construct was transfected together with baculovirus genomic DNA into SF-9 cells by lipofection.

Recombinant virus was purified, amplified and used for COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 0 1 6 2 0 7 7 0 F A 6 1 3 9 4 3 8 3 3 R I F I h H A C I P A U S T R A L I A [it 0 4 2 01/06 2007 17:07 FAX 61 3 92438333 GRIFFITH BACK inffection of.Hflig- p~ve c lls (Invitrog n, S n D e o A ;Z using methods standard in the art. Sae Dieot4A extracexlul1a. domain (Plt4EC) was Puified from the cUlture medium orteifetdHgh-Five cells Using Ni- NTA affinity chromatography according'to manuactrerrs instructon 1 s (Qiagenj f or binding and Eilution, of the Sxuis tag encoded 1 in the COQR-terninus ot the recomabinant Plt4 extracellular domain.c~KI R flMLE 4 Isolation Of an Plt4 Ligand from Conditioned Media 0 A human Flt4 ligand according to the invention C was isolated fromL media Conditioned by a P0-3 prostatic &denocarcinoma cell line (ATOC CRL 1435) in Ham's F-12 Nutrient, mixture (GIBco) containing 7!k fetal calf serum (PCS). The cells were grown according to the Sjupplier's instructions- In, order to prepare the Conditioned media, Confluent PC-3 cells were cultured for 7 days in flawas F- 12 Nutrient laixture (GIBCO) in the absence of fetal bovine serumn (PBS) Medium was then clear-ed by Cenltrifugation at 10,0j0Vc g for 20 minutes. The medium was then screened to determ4in 8 its ability to induce tyrosine phosphoryjatj 0 n of Plt4 by exposure to wIH 3T3 cells which had been transfected with Flt4-aencoding cDNA using the pLTRplt4l vector. For receptor stimuaetion experiments, subontinent N~I 3T3 cells were starved overnight. in serum-free DMEM medium (GIBCa) containing 0.2-V bovine Ser-um albumin (BSA). The cells were stimulat.4 with the Confditioned media for 5 -minutes, washed twice with cold -PBS containing 100 micromolar Yanadate, and lysed in RIPA buffer (10 mff Tris p1I 7.5, nfl NaCi, 0.5-1 sodiuia deoxycholate, 0.51 Nonidet P40 (81)11 Poole, England), 0.1k SDIS, 0.1 U/mi Aprotinmn (Boebringer M~annheim), 1 MM Vanadate) for receptor lmmUnoprecipitation analysis. The lysates werecentrifuged for :20 minutes. at 15,000 x g. The supernattants were incubated for 2 hours on ice with3 COMS ID No: SBMI-07622503 Received by 1P Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:07 FAX 61 3 92438333 GRIFFITh HACK IFAUSTRALIA F~i043 01/06 2007 17:07 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 043 39 microliters of the antiserum against the Flt4 C-terminus dciedinEaple. See also Pajusola et al., Oncogene, 8:2931-2937 (1993), incorporated by reference o herein.

After a two hour incubation in the presence of Santi-Pt 4 antiserum, protein A-Sepharose (Pharmacia) was added and incubation was continued for 45 minutes with C rotation The immunoprecipitates were washed three times with the immunoprecipitation buffer and twice with 10 mM Tris, pH 7.5, before analysis by SDS-PAGE. Polypeptides were transferred to nitrocellulose and analyzed by Western blotting using Flt4- or phsphotyrosine-specific antisera and the ECL method (Amersham Corp.). Anti- Phosphotyrosine monoclonal antibodies (anti-PTyr; were purchased from Transduction Laboratories (Lexington, Kentucky). In some cases, the filters were restained with a econd antibody after stripping. The stripping of the filters was done for 30 minutes at-50c in 100 mM 2mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7, with occasional agitation.

As shown in Fig. 4, the PC-3 conditioned medium (PC-3CM), stimulated tyrosine phosphorylation of a 125 kD polypeptide when-Fit4- expressing NIH 3T3 cells were treated with the indicated preparations of media, lysed, and the lysates were immunoprecipitated with anti-Flt4 antiserum followed by SDS-PAGE, Western blotting, and staining using anti-PTyr antibodies. The resulting band was weakly Phosphorylated upon stimulation with ulnconcentrated PC-3 conditioned medium (lane The 125 kD band comigrated with the tyrosine phosphorylated, processed form of the mature Flt4 from pervanadatetreated cells (compare lanes 2 and 7 of Fig. 4, see also Fig. 5A). Comigration was confirmed upon restaining with anti-Flt4 antibodies as is also shown in Fig. 5A (anel on the right). In order to show that the 125 kD Polypeptide is not a non-specific component of the conditioned medium reactive with anti-pospshotyrosine COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:07 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA Z044 antibodies, 15 microliters of Conditioned medium ere separated by SDS-PAGE, blotted on itrocellulse and the blot was stained with anti-yr anltibodies. No signal S was obtained (Pig. u Also, unconditioned medium failed to stiulate Flt4 Phsphorylation, as shown in Fig. 4, lane i.

3 Fig 5C sthows a comparison of the effects of PC-3 4 stimulation on untransfected (lanes 4 and FGR-4transfeCtd (lanes 8 and 9) and Flt4-transfectad IH 3T3 cells (lanes 1-3, 6 and 7) These results i ndicate that neither untransfected NIR 3T3 cells nor

NIH

3T3 cells transfected with FGFR-4 showed tyrosine phosphorylation of apo hslation o a protein of about 125 kD upon stimulation with the conditioned medium from PC-3 cells.

SAnalysis of stimulation by PC-3 C pretreated with Heparin...SPar CL- (Phanacia for 2 hours at room teperatindute (lane 3) showed that the Flt4 ligand does not bind to heparin, 0 i As shown in Fig. 4, lane 3, stimulating activity was cosiderably increased when the PC-3 Centicon0ed medium was concentrated four-fold using a Centri 00 n.

10 concentrator (Amicicn)- Fig. 4, lane 4, shows that pretreatment of the concentrated PC-a condtiond meium cocenrtrated PC--3 Conditioned medium with 50 microliters of the Plt4 extracellular domain coupled to CNBr-activated sepharose CL-4B (Pharmacia; about 1mg of Flt4zC domain/na sepharose resin) COmpletely abolished Flt4 tyrosin phosPuhorylation Similar pretreatment of the conditioned medium with uaSUbstituted sepharose CL-48 did not affect stimulatry activity, as shown in Fig. 4, lane 5. Also the flow through obtained after oncentration, which contained proteins of less than 10,000 molecular weight, did not stimulate P14 phosphorylation, as shown in Pig.

4, lane 6.-r another experiment, a comparison of Flt4 exprephosphorlatio in transformed III 3T3 Cells expressing LTRFlt4l was Conductead, using unconditioned COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:07 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0045 41 medium, medium from PC-3 cells expressing the Flt4 Sligand, or unconditioned medium containing either ng/ml of VEGFI65 or 50 ng/ml of PIGF-I. The cells were lysed, immunopreciptated using anti-Flt4 antiserum and analyzed by Western blotting using anti-phosphotyrosine antibodies Only the PC-3 conditioned medium expressing the Flt4 ligand (lane Flt-4L) stimulated Flt4 Ci autophosphorylation.

SThe foregoing data show that PC-3 cells produce a liand which binds to the extracellular domain of Flt4 0 and activates this receptor.

EXAMPLE Purification of the Flt4 Ligand The ligand expressed by human PC-3 cells as characterized in Example 4 was purified and isolated using a recombinantly-produced Flt4 extracellular domain (Ft4EC) in affinity chromatography.

Two harvests of serum-free conditioned medium, comprising a total of 8 liters, were collected from 500 confluent 15 cm diameter culture dishes containing confluent layers of PC-3 Cells. The conditioned medium was clarified by centrifugation at 10,000 x g and concentrated 80~fold using an Ultrasette Tangential Flow Device (Filtron, Northborough, MA) with a 10 kD cutoff Omega Ultrafiltration membrane according to the manufacturer's instructions. Recombinant Flt4 extracellular domain was expressed in a recombinant baculovirus cell system and purified by affinity chromatography on Ni-agarose (Ni-NTA affinity column obtained from Qiagen). The purified extracellular domain was coupled to CNBr-activated Sepharose CL-4B at a concentration of 5 g/ml and used as an affinity matrix for ligand affinity chromatography.

Concentrated conditioned medium was incubated with 2 ml of the recombinant Flt4 extracellular domain- Sepharose affinity matrix in a rolling tube at room COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:08 FAX 61 3 92438333 GRIFFITH HACK -*IPAUTSTRALIA 0046 temuperature .for 3 hours. All sb pe~Prfcto ;Zsteps were at T11 affniyiatricaSthen tra sfe red toa Columni With an inner diameter of is m and wa~hed sUccessi'ejy with, io0 M1 Of PBS and So Ml of 1m Ha&-phosphate butler (PR -Bound material was eluted step-wise With 100 MNg 9lYCine-..ucx successive 6 m e l u t o~ avin pf s Of 4. 1 2 .4 a rn d 1 .9 Several 2 l Infractions o'f the eluate were collected in tubes o ~~~ontaining 0..s ml 1 H4 PNp a e R 0

I

immediately and 'dialyzed in :X nM Tris;Lca (pHi Aliquots of 75 p1 each Were analyzed for their 0 ~ability to stimulate tyrosine phosph~~rylation of The ultraailfrate, loo gl aliquots of the concentrated conditioned medim before and after ligami affinity is cromaography, as Well as 15-fold concentrated fractions of material released from the flt4 extr-acelluaar domain- Sepharose muatrjjx during the washings were also analyzed for their ability to stimulate. Plt4 tyrosine PhOsphoryiatpon.

As shown in Fig- 6, lane 3r the concentrated conditiOned Medium induced Prominent tyrosine Ph~~h~~laionof Flt4 in tras~f ected flHi 3T3 cells Overe~resingFlt4. This activity was not observed in coflditioned medium taken after mnedilum Was exposed to the Plt4 Saphar 050 afrinitY mnatrix described above (Fig. 6, lane The specifically-boundi Flt4 -Stim~ulatin 9 material was retained on- the affinity matrix after washing in pB$, 10 UMi Ha-phosphate buffer (pH and at PHl 4-o (Pigr. Er lanes 5-7 respectively), and it was elutedi in the first bwo 2 Nl aliguote at PH 2.4 (lanes

S.

and A further decrease of the PH or the elution buffer did not cause release of additional Flt4-" StiMulating material (Fig-. 6, lane 11) Fig. 6, lane

I

depict 8 a control wherein Plt4-expressing cells were treated with unconditioned medium; lane 2 depicts the- results following treatMen Of Flt4-expesn el ihj the liltrariltrate fraction of conditioned medium COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:08 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA JN47 0 S- 43 Scontaining polypeptides of less than 0o kD molecular weight.

Small aliquots of the chromatographic fractions were concentrated in a SpeedVac concentrator (Savant, Farmingdale, and subjected to SDS-PAGE under reducing conditions with subsequent silver staining of Sthe gel, a standard technique in the art. As shown in l Fig. 7, the major polypeptide, having a molecular weight of approximately 23 kD (reducing conditions), was detected in the fractions containing Flt4 stimulating Sactivity (corresponding to lanes 8 and 9 in Fig. 6).

That polypeptide was not found in the other chromatographic fractions. On the other hand, besides these bands and a very faint band having a 32 kD mobility, all other components detected in the two active fractions were also distributed in the starting material and in small amounts in the other washing and eluting steps after their concentration. Similar results were obtained in three independent affinity purifications, indicating that the 23 kD polypeptide specifically binds to Flt4 and induces tyrosine phosphorylation of Flt4.

Fractions containing the 23 kD polypeptide were combined, dried in a SpeedVac concentrator and subjected to SDS-PAGE in a 12.5% gel. The proteins from the gel were then electroblotted to Immobilon-P (PVDF) transfer membrane (Millipore, Marlborough, MA) and visualized by staining of the blot with Coomassie Blue R-250. The region containing only the stained 23 kD band was cut from the blot and subjected to N-terminal amino acid sequence analysis in- a Prosite Protein Sequencing system (Applied Biosystems, Foster city, CA). The data were analyzed using a 610A Data Analysis System (Applied liosystems). Analysis revealed a single N-terminal sequence of NHr-XEETIKFAAAHYNTEILK-COOH (SEQ ID NO. 13).

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:08 FAX 61 3 92438333 GRIFFITH HACK IFAUSTRALIA Q~048 0 44 EXAMPLE 6 ;Z ~ContrUcti 0 n If PC-3 cell- eDZM l ibrary in a enkaryotic expressfion Vector Human Poly(A)+p NA was isolated frot five is cm diameter4dishes'of Confluent PC-3 cells by a single. step method USing Oligo~ T) (Type 113:, Collaborative 11hBiomedcal Products, Becton-njkiso abwae Bedford, I4A) cellulose affinity, ohromatouraphy (Salubrook et al-, ci1989) -The yield was 70 micrograms. Six micrograms of the POly(p) t RUA Were used to prepare an oligo(dT).-primed DKA library in the mnaalian expression Vector PcDNAI ci and the Librarian kit of Invitroqen according to the

I

instructions included in the kit-. The library was. estimated to contain about iLo' independent recombinants with an average insert size of approximately 1.8 kb.

EXAMpLE 7 2liPlification of a Unique uucieotide sequence encodinmg the P1t4 .igjan a wine terminus Degenerate oligonucleotjd 8 6 were designed based on the N-tenminai amino acid sequence of the isolated huMnan Flt4 Itigand and were used as privers in a POlYmerase chain reaction (Pal) to amplify cDNA encoding the Flt4 ligand fron the PC-3 CDNA library. The overall strateg-y described in Examples 7 and 8 is schematically depicted in Fig. 9, where the different primers have been marked with arrows.

The PCR was carried out using I microgram of DNA from the aupliZie 'd PC-3 ODNA library and a mixture of 483 sense-strand primers present in equal proportionsr the Primer sequences collectively comprising the seq~uence

GCAGARCARACNATIIJ-

3 (SEQ ID NO: 14) (wherein R 3-s A or N, is A, G, C or T and H is A, c or encoding alvino acid residues 2-6 (EETIC, SEQ ID No: 15) and 384 -antisense-strand primers present in equal proportions, the Anti-sense strand primers collectively comprisingi the sequence S'-GCAYrNpARnATncmNGTJ,1 (SEQ ID NO: 16) COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06O0 01/06 2007 17:09 FAX 61 3 92438333 GRIFFITH HACK -)IPAUSTRALIA Um049 0 45 (wherein Y is c or T and D is A, G or corresponding Sto amino acid residues 14-18 (TEILK, SEQ ID NO; 17).

Three extra nucleotides (GCA) were added to the S terminus of each primer to increase annealing stability.

Two successive PCR runs were carried out using 1 U per reaction of DynaZyme (F-500L, Finnzymes, Espoo, Finland), a thermostable DNA polymerase, in a buffer supplied by C the manufacturer (10 mM Tris-HC1, pH 8.8 at 25 C, 1.5 mM MgC1, 50 mM KCI, 0.1% Triton-X100), at an extension temperature of 72c. The first PCR run was carried out Sfor 43 cycles. The first three cycles were run at an C -annealing temperature of 33 C for 2 minutes, and the remaining cycles were run at 42 C for 1 minute. i The region of the gel containing a weak band of the expected size (57 bp) was cut out from the gel and eluted. The eluted material was reamplified for cycles using the Same primer pairs described above at 42 C for 1 minute. The amplified fragment was cloned into a PCR I1 vector (Invitrogen) using the TA cloning kit (Invitrogen) and sequenced using the radioactive dideoxynucleotide sequencing method of Sanger. Six clones were analyzed and all six clones contained the sequence encoding the expected peptide (amino acid residues 104-120 of the Flt4 ligand precursor).

Nucleotide sequence spanning the region from the third nucleotide of codon 6 to the third nucleotide of codon 13 (the extension region) was identical in all six clones: AAC-3, (SEQ ID NO: 18) and thus represented an amplified product from the unique sequence encoding part of the amino terminus of the Flt4 ligand.

EXAMPLE 8 Amplification of the 5'-end of the cDNA encoding the Wlt4 ligand Based on the unique nucleotide.sequence encoding the N-terminus of the isolated human Flt4 ligand, two pairs of nested primers were designed to COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:09 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1050 f the corresponding DNA f one rog of DNA of the above-described PC-3 CDNA library. First, amplification was performed with an equal mixture of 4 S primers collectively defining the sequence 5 o TCNGTGTLGTGTGTGCTG_3, (SEQ ID NO: 19), which is the antisense-strad primer corresponding to amino acid V residues 9-15 (AAITE, SEQ ID NO: 2 0 and snse-strand A primer 5-TAATACGACTCACTATAGG (EQ ID NO: 21) exten s ion 'at3 ea Dl NO: coucd2 1)o corresponding to the T7 PNA promoter of the pcfDNA vector Used for construction of the library. "Touchdwni

PCR

Swas Used as disclosedin Don et u. Acids R S(1991), incorporatd by reference herein The annealing temperature of t two first cycles was 62'C and subsequently the annealing temperatue was decreased in every other cycle by 'C until a final temperature of 53i was reached, t which temperature 16 additional cycles were COnducted. Annealing time Was 1 minute and 2 extension at each cycle was conducted at 72 o for 1 minute. Multiple a jplified DNA fragments were obtained in the first reaction The products of the first admplification (I Al of a 1:100 dilution in water) were Used in the second amplification reaction employing a Pair of nested primers comprising an antisense-strand Primer 51-GTTGTAGGTGCTGCAGCGAATTT3,; SEQ ID NO: 22) encoding amino acid residues 6-13 (KFAAAHYN, SEQ ID NO: 23) of the Flt4 ligand, and a sense-strand primer TCACTATAGGGAGACCCAAGC_3,; SEQ ID NO: 24), corresponding to nucleotides 2179-2199 of the pcDNAIX vector. The sequences of these sense and antisense Primers overlapped with the 3' ends of the corresponding Primers used in the first PCR. "TOUchdown, PCR was carried out by decreasing the annealing temperature from 72"C to 66"C and continuing with 18 additional cycles at 66C. The annealing time was 1 minute and extension at each cycle was carried out at 72 C for 2 minutes. One major product of about 220 bp and three minor products of about 270 bp, 150 bp, and 100 bp COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:09 FAX 61 3 92438333 GRIFFITH.HACK IPAUSTRALIA 1051 47 were obtained.

The amplified fragment of approximately 220 bp Was excised from an agarose gel, cloned into a pcRII vector using the TA cloning kit (Invitrogen), and sequenced. Three recombinant clones were analyzed and they contained the sequence

TCACTATAAGGGAGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAAGGCCGC

AGTGTGGTGGAnTTCGAC LAC'AC

TGACMATA

AA AATCATCAG CA.

ACTC

AA'CTCAAQGACAGAGCAahr-nATO_ GCAT 3' (SEQ ID NO: 25). The beginning of the sequence represents the 0 pcDNAI vector and the underlined sequence represents the amplified product of the 5'-end of the cDNA insert, EXAMPLE 9 Amplification of the 3'-end of cDNA encoding the Plt4 ligand Based upon the amplified 5'-sequence of the clones encoding the amino terxinus of the 23 kD human Flt4 ligand, two pairs of non-overlapping nested primers were designed to amplify the 3 '-portion of the Flt-4ligand-encoding cDNA clones. The sense-strand primer ACAGAGAACAGGCCAACC-3' (SEQ ID NO: 26), corresponding to nucleotides 152-169 of the amplified 5'-sequences of the Plt4 ligand (SEQ ID NO: 25), and antissanse-strand primer S'-TCTAGCATTTAGGTGCACA-3r (SEQ ID NO: 27) corresponding to nucleotides 2311-2329 of the pcDNAI vector were Used in a first "touchdown" FCR. The annealing temperature of the reaction was decreased I'C every two cycles from 72 C to 52C, at which temperature 15 additional cycles were carried out. The annealing time was 1 minute and extension at each cycle was carried out at 72"C for 3 minutes. DNA fragments of several sizes were obtained in the first amplification- Those products were diluted 1:200 in water and reamplified in PCR using the second pair of primers: 5'-AAGAGACTATAAAfTTCGCTGCACC-3' (SEQ ID NO: 28} and 5'-CCCTCTAGATGCATGCTCGA-3' (SEQ ID NO: 29) (antisense-strand primer corresponding to nucleotidbe COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 0 01/06 2007 17:10 FAX 61 3 92438333 GRIFFITH HACK -*IFALSTRALIA Q~052 0 -48ci 27~ z gs fohbPCaAI Ve to Two DNA fragments wer ;Zbaie having sizes Of 1350 b1P and 570 bp. hs fragments aer clone of heCloeswere sequenced. Both of these fragments 0 were found to contain sequenc e nc dnsn a~io a i Sequece homologous to theodVZCFanSemience..

ci Sreening the PC-s cell oDfl library "isnq the ci POR fragment Of Flt ligana

CDXI

0 10 A 219 bp S -te mal fragment Of human Flt4 Cjan DNA was amplified by PCR using the 5' PcR fragmnt~ described above and pribers GTTGTAGTGTGCTGCGCGAATT-3 (antisense-strand primer,

SEQ

ID NO! 30) and S'-TCAaATA-GAGACAA;-3 SQINO 1 331) (sense-priner Corresponding to hUCiaotides 2179-2199 of the POcDNAI vector} The amplified product was 0 d to digestion with BCORI (Boehringer Mannheim) to remove the port-ion of the DNA Seqluence amlplified from the PODUAT vector and the resulting 153 bp fragment encoding the 5' end Of the Flt4 ligand was labeled with 3 2 p,1-cTp using the Klenow fragment of E. qoli

DNA

POlymerase I (Boehringer Mannheim). That fragment was used as a probe for hybridization s1creening of the amplified PC-s cell eDNA library-.

Filter replicas of the library were hybridized With the radioactively labeled probe at 42'C for 20 hours in a solution containing Sot formamide 1 5x SSPE, Derdwxdtts solution, O.k EDS and 0-1 mg/mi denatured gal-won sperm DNA. -Fiters were washed twice in lx 0.1% SDS for 3o minutes at room temperature, then twice for 30 minutes at 65'C and exposed overnight.

On the basis of autoraaiography, 10 Positive recomnbinant bacterial colonies hybridizing with the probe were chosen from the library. Plasmid DNA was puriflied from these colonies and analyzed by EcoRz -and Mo ttI digest ion and agarose gel electrophoresis followea 1w COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:10 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 053 S49 ethidium bromide staining. The ten plasmid clones were divided into three groups on the basis of the presence of insert sizes of approximately 1.7, 1.9 and 2.1 kb, Srespectively. Inserts of plasmids from each group were sequenced using the T7 oligonueleotide as a primer and walking primers for subsequent sequencing reactions.

Sequence analysis showed that all clones Scontain the open reading frame encoding the NH2-terminal sequence of the 23 kD human Plt4 ligand. Dideoxy sequencing-was continued using walking primers in the O downstrea direction. A complete human CDNA sequence and deduced amino acid sequence from a 2 kb clone is set forth in SEQ ID NOs: 32 and 33, respectively. A putative cleavage site of a "prepro" leader sequence is located between residues 102 and 103 of SEQ lD NO: 33. When compared with sequences in the GenBank Database, the predicted protein product of this reading frame was found to be homologous with the predicted amino acid sequences of the PDGF/VEGF family of growth factors, as shown in Fig. 10.

Plasmid pFLT4-L, containing the 2.1 kb human cDNA clone in pcDNAI vector, has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, ROckville, MD 20852 as accession number 97231.

EXAMPLE 11 stimulation of Flt4 autophosphorylation by the protein product of the Plt4 ligand vector The 2.1 kb human ODNA insert of plasmid pFlt4- L, which contains the open reading frame encoding the sequence shown in SEQ ID Nos: 32 and 33; human

VEGF-C,

see below), was cut out from the pcDNAI vector using HfndIII and NotI restriction enzymes, isolated from a preparative agarose gel, and ligated to the corresponding sites in the pREP7 expression vector (Invitrogen). -The pREP7 vector containing the pFlt4-L insert was transfected into 293-EBNA cells (Invitrogen) using.the COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:10 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 054 So Calcium phosphate transfection method (Sambrook et al S1989). About 48 hours after transfection the medium of the transfectod cells was changed to DMEK medium lacking fetal calf serum and incubated for 36 h, The Colditionea medium was thenThe Conditioned e s then collectea, centrifuged at 5000 X g for minut the supe natant was Concentrated 5-fold Using Centriprep 10 (Amicon) and used to stimula

T

Vused to stimulate ?IH 3T3 cells expressing LTRFlt41 (the Flt4 receptor), i Example4 4 4 eetras in 4. The cells Were lysed, infnunoprecipitated using anti-Flt4 antiseru and analyzed by Western blotting using anta-phosphotrosin antibodies.

The Conditioned medium from two different dishes ofthe transfeced cells stimulated Flt4 atophosphorYlati in comparison with the medium from is mocktransfected cells, Which gave only background levels of phosphorylation of the Flt4 receptor When the concentrated conditioned medium was pre-absorbed with microliters of a slurry of Flt4EC domain coupled to (see example no phosphorylation was obtained, shouing that the activity responsible for Flt4 autophosphorylatio was indeed the Flt4 ligand. Thus, these results demonstrate that an expression vector having an approximataly 2.1 kb insert and containing an reading frame as shown in SEQ ID NO; 32 is expressed as a biologically active Flt4 ligand (VEOF-c) in transfected cells The sequence encoded by that open reading frame Is shown in SEQ ID NO: 33.

The deduced molecular weight of a polypeptide Consisting of the complete amino acid sequence in SEQ 1D No: 33 (residues i.to 419) 16 46,883. The deduced Molecular weight of a Polypeptide consisting of amino acid residues 103 to 419 of SEQ ID NO: 33 is 35,881. The Flt ligand purified from PC-3 cultures had an observed molecular weight of about 23 kD as assessed by SS-PAGE under reducing conditions Thus, it appears that the Flt4 ligand mERA is translated into a precursor polypeptide, from which the mature ligand is derived by COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:10 FAX 61 3 92438333 GRIFFITH BACK 4 IPAUSTRALIA 2i055 o- 51 C proteolytic cleavage. Also, the Flt4 ligand may be Z glycosylated at three putative N-linked glycosylation sites conforming to the consensus which can be identified O in the deduced Flt4 ligand amino acid sequence

(N-

residues underlined in Fig. The carboxyl terminal amino acid sequences, which increase the predicted molecular weight of the Flt4 IC ligand subunit in comparison with other ligands of this Sfamily, show a pattern of spacing of cysteine residues reminiscent of the Balbiani ring 3 protein (BR3P) Ssequence (Dignam et al., Gene, 8:133-140 (1990)), as 0 depicted schematically in Fig. 9. Such a sequence may encode an independently folded domain present in a Flt4 ligand precursor and it may be involved, for example, in the regulation of secretion, solubility, stability, cell surface localization or .activity of the Flt4 ligand.

Interestingly, at least one cysteine motif of the BR3P type is also found in the VEGF carboxy terminal amino acid sequences.

Thus, the Plt4 ligand mRNA appears first to be translated into a precursor from the mRNA corresponding to the cDNA insert of plasmid FLT4-L, from which the mature ligand is derived by proteolytic cleavage. To define the mature Flt4 ligand polypeptide, one first expresses the cDNA clone (which is deposited in the pCDNAI expression vector) in cells, such as COS cells.

One uses antibodies generated against encoded Polypeptides, fragments thereof, or bacterial Flt4 fusion Proteins, such as a GST-fusion protein, to raise antibodies against the VEGF-homologous domain and the amino- and carboxyl-terminal propeptides of Flt4 ligand.

One then follows the biosynthesis and processing of the Flt4 ligand in the transrected cells by pulse-chase analysis using radioactive cysteine for labelling -f the cells, immunoprecipitation and gel electrophoresis.

Using antibodies against the three domains of the product encoded by the cDNA insert of plasaid FLT4-L, material COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:11 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA I056 52 for rad ioactive or onradioactive amino-terminal sequence analysis is isolated The determination of the aminoterminal sequence of the mature VEGF-c of leptide allows for Identification of the aino-terminal proteolytic S processin site. The determination of the amino-terminal sequence of the arbolterm propept will iv the caboxyl-termnal processing site. This is confirmed by site-directed Mutagenesis of the amino acid N residues adjacent to the cleavage sites, which wpuld O The Flt4 ligand is further characterizeable by progressive 3" deletions in the 3' coding sequences of (N the Flt4 ligand precursor clone, introducing a stop codon resulting in arboxy-termin tr u cations of its protein e siduDNO t roiatey of 1 2 0 m i no a c id product The activities of such truncated forms are assayed by r for example, studying Flt4 Utophosphorylation induced by the truncated proteins when applied to Cultures of cells, such as NIH 3T3 cells expressing LTRFt4. By extrapolation from studies of the strlcture of the related platelet derived growth factor (PDG, Heldin et al., Growth Factors, 8:245-252 (1993)) one determines that the region critical for receptor activation by the Flt4 ligand is contained within the first approximately 180 amino acid residues of the secreted VEGF-C protein lacking the putative 102 amino acid prepro leader (SEQ ID NO: 33, residues 103-282), and apparently within the first approximately 120 amino acid residues (SEQ ID NO: 33, residues 103-223).

on the other hand, the difference between the molecular weights observed for the purified ligand and dduced from the open reading frame of the Flt4 ligand clone may be due to the fact that the soluble ligand was Produced from an alternatively spliced mRNA which would also be present in the Pc-3 cells, from which the isolated ligand was derived. To isolate such alternative ODNA clones one uses ODNA fragments of the deposited clone and PeR primers made according to the sequence COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:11 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1057 0 53 provided as well as techniques standard in the art to isolate or amplify alternative cDNAs from the PC-3 cell CDNA library. One may also amplify using reverse transcription (RT)-PcR directly from the PC-3 mRNA using the primers provided in the sequence of the cDNA insert of plasmid FLT4-L. Alternative cDNA sequences are determined from the resulting cDNA clones. One can also isolate genomic clones corresponding to the Flt4 ligand O mRNA transcript from a human genomic DNA library using 1i methods standard in the art and to sequence such clones Sor their subcloned fragments to reveal the corresponding exons. Alternive exons can then be identified by a number of methods standard in the art, such as heteroduplex analysis of cDNA and genomic DNA, which are subsequently characterized.

EXAMPLE 12 Ezpression of the Gene Encoding VEGF-C in Human Tumor Cell Lines Expression of transcripts corresponding to the F1t4 ligand (VEGP-C) was analyzed by hybridization of Northern blots containing isolated poly(A)* RNA from

HT-

1080 and PC-3 human tumor cell lines. The probe was the radioactively labelled insert of the 2.1 kb cDNA clone (pFlt4-L/VEGF-C, specific activity lo- 1 0 9 cpm/mg of DNA).

The blot was hybridized overnight at 42 C using formamide, 5x SSPE buffer, 2% SDS, 10 x Denhardt's solution, 100 mg/ml salmon sperm DNA and 1 x 10' cpm of the labelled probe/ml. The blot was washed at room temperature for 2 x 30 minutes in 2x ssc containing 0.05% SDS, and then for 2 x 20 minutes at 52C in 0.lx SSC containing 0.1% SDS. The blot was then exposed at for three days using intensifying screens and Kodak

XAR

film. Both cell lines expressed an Flt4 ligand miDA of about 2.4 kb, as well as VEGF and VEGF-B mRNAs (Fig...12).

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:11 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1058 -54- ZXAXPLE 13 VEGF-C Chins Are otely Poceased Lafter 1 QEanthesjS and Dfbigffide Linked The predicted Molecular mass of a secreted 0 human EPCoasced a5 inEGp'-c Polypeptide, as deaduced from the VEGF-C Open reading frame, is 46,883 kD, Suggesting that VEGF-C IuRNA may be first translated into a precursor, from which the V igans of 21/23 kDa precursor, from which the igands, of 21123 k] and 29/32 kD are derived by o proteolytic cleavage l This possibility was explored by metabblic Slabelling 93 EBA cells expressing VEGP-c.

oInitially, 293 E3NA calls were transfectea with the VEGF-C construct. Expression products were labeled by the addition of 100 ACi/l of Pro-ixh

L-(

5 sj in vitro tell labelling mix ((containing "S-methionine and cysteine) Amersham, Buckinghamshire, England) to the culture inedium devoid or cysteine-and methionine. After two hours, the cell layers were washed twice with PBS and 2 the ediu was then replaced with DMEM-0.2* BSA. After 1, 3, 6, 12 and 24 hours of subsequent incubation, the culture medium was collected, clarireed by centrifugation, and concentrated, and human VEGF-C was bound to 30 ul of a slurry of Flt4EC-Sepharose overnight at t4-c, followed by three washes in PBS, two washes in Mfl Tris-lCI (pH alkylation, SDS-PAGE and autoradiography. Alkylation was carried out by treatment Of the Samples with 1Ol 1,4 Dithiothreitoi (Boehringer- Mannheim, Mannheim, Gemany) for one hour at z52C, and SubsequentLy with 30 WNj iodoacetamide (Fluka, Buchs, Switzerland).

These experiments demonstrated that a putative precursor polypeptide of 32 kD apparent moleculajr mass was bound to the Plt4EC affinity matrix from the conditioned medium of metabolically labelled cells transfocted with the human VEGF-C expression vector (Fig.

13A), but not from mock transfected cells. Increased amounts of a 23 kD receptor binding polypeptide COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:12 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA @059 0 accumulated in the culture medium Of VEGF-C transfected cells during a subsequent chase peiod of three hours, but not thereafter (lanes 2-4 and data not shown) suggesting that the 23 kD form is produced by proteolytic processing, which is incomplete, at least in the transiently transfected cells. The arrows in Fig. 13A indicate the 32 D and 23 kD polypeptides of secreted g VEGF-C subsequent experiments showed that the 32kD SVEGF-C form contains two components migrating in the absence o alkylation as-polypeptides of 29 and 32 kD (Figs. 21-23).

C In a related experiment, human VEGF-C isolated using Flt4EC-sepharose after a 4 h continuous metabolic labelling was analyzed by polyacrylamide gel electrophoresis in nonreducing conditions (Fig. 13B).

Higher molecular mass forms were observed under nonreducing conditions, suggesting that the VEGF-C Polypeptides can form disulfide-linked diners and/or multimers (arrows in Fig. 13B).

EXAMPLE 14 Stimulation Of VEGFR-2 Autophosphorylation By VEGP-C Conditioned medium (CM) from 293 EBNA cells transfected with the human VEGF-C vector also was used to stimulate porcine aortic endothelial (PAE) cells expressing VEGFR-2 (Kdr). Pajusola et al., oncogene, 9:3545-55 (1994); Waltenberger et al., J. Biol. Chem..

269:26988-26995 (1994). The cells were lysed and immunoprecipitated using VEGFR-2 specific antiserum (Waltenberger et al, 1994).

PAE-KDR cells (Waltenberger et al., 1994) vere grown in Ham's F12 medium-10% fetal calf serum

(FCS).

Confluent NIH 3T3-Flt4 cells or PAE-KDR cells were starved overnight in DMEM or Hamrs F12 medium, respectively, supplemented with 0.2% bovine serum albumin (BSA), and then incubated for 5 minutes with the analyzed media. Recombinant human VEGF (R&D Systems) and PDGF-BB, COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:12 FAX 61 3 9243833 3 GRIFFITH HACK IFAUTSTRALIA lamoo 0~ -56i functional as stimulating agents, were Used as controls.

;Z The cell3s were washed twice with ice-cold Tris-enfrered Salie (ES)containing 100o MM sodium Qthovanadate and lysed i1n RIPA buffer containing I MMN PhenYlmethylsulfonyi fluoride, (nxsp) r0.13 U/mi aprotinin and I. mf4 sodium orthoVanadate. The lysates 'were sonicatea, clarified by Centrifugation at Is, 000 X g for 20 minutes and incubated for 3-6 hours on ice with*3-5 gi of antisera specific for ci Flt4 (Pajusola et at-, 1L993),* V.EGFR-2 or PDCFR-l (Claeson..wesh et at-, J. Riol. Chem., 24:174: -1747 (1989)j; Wfaltenberger et atr 1994). Imnaunoprecipitates were bound to protein A-Sepharose, washed three times- ar1, With RIPA buffer containing inN PNSEF, IN sodium orthovanadate, washed twice with 10 maN Tris-liCI (pH 7.4), and subjected to SOS-PAGE using a gel-. Polypeptiaes were transferred to nitrocellulose by Western blottin and analyzed using PY20 Phosphotyrosine-specif 10 .In monfoclonal antibodies (Transduction Laboratories3 or receptor-..specific antiserum and the ECL detection method (Anershan Corp.)- The results of the experiment are prevented in Figs- 14A and 14B. As shown in Fig- 14A, PAE cells expressing VEGPX-2 were stimulated with 10- or 2-fold concentrated mnedium from mock-transrectea 293-EDNA cells (lanes I and or with 5- or 10-fold concentrated) medium, from 2 93-EBNA cell cultures expressing the recombinant VEGF-C (lanes VEGFR-2 was imlnunopreipitated with specific antibodies and analyzed by SDS-PAGE and Western blotting using phosphotyros ine antibodies. For comparison. the stimuation were carried out with Don-conditioned tuedtiuu containing so ng/ml of purified recombinant VEGF (lanes 7 and Lanes 6 and 7 show stimunlation with VEGF-c- or VBGFcontaining media pretreated with Plt4Ec. As depioAed in Fig. 14B, PDGFR-q-expressjng NIH 3T3 cells were stimlulated with non-conditioned medium (lane concentrated CK from flock-traarectea (lane 2) or VRGF-C COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:12 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 0061 57 S- transfected (lanes 3 and 4) cells, or with Z fnon-conditioned medium containing 50 ng/ml of recombinant human PDGF-BB (lane Medium containing VEGF-C was Salso pretreated with recombinant Flt4EC (lane

PDGFR-

was immunoprecipitated with specific antibodies and analyzed by SDS-PAGE and Western blotting using phosphotyrosine antibodies with subsequent stripping and S reprobing of the membrane with antibodies Specific for 0. PDGFR-p- Referring again to Fig. 14A, a basal level of O tyrosine phosphorylation of VEGFR-2 was detected in cells stimulated by CM from the mock-transfected cells.

A

further concentration of this medium resulted in only a slight enhancement of VEGFR-2 phosphorylation (lanes 1 and CM containing recombinant VEGF-C stimulated tyrosine autophosphorylation of VEGFR-2 and the intensity of the autophosphorylated polypeptide band was increased upon concentration of the VEGF-C CM (lanes Furthermore, the stimulating effect was abolished after pretreatment of the medium with the Flt4EC affinity matrix (compare lanes 1, 5 and The maximal effect of VEGF-C in this assay was comparable to the effect of recombinant VEGF added to unconditioned medium at concentration of 50 ng/ml (lane-8). Pretreatment of the medium containing VEGF with F1t4EC did not abolish its stimulating effect on VEGPR-2 (compare lanes 7 and 8).

These results suggest that the VEGF-C expression vector encodes a ligand not only for Flt4 (VEGFR-3), but also for VEGFR-2 (Kdr).

In order to further confirm that the stimulating effect of VEGF-C on tyrosine phosphorylation of VEGFR-3 and VEGFR-2 was receptor-specific, we analyzed the effect of VEGF-C on tyrosine phosphorylation of PDGF receptor P (PDGFR-$) which is abundantly expressedron fibroblastic cells. As can be seen from Fig. 14B, 4 weak tyrosine phosphorylation of PDGFR- was detected upon stimulation of Flt4-expressing NIH 3T3 cells with CM from COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:13 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 1@062 58 the mock-transfected cells (compare lanes -1 and

A

similar low level f PDGFR- phosphorylation was obseved Shen the cevlls ere incubated with CM from the VEGF-C transfected ells, with or without prior treatment with S Flt4EC (lanes 3 and In contrast, the addition of ng/ml of PDGF-BB induced a. promient tyrosine autophosphrylation of PDGFR-5 (lane ci EXAMPLE 010

V

EG

P-C Stimulates Endothelial cell 0 Migration In Collages Gel Conditioned media from cell cultures transfected with the VEGF-C expression vector was placed in a well made in collagen gel and used to stimulate the migration of bovine capillary endothelial (BCE) cells in the threer-dimensional collagen gel as follows.

BCE cells (Folkman et al, Proc. Natl. Acad.

Sc. 76:5217-5221 (1979) were cultured as described in Pertovaara et al., Biol. Chem., 269:6271- 74 (1994t. The collagen gels were prepared by mixing type I collagen stock solution (5 mg/ml in 1 mM HC1) with an equal volume of 2x MIEM and 2 volumes of HEM containing newborn calf serum to give a final collagen concentration of 1.25 mg/ml. The tissue culture plates cm diameter) were coated with about 1 mm thick layer f the solution, which was allowed to polymerize at 37C.

BCE cells were seeded on top of this layer. Por the migration assays, the cells were allowed to attach inside a plastic ring (1 c diameter) placed on top of the first collagen layer. After 30 minutes, the ring was removed and unattached cells were rinsed away. A second layer of collagen and a layer of growth medium newbotn calf serum solidifiea by 0.75% low melting point agar (FMC BioProdUcts, Rockland, ME), were added. A well-(3 Im diameter) was punched through all the layers on both sides of the cell spot at a distance of 4 mm, and the sample or control media were Pipetted daily into the COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:13 FAX 61 3 92438333 GRIFFITH HACK 4 IAUSTALIA IN083 0 S9 Swells. Photomicrographs of the cells migrating out from the spot edge were taken after six days through an 2 Olympus CK 2 .inverted microscope equipped with O phase-contrast optics. The migrating cells were counted after nuclear staining with the fluorescent dye bisbenzimide (1 mg/ml, Hoechst 33258, Sigma).

Fig. 15 depicts a comparison of the number of cells migrating at different distances frbo the original Sarea of attachment towards wells containing media conditioned by the non-transfected (control) or transfected (mock; VEGF-C; VEGF) cells, 6 days after C addition of the media. The number of cells migrating out from the original ring of attachment was counted in five adjacent 0.5 am x 0.5 mm squares using a microscope ocular lens grid and 10x magnification with a fluorescence microscope. Cells migrating further than am were counted in a similar way by moving the grid in 0.5 mm steps. The experiments were carried out twice with similar results, and medium values from the one of the experiments are presented with standard error bars.

As can be seen from the columns, VEGF-C-containing

CM

stimulated cell migration more than medium conditioned by the non-transfected or mock-transfected cells but less than medium from cells transfected with a VEGP expression vector. Daily addition of 1 ng of FGF2 into the wells resulted in the migration of approximately twice the number of cells when compared to the stimulation by CM from VEGF-transfected cells.

EXAMPLE 16 VEGP-C Is Expressed In Multiple Tissues Northern blots containing 2 micrograms of isolated poly(A)* RNA from multiple human tissues (blot from Clontech Laboratories, Inc., Palo Alto, CA) were probed with radioactively labelled insert of the 2,X kb VEGF-C CDNA clone. Northern blotting and hybridization analysis showed that the 2.4 kb RNA and smaller amounts COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/08 2007 17:13 FAX 81 3 92438333 GRIFFITh HACK IPAUSTRALIA ~I084 01/06 2007 17:13 FAX 61 3 92438333 GRIFFITH HACK IFAUSTRALIA Z0644 0 o Ofa 2.o kb mRNA are expressed in multiple human. tssues, most prominently in the heart, lacenta, muscle, ovary and small intestine (Fig. 16A). Very little VEGF-C

RNA

was seen in the brain, liver or thymus and peripheral blood leukocytes (PBL) appeared negative. A similar analysis of RNA from hutan fetal tissues (Fig. 16B) shows that VEGF-C is highly expressed in the kidney and lung and to a lesser degree in the liver, while essentially no expression is dtected in thebrain. nterestingly,

VEG

epression correlates with VEGF-C expression in these Stissues, whereas VEGF-B is highly expressed in all Stissues analyzed.

EXAMPLE .7 The VEGF-C Gene Localizes To Chromosome 4q34 A DNA panel of 24 interspecies somatic cell ybrids, which had retained one or two human chromosomes, was used for the chromosomal localization of the VEGF-C gene (Bios Laboratories, Inc., New Haven, CT). Primers were designed to amplify an about 250 bp fragment of the VEGF-C gene from somatic cell hybrid DNA. The primers and conditions for polymerase chain reaction (PCR) were 3 (forward) [SEQ ID NO; 34] and s5-TATTGCAGCAACCCCCACATCT-3' (reverse) [SEQ ID NO: for VEGF-c (94 C, 60s/62'C, 45s/72C, 60s). The PCR products were evaluated by electrophoresis in 1% agarose 0 gels and visualized by ethidium bromide staining in ultraviolet light. a 3 zP-dCTP- labelled cDNA inserts of a plasmid representing the complete VEGF-C coding domain was used as a probe in Southern blotting and hybridization analysis of the somatic cell hybrid DNAs as instructed by the supplier (Bios Laboratories)..

The cell lines for fluorescence in situ hybridization (FISH) were obtained from the America. Type Culture Collection (Rockville, MD). Purified DNA from P1 clones 7660 and 7661 (VEGF-C) (Gename Systems, Inc., St.

Louis, MO) were confirmed positive by Southern blotting COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:14 FAX 61 3 92438333 GRIFFITH HACK 4, IFAUSTRALIA 0065 0 -61 Sof EcoRI- digested DNA followed by hybridization with the VEGF-C CDNA. The P1 clones were then labelled by nick translation either with biotin-11-dUTp, biotin-14-ATP O (Sigma Chemical Co., st. Louis, MO) or digoxigenin 11-dUTP (Boehringer Mannheim GmbH, Mannheim, Germany) according to standard protocols. PHA-stimulated Speripheral blood lymphocyte cultures were treated with (BrdU) at an early replicating phase c to induce G-banding. See Takahashi et al., Human Genet., 86:14-16 (1995); Lemieux et al., Cytogenet. Cell Genet.

0 59:311-12 (1992). The FISH procedure was carried out in c 50% formamide, 10% dextran sulphate in 2x SSC using well- Sknown procedures- See Rytk3nnen et al., Cytogenet Cell Genet., 68:61-63 (1995); Lichter et al., Proc. Natl.

Acad. Sci. (USA), 85:9664-68 (1988). Repetitive sequences were suppressed with 50-fold excess of Cot- DNA (BRL, Gaithersburg, MD) compared with the labeled probe. Specific hybridization signals were detected by incubating the hybridized slides in labelled antidigoxigenin antibodies, followed by counterstaining with O.1mmol/L 4,6-diamino-2-phenylindole. Probe detection for two-color experiments was accomplished by incubating the slides in fluorescein isothiocyanate (FITC)-anti-digoxigenin antibodies (Sigma Chemical co.) and Texas red-avidin (Vector Laboratories, Burlingame, CA) or rhodamine-anti-digoxigenin and FITC-avidin.

Multi-color digital image analysis was used for acquisition, display and quantification of hybridization signals of metaphase chromosomes. The system contains a PXL camera (Photometrics Inc., Tucson, AZ) attached to a PowerMac 7100/Av workstation. IPLab software controls the camera operation, image acquisition and Ludl Filter wheel. At least 50 nuclei were scored. Overlapping nuclei and clusters of cells were ignored. A stide containing normal lymphocyte metaphase spreads and I- interphase nuclei was included in each experiment to control for the efficiency and specificity of the COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:14 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA [066 o 62- N hybridization.

In order to determine the chromosomal Slocalization of the human VEGF-C gene, DNAs from human rodent somatic cell hybrids containing defined sets of S human chromosomes were analyzed by Southern blotting and hybridization with the VEGF-C cDNA probe. Among 24 DNA Samples on the hybrid panel, representing different human Shromosomes human-specific signals were observed only in hybrids which contained human chromosome 4. The results 0 were confirmed by PCR of somatic cell hybrid DNAs using gVEGF-C Specific primers, where amplified bands were Sobtained only from DNAs containing human chromosome 4.

c A genomic p l plasmid for VEGF-C was isolated using specific primers and PCR and verified by Southern blotting and hybridization using a VEGF-C specific cDNA probe. The chromosomal localization of VEGP-C was further studied using metaphase FISH. Using the 1F probe for VEGF-c in FISH a specific hybridization to the 4q34 chromosomal band was detected in 40 out of 44 metaphases.

Double-fluorochrome hybridization using a cosmid probe specific for the aspartylglucosaminidase (AGA) gene showed that VEGF-C is located just proximal to the AGA gene previously mapped to the 4q34-35 chromosomal band.

Biotin labelled VEGF-C P1 and digoxigenin labeled AGA cosmid probes were hybridized simultaneously to metaphase chromosomes- This experiment demonstrated that the AGA gene is more telomerically located than the VEGP-C gene. The foregoing example demonstrates the utility of polynucleotides of the invention as chromosomal markers and for the presence or absence of the VEGF-C gene region in normal or diseased cells. The VEGF-c locus at 4q34 is a candidate target for mutations leading to vascular malformations or cardiovascular diseases.

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:14 FAX 61 3 92438333 GRIFFITH HACK 4IPAUSTRALIA Z0677 63 EXAMPLE 18 ;Z Effect of glucose concentration and hypoxia on SVEGF, VEGF-B and VEGF-C mRNA o levels in CS glioblastoma cells Confluent cultures of C6 cells (ATCC CCL 107) were grown on 10 cm diameter tissue culture plates Scontaining 2.5 ml of DMER and 5% fetal calf serum plus antibiotics. The cultures were exposed for 16 hours to o normoxia in a normal cell culture incubator containing C 10 5% Co z or hypoxia by closing the culture plates in an Sairtight glass chamber and burning a piece of wood inside o until the flame was extinguished due to lack of oxygen.

Polyadenylated RNA was isolated (as in the other 6 examples), and 8 micrograms of the RNA was electrophoresed and blot-hybridized with a mixture of the VEGF, VEGF-B and VEGF-C probes (see Fig. 12). The results show that hypoxia strongly induces VEGF mnUA expression, both in low and high glucose, but has no significant effect on the VEGF-B mRNA levels. The VEGF-C mRNA isolated from hypoxic cells rdns slightly faster in gel electrophoresis and an extra band of faster mobility can be seen below the upper mRNA band. This observation suggests that hypoxia affects VEGF-C RNA processing. One explanation for this observation is that VEGF-C mRNA splicing is altered, affecting the VEGF-C open reading frame and resulting in an alternative VEGF-C protein being produced by hypoxic cells. Such alternative forms of VEGF-C and VEGF-C-encoding polynucleotides are contemplated as an aspect of the invention. This data indicates screening and diagnostic utilities for polynucleotides and polypeptides of the invention, such as methods whereby a biological sample is screened for the hypoxia-induced form of VEGF-C and/or VEGF-C mRNA.

The data further suggests a therapeutic indicationfor antibodies and/or other inhibitors of the hypoxia-induced form of VEGF-C or the normal form of VEGF-C.

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:14 FAX 61 3 92438333 GRIFFITH HACK -IPAUTSTRALIA R068 0 64 EXAMPLE 19 Pulse-chase labeling and immuopreaipjtation of VEGP-C polYpeptides from 293 EBNA cells transfected with VEGF-c expression vector.

The following VEGF-C branched amino-terminal peptide, designated PAM126, was synthesized for production of anti-VEGF-C antiserum- NH2-E-E-T-I-K-F-A-A-A-H-Y-N-T-E-I-L-K-COOH (SEQ ID NO: 39).

In particular, PAM126 was synthesized as a branched polylysine structure K3PA4 having four peptide acid (PA) Schains attached to two available lysine residues..

The synthesis was performed on a 433A Peptide Synthesizer (Applied Biosystems) using Fmoc-chemistry and TentaGel

S

MAP RAM10 resin mix (RAPP Polymere GmbH, Tubingen, Germany), yielding both cleavable and resin-bound peptides. The cleavable peptide was purified via reverse phase HPLC and was used together with the resin-bound Peptide in immunizations. The correctness of the synthesis products were confirmed using mass-spectroscopy (Lasermatt).

The PAM126 peptide was dissolved in phosphate buffered saline (PBS), mixed with Freund's adjuvant, and used for immunization of rabbits at bi-weekly intervals using methods standard in the art (Harlow and Lane, Antibodies, a laboratory manual, Cold Spring Harbor Laboratory Press (1988)). Antisera obtained after the fourth booster immunization was used for immunoprecipitation of VEGF-C in pulse-chase experiments, as described below.

For-pulse-chase analysis, 293 EBNA cells transfected with a VEGF-C expression vector the FLT4-L cDNA inserted into the pREP7 expression vector as described above) were incubated for 30 minutes in methionine-free, cysteine-free, serum-free DMEM culture medium at 37 C. The medium was then changed, and 200 1 YCi of Pro-mix (Amersham), was added. The cell layers were incubated in this labeling medium for two hours, washed COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:15 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA U069 0 0- 65 Swith PBS, and incubated for 0, 15, 30, 60, 90, 120, or ;Z 180 minutes in serum-free DMEM (chase). After the various chase periods, the medium was collected, the o cells were again washed two times in PBS, and lysed in immunoprecipitation buffer. The VEGF-C polypeptides were analyzed from both the culture medium and from the cell lysates by.immunoprecipitation, using the VEGF-C-specific 3 antiserum raised against the NHz-terminal peptide (PAM126) c of the 23 kD VEGF-C form. Immunoprecipitated polypeptides were analyzed via SDS-PAGE followed by o autoradiography.

i Referring to Fig. 19, the resultant autoradiograms demonstrate that immediately after a 2 hour labeling (chase time the VEGF-C vectortransfected cells contained a radioactive 55 kD polypeptide band, which is not seen in mock-transfected cells This 55 kD polypeptide band gradually diminishes in intensity with increasing chase periods, and is no longer detected in the cells by 180 minutes of chase. A 32 kD polypeptide band also is observed in VEGF-C transfected cells (and not mock-transfected cells). This 32 kD band disappears with similar kinetics to that of the 55 kD band. Simultaneously, increasing amounts of 32 kD (arrow) and subsequently 23 kD (arrow) and 14 kD polypeptides appear in the medium.

Collectively, the data from the pulse-chase experiments indicate that the 55 kD intracellular polypeptide represents a pro-VEGF-C polypeptide, which is not secreted from cells, but rather is first proteolytically cleaved into the 32 kD form. The 32 kD form is secreted and simultaneously further processed by proteolysis into the 23 kD and 14 kD forms. Without intending to be limited to a particular theory, it is believed that processing of the VEGF-C precursor"occurs as removal of a signal sequence, removal of the COOH-terminal domain (BR3P), and removal of an amino terminal polypeptide, resulting in a VEGF-C polypeptide COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/00 2007 17:15 FAX 01 3 92438333 GRIFFITh HACK IPAUSTRALIA [~]070 01/06 2007 17:15 FA48 61 3 92438333 GRIFFITH BACK 4, IPAUSTRALIA 0 66- 1 having the TEE... amino terminus.

At high resolution, the 23 kD polypeptide band appears as a closely-spaced polypeptide doublet, Ssuggesting heterogeneity in cleavage or glycosylation.

EXAMPLE SIsolation of House and Quail e CDA Clones Encoding VEGFc To clone a mouse variant of VEGF-C, approximately 1 x 106 bacteriophage lambda clones of a commercially-available 12 day mouse embryonal cDNA library (lambda EXlox library, Novagen, catalog number 69632-1) were screened with a radiolabeled fragment of human VEGF-C cDNA containing nucleotides 495 to 1661 of SEQ ID NO: 32. One positive clone was isolated.

A 1323 bp EcORI/HindIII fragment of the insert of the isolated mouse cDNA clone was sub c loned into the corresponding sites of the pBluescript SK+ vector (Stratagene) and sequenced. The cDNA sequence of this clone was homologous to the human VEGF-C sequence reported herein, except that about 710 bp of sequence present in the human clone was not present in the mouse clone.

For further screening of mouse cDNA libraries, a HindIII-BstXI (RindIII site is from the pBluescript

SK+

polylinker) fragment of 881 bp from the coding region of the mouse CDNA clone was radiolabeled and used as a probe to screen two additional mouse cDNA libraries. Two additional cDNA clones from an adult mouse heart ZAP II cDNA library (stratagene, catalog number 936306) were identified. Three additional clones also were isolated from a mouse heart 5'-stretch-plus cDNA library.in Xgtll (Clontech Laboratories, Inc., catalog number MLS002b).

Of the latter three clones, one was found to contain an insert of about 1.9 kb. The insert of this cDNA clone was subcloned into EcoRI sites of pBluescript SK+ vector and both strands of this clone were completely sequenced, resulting in the nucleotide and deduced amino acid- COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:15 FAX 61 3 92438333 GRIFFITH HACK -*IPAUSTRALIA Z5071 0 67 l sequences shown in SEQ ID Nos: 40 and 41.

It is contemplated that the polypeptide corresponding to SEQ ID NO: 41 is processed into a mature mouse VEGF-C protein, in a manner analogous to the processing of the human VEGF-C prepropeptide. Putative cleavage sites for the mouse protein are identified using pnrocedures outlined above for identification of cleavage Ssites for the human VEGF-C polypeptide.

SThe foregoing results demonstrate the utility of polynucleotides of-the invention for identifying and Sisolating polynucleotides encoding other non-human c mammalian variants of VEGF-C Such identified and isolated polynucleotides, in turn, can be expressed (using procedures similar to those described in preceding examples) to produce recombinant polypeptides corresponding to non-human mammalian variants of VEGP-C.

The mouse and human VEGF-C sequences were used to design probes for isolating a quail VEGF-C cDNA from a quail cDNA library. A fragment of the human VEGF-C cDNA comprising nucleotides 495-1670 of SEQ ID NO: 32 was obtained by PCR amplification, cloned into the pCRII vector (Invitrogen) according to the manufacturer's instructions, and amplified. The insert was isolated by Eco RI digestion and preparative gel electrophoresis and then labelled using radioactive dCTP and random priming.

A cDNA library made from quail embryos of stage E-4 in pcDNA-i vector (Invitrogen) was then screened using this probe. About 200,000 colonies were plated and filter replicas were hybridized with the radioactive probe.

Nine positive clones were identified and secondarily plated- Two of the nine clones hybridized in'secondary screening. The purified clones (clones 1 and 14) had approximately 2.7 kb Eco RI inserts. Both clones-were amplified and then sequenced using the T7 and SP6 primers (annealing to the vector). In addition, an internal Sph I restriction endonuclease cleavage site was identified COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:16 FAIX 61 3 92438333 GRIFFITH HACK SIPAUSTRALIA 0 072 S 68 about 1.9 kb from the T7 primer side of the vector and Sused for subcloning and Sph I fragments, followed by sequencing from the Sph I end .of the subclones. The equences obtained were identical from both clones and showed high degree of similarity to the human VEGF-c coding region. Subsequently, walking primers were made in both directions and double~stranded sequencing was gcompleted for 1743 base pairs, including the full-length O open reading frame.

The c DNA sequence obtained includes a: long open reading frame and 5' untranslated region. The DNA and deduced amino acid sequences for the quail cDNA are set forth in SEQ ID NOs: 52 and 53, respectively. As shown in Fig. 8, the human, murine, and avian (quail)

VEGF-C

precursor amino acid sequences share a significant degree of conservation- This high degree of homology permits the isolation of VEGF-C encoding sequences from other species, especially vertebrate species, and more particularly mammalian and avian species, using polynucleotides of the present invention as probes and using standard molecular biological techniques such as those described herein.

EXAZPLE 21 N-terminal peptide sequence analyses of recombinant

VEGF-C

Cells (293 EBNA) transfected with VEGF-C cDNA (see Example 13) secrete several forms of recombinant VEGF-C (Fig. 21A, lane IP). In the absence of alkylation, ththree major, proteolytically-processed forms of VEGP-C migrate in SDS-PAGE as proteins with apparent molecular masses of 32/29 kD (doublet), 21 kD and 15 kD, Two minor polypeptides exhibit approximate molecular masses of 63 and 52 lD, respectively. Ole of these polypeptides is presumably a glycosylated and nonprocessed form; the other polypeptide is presumably glycosylated and partially processed.

To determine sites of proteolytic cleavage of COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:16 FAX 61 3 92438333 GRIFFITH HACK -*IPAUSTRAILIA Z0o73 0 0 69 C the VEGF-C precursor, an-immunoaffinity column was used ;Z to purify VEGF-C polypeptides from the conditioned medium of 293 EBNA cells transfected with VEGF-C cDNA. To O prepare the immunoaffinity column, a rabbit was immunized with a synthetic peptide corresponding to amino acids 104-120 of SEQ ID NO: 33: HZN-EETIKFAAAHYNTEILK (see PAM126 in Example 19). The IgG fraction was isolated c from the serum of the immunized rabbit using protein A C Sepharose (Pharmacia). The isolated IgG fraction was covalently bound to CNBr-activated Sepharose CL-4B o (Pharmacia) using standard techniques at a concentration Ci of 5 mg IgG/ml of Sepharose. This immunoaffinity matrix was used to isolate processed VEGF-C from 1.2 liters of the conditioned medium

(CM).

The purified material eluted from the column was analyzed by gel electrophoresis and Western blotting.

Fractions containing VEGF-C polypeptides were combined, dialyzed against 10 mM Tris HC1, vacuum-dried, electrotransferred to Immobilon-P (polyvinylidene difluoride or PVDF) transfer membrane (Millipore, Marlborough, MA) and subjected to N-terminal amino acid sequence analysis.

The polypeptide band of 32 kD yielded two distinct sequences: NHa-FESGLDLSDA_-- and NH 2 AVVTQTPAS... (SEQ ID NO: 51), the former corresponding to the N-terminal part of VEGF-C after cleavage of the signal peptide, starting from amino acid 32 (SEQ ID NO: 33), and the latter corresponding to the kappa-chain of IgG, which was present in the purified material due to "leakage" of the affinity matrix during the elution procedure.

In order to obtain the N-terminal peptide sequence of the 29 kD form of VEGF-C, a construct

(VEGF-C

NHis) encoding a VEGF-C variant was generated.

I

particular, the construct encoded a VEGF-C variant that fused a GxHis tag to the N-terminus of the secreted precursor between amino acids 31 and 33 in SEQ.ID COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:16 FAX 61 3 92438333 GRIFFITH HACK 4, IPAUSTRALIA 074 0 70 NO; 33). The phenylalanine at position 32 was removed to prevent possible cleavage of the tag sequence during Ssecretion of VEGF-C. The VEGF-C NHis construct was Scloned into pREP as a vector; the construction is described more fully in Example 28, below.

The calcium phosphate co-precipitation technique was used to transfet VEGF-C Nuis into 293 EBNA l cells. Cells were incubated in DMEM/10% fetal calf serum O in 15 cm cell culture dishes (a total of 25 plates). The following day, the cells were reseeded into fresh culture Sdishes (75 plates) containing the same medium and eq incubated for 48 hours. Cell layers were then washed once with PBS and DMEM medium lacking FCS was added.

Cells were incubated in this medium for 48 hours and the medium was collected, cleared by centrifugation at 5000 x g and-concentrated 500X using an Ultrasette Tangential Flow Device (Filtron, Northborough, MA), as described in Example 5 above. VEGF-C NHis was purified from the concentrated conditioned medium using TALON' Metal Affinity Resin (Clontech Laboratories, Inc.) and the manufacturer's protocol for native protein purification using imidazole-containing buffers. The protein was eluted with a solution containing 20 mM Tris-HCl (pH 100 mM NaCI, and 200 mM imidazole. The eluted fractions containing purified VEGF-C NHis were detected by immunoblotting with Antiserum 882 (antiserum from rabbit 882, immunized with the PAM-126 polypeptide) Fractions containing VEGF-C NHis were combined, dialyzed and vacuum-dried. As can be seen in Fig. 27, due to the presence of the 6xHis tag at the N-terminus of this form of VEGF-C, the upper component of the major doublet of the VEGF-CNHis migrates slightly slower than the 32 kD form of wild type VEGF-C, thereby improving the separation of the VEGF-CNHis 32 kD variant from the-29

KD

band using SDS-PAGE. Approximately 15 jg of the purified VEGF-C were subjected to SDS-PAGE under reducing conditions, electrotransferred to Immobilon-P

(PVDF)

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:17 FAX 61 3 92438333 GRIFFITH HACK -*IPAUSTRALIA 20o75 S-71ci Stransfer membrane (Millipore, Inc., Marlborough, MA) and the band at 29 kD was subjected to N-terminal amino acid sequence analysis. This sequence analysis revealed an N- O terminal sequence of H2N-SLPAT corresponding to amino acids 228-232 of VEGF-C (SEQ ID NO: 33).

The polypeptide band of 21 kD yielded the sequence HzN-AHYNTEILKS corresponding to an amino-terminus Ci starting at amino acid 112 of SEQ ID NO: 33. Thus, the 0 prdteolytic processing site which results in the 21 kD form of VEGF-C produced by transfected 293 EBNA cells apparently occurs nine amino acid residues downstream of Ci the cleavage site which results in the 23 kD form of VEGF-C secreted by PC-3 cells.

The N-terminus of the 15 kD form was identical to the N-terminus of the 32 kD form (NH 2

-FESGLDLSDA...).

The 15 kD form was not detected when recombinant VEGF-C was produced by COS cells. This suggests that production of this form is cell lineage specific.

Example 22 Dimerio and monomeric forms of VEGF-C The composition of VEGF-C dimers was analyzed as follows. Cells (293 EBNA Cells), transfected with the pREP7 VEGF-C vector as described in Example 11, were metabolically labelled with Pro-mix L-[3S] labelling mix (Amersham Corp.) to a final concentration of 100 MCi/ml.

In parallel, a VEGF-C mutant, designated "RI02S", was prepared and analyzed. To prepare the DNA encoding VEGF-C-R102S, the arginine codon at position 102 of SEQ ID NO: 33 was replaced with a serine codon. This VEGF-C-R102S-encoding DNA, in a pREP7 vector, was transfected into 293 EBNA cells and expressed as described above. VEGF-C polypeptides were immunoprecipitated using antisera 882 (obtained by immunization of a rabbit with a polypeptide corresponding to residues 104-120 of SEQ ID NO: 33 (see previous Example)) and antisera 905 (obtained by immunization of a COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:17 FAX 61 3 92438333 GRIFFITH HACK -)IPAUSTRALIA 0076~ 0 o 72- C rabbit with a polypeptide corresponding to a portion of the prepro- VEGF-C leader: H2N-ESGLDLSDAEPDAGEATAYASK (residues 33 to 54 of SEQ ID NO: 33).

O The immunoprecipitates from each cell culture were subjected to SDS-PAGE under non-denaturing conditions (Fig. 21B). Bands 1-6 were cut out from the gel, soaked for 30 minutes in Ix gel-loading buffer C containing 200 mM -maercaptoethanol, and ihdividually Ssubjected to SDS-PAGE under denaturing conditions (Figs.

21A and 21C, lanes 1-6).

0 As can be seen from Figures 21A-C, each high Smolecular weight form of VEGF-C (Fig. 21B, bands 1-4) consists of at least two monomers bound by disulfide bonds (Compare Figs. 21A and 21C, lanes 1-4, in the reducing gels). The main component of bands 1-3 is the doublet of 32/29 kD, where both proteins are present in an equimolar ratio. The main fraction of the 21 kD form is secreted as either a monomer or as a homodimer connected by means other than disulfide bonds (bands 6 and lanes 6 in Figs. 21A-C).

The R102S mutation creates an additional site for N-linked glycosylation in VEGF-C at the asparagine residue at position 100 in SEQ ID NO: 33. Glycosylation at this additional glycosylation site increases the apparent molecular weight of polypeptides containing the site, as confirmed in Figures 21A-C and Figures 22A-B.

The additional glycosylation lowers the mobility of forms of VEGF-C-R102S that contain the additional glycosylation site, when compared to polypeptides of similar primary structure corresponding to VEGF-C. Figures 21A-C and Figures 22A-B reveal that the VEGF-C-R102S polypeptides corresponding to the 32 kO and 15 kD forms of it VEGF-C exhibit increased apparent molecular weights, indicating that each of these polypeptides contains the newlyintroduced glycosylation site. In particular, the VEGF- C-R102S polypeptide corresponding to the 15 kD polypeptide from VEGF-C comigrates on a gel with the 21 COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:17 FAX 61 3 92438333 GRIFFITH HACK 4 IAUSTRALIA [077 S- 73 SkD form of the wild type (wt) VEGF-C, reflecting a shift ;Z on the gel to a position corresponding to a greater apparent molecular weight. (Compare lanes 4 in Figures O 21A and 21c).

In a related experiment, another VEGF-C mutant, designated "R226,227S," was prepared and analyzed. To IC prepare a DNA encoding VEGF-C-R226,227S, the .arginine Ccodons at positions 226 and 227 of SEQ ID'NO: 33 were 0 replaced with serine codons by site-directed mutagenesis.

The resultant DNA was transfected into 293 EBNA cells as Sdescribed above and expressed and analyzed under the same

C

conditions as described for VEGF-C and VEGF-C-R102S. In the conditioned medium from the cells expressing VEGP-C- R226,227S, no 32 kD form of VEGF-C was detected. These results indicate that a c-terminal cleavage site of wildtype VEGF-C is adjacent to residues 226 and 227 of SEQ ID NO: 33, and is destroyed by the mutation of the arginines to serines. Again, the mobility of the 29 kD component of the doublet was unchanged (Figures 22A-B).

Taken together, these data indicate that the major form of the processed VEGF-C is a heterodimer consisting of a polypeptide of 32 kD containing amino acids 32-227 of the prepro-VEGF-C (amino acids 32 to 227 in SEQ ID NO: 33) attached by disulfide bonds to a polypeptide of 29 kD beginning with amino acid 228 in SEQ ID NO: 33. These data are also supported by a comparison of the pattern of immunoprecipitated, labelled VEGP-C forms using antisera 882 and antisera 905.

When VEGF-C immunoprecipitation was carried out using conditioned medium, both antisera (882 and 905) recognized some or all of the three major processed forms of VEGF-C (32/29 kD, 21 kD and 15 kD). When the conditioned medium was reduced by incubation in the presence of 10 mM dithiothreitol for two hours at-room temperature with subsequent alkylation by additional incubation with 25 mM iodoacetamide for 20 minutes at room temperature, neither antibody precipitated the 29 kD COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:18 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1078 o 74 component, although antibody 882 still recognized ;Zpolypeptides of 32 kD, 21 kD and 15 kD. These results are consistent with the nature of the oligopeptide antigen used to elicit the antibodies contained in antisera882, an oligopeptide containing amino acid residues 104-120 of SEQ ID NO: 33. On the other hand, 4 antisera 905 recognized only the 32 kD and 15 kD SPolypeptides, which include sequence of the oligopeptide (amino acids 33 to 54 of SEQ ID NO: 33) used for immunization to obtain antisera 905. Taking into account o the mobility shift of the 32 kD and 15 kD forms, the immunoprecipitation results with the R102S mutant were

C

similar (Pigs. 23A-B). The specificity of antibody 905 is confirmed by the fact that it did not recognize a VEGF-C AN variant form wherein the N-terminal propeptide spanning residues 32-102 of the unprocessed polypeptide had been deleted (Fig. 23B).

The results of these experiments also demonstrate that the 21 kD polypeptide is found in heterodimers with other molecular forms (see Figs. 21A-C and Figs. 22A-B), and secreted as a monomer or a homodimer held by bonds other than disulfide bonds (Figs.

21A and 218, lanes 6).

The experiments disclosed in this example demonstrate that several forms of VEGF-C exist.

A

variety of VEGF-C monomers were observed and these monomers can vary depending on the level and pattern of glycosylation. In addition, VEGF-C was observed as a multimer, for example a homodimer or a heterodimer. The processing of VEGP-C is schematically presented in Fig.

18 (disulfide bonds not shown). All forms of VEGF-C are within the scope of the present invention.

Example 23 In situ Hybridization of Mouse Embryos To analyze VEGF-C mRNA distribution in different cells and tissues, sections of 12.5 and 14.5- COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:18 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA lit079 7 Sday post-coitus mouse embryos were prepared and ;Z analyzed via in situ hybridization using labeled VEGF-C probes. In situ hybridization of tissue sections was O performed as described in Vstrik et al., J. Cell Biol., 128:1197-1208 (1995). A mouse VEGF-C antisense RNA probe was generated from linearized pBluescript II SK+ plasmid (Stratagene Inc., La Jolla, CA), containing a cDNA fragment corresponding to nucleotides 499-979 of a mouse 0 VEGF-C cDNA (SEQ ID NO: 40). Radiolabeled RNA was synthesized using T7 polymerase and ("SS]-UTP (Amersham).

oMouse VEGF-B antisense and sense RNA probes were synthesized in a similar manner from linearized pCRII plasmid containing the mouse VEGF-B cDNA insert as described Olofsson et al., Proc. Natl. Acad. Sci. (USA), 93-2576-2581 (1996).. The high stringency wash was for minutes at 65'C in a solution containing 30 mM dithiothreitol (DTT) and 4 x SSC. The slides were exposed for 28 days, developed and stained with hematoxylin. For comparison, similar sections were hybridized with a VEGFR-3 probe and the 12.5-day p.c.

embryos were also probed for VEGP-B mRNA.

Figures 34A-D show darkfield (Figures 34A-C) and lightfield (Figure 34D) photomicrographs of 12.5 day p.c. embryo sections probed with the antisense (Fig. 34A) and sense (Figs. 34C-D) VEGF-C probes. Fig. 34A illustrates a parasagittal section, where VEGF-C mRNA is particularly prominent in the mesenchyme around the vessels surrounding the developing metanephros In addition, hybridization signals were observed between the developing vertebrae in the developing lung mesenchyme in the neck region and developing forehead. The specificity of these signals is evident from the comparison with VEGF-B expression in an adjacent section (Fig. 34B), where the myocardium gives a very strong signal and lower levels of VEGF-B mRNA are detected in several other tissues. Both genes appear to be expressed in between the developing vertebrae in COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:18 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 0080 0 76 Sthe developing lung (lu) and forehead. Hybridization of the VEGF-C sense probe showed no specific expression within these structures (Fig. 34C).

Figs. 35A-D show a comparison of the expression patterns of VEGF-C and VEGFR-3 in 12.5 day p-c. mouse embryos in the jugular region, where the developing Sdorsal aorta and cardinal vein are located. This is the area where the first lymphatic vessels sprout from venous 0 sac-like structures according to the long-standing theory of Sabin, Am. J. Anat., 9:43-91 (1909). As can be seen Sfrom Figs. 35A-D, an intense VEGF-C signal is detected in O the mesenchyme surrounding the developing venous sacs (Figs. 35A and 35C) which are positive for VEGFR-3 (Figs.

and The mesenterium supplies the developing gut with blood and contains developing lymphatic vessels.

The developing 14.5 day p.c. mesenterium is positive for VEGF-C mRMA, with particularly high expression in connective tissue surrounding certain vessels (arrowheads in Figs. 35E-H). This signal in Fig. 35E should be distinguished from the false positive reflection of light from.red blood cells within the vessel. The adjacent mesenterial VEGFR-3 signals shown in Fig. 35F originate from small capillaries of the mesenterium (arrowhead).

Therefore, there appears to be a paracrine relationship between the production of the mRNAs for VEGF-C and its receptor. This data indicates that VEGF-C is expressed in a variety of tissues. Moreover, the pattern of expression is consistent with a role for VEGF-C in venous and lymphatic vessel development. Further, the data reveals that VEGF-C is expressed in non-human animals.

Example 24 Analysis of VEGF, VEGF-B, and VEGP-C IMNA Expression in Petal and Adult Tissues A human fetal tissue Northern blot containing 2 pg of polyadenylated RNAs from brain, lung, liver and kidney (Clontech Inc.) was hybridized with a pool of the COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:18 FAX 61 3 92438333 GRIFFITH HACK 4IPAUSTRALIA 0081 0 C -77 following probes: a human full-length VEGF-C cDNA insert ;Z (Genbank Ace. No. X94216), a human VEGF-B,,, cDNA fragment (nucleotides 1-382, Genbank Ace. No. U48800) obtained by O PCR amplification; and a human VEGF 581 bp cDNA fragment covering base pairs 57-638 (Genbank Ace. No. X15997).

Blots were washed under stringent conditions, using Stechniques standard in the art.

C Mouse embryo multiple tissue Northern blot 0 (Clontech Inc.) containing 2 pg of polyadenylated RNAs from 7 11, 15 and 17 day postcoital embryos was Shybridized with mouse VEGF-C cDNA fragment (base pairs 499-656). A mouse adult tissue Northern blot was hybridized with the probes for human VEGF, VEGF-B,,,, VEGF-C and with a VEGFR-3 cDNA fragment (nucleotides 1- 595; Genbank Ace. No. X68203).

In adult mouse tissues, both 2.4 kb and 2.0 kb mRNA signals were observed with the VEGF-C probe, at an approximately 4:1 ratio. The most conspicuous signals were obtained from lung and heart RNA, while kidney, liver, brain, and skeletal muscle had lower levels, and spleen and testis had barely visible levels. As in the human tissues, VEGF mRNA expression in adult mice was most abundant in lung and. heart RNA, whereas the other samples showed less coordinate regulation with VEGF-C expression. Skeletal muscle and heart tissues gave the highest VEGF-B RENA levels from adult mice, as previously reported olofsson et al., Proc. Natl. Acad, Sci. (USA), 93:2576-2581 (1996). Comparison with VEGFR-3 expression showed that the tissues where VEGF-C is expressed also contain mRNA for its cognate receptor tyrosine kinase, although in the adult liver VEGFR-3 mRNA was disproportionally abundant.

To provide a better insight into the regulation of the VEGP-C mRNA during embryonic development, polyadenylated RNA isolated from mouse embryos of various gestational ages 11, 15, and 17 day was hybridized with the mouse VEGF-C probe. These analyses COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:19 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1 082 078 showed that the amount of 2.4 kb VEGF-C mRNA is ;Z relatively constant throughout the gestational period.

xample Regulation of maRN for VEGF family members by serum, interlajin- 1 and daexsamethasone in human fibroblasts in culture t Human IMR-90 fibroblasts were grown in DMEM c medium containing 10% FCS and antibiotics. The cells Swere grown to 80% confluence, then starved for 48 hours in 0.5 t FCS in DMEM. Thereafter, the growth medium was 0 changed to DMEM containing 5% FCS, with or without ng/ml interleukin-i (IL-1) and with or without 1 mM 0 dexamethasone, as indicated in Figs. 24A-B. The culture plates were incubated with these additions for the times indicated, and total cellular RNA was isolated using the TRIZOL kit (GIBCO-BRL). About 20 pg of total RNA from each sample was electrophoresed in 1.5% formaldehydeagarose gels as described in Sambrook et al., supra (1989). The gel was used for Northern blotting and hybridization with radiolabeled insert DNA from the human VEGF clone (a 581 bp cDNA covering bps 57-638, Genbank Ace. No. 15997) and a human VEGF-B1 cDNA fragment (nucleotides 1-382, Genbank Ace. No. U48800) (Fig. Subsequently, the Northern blots were probed with radiolabelled insert from the VEGF-C cDNA plasmid (Fig.

24A). Primers were labelled using a standard technique involving enzymatic extension reactions of random primers, as would be understood by one of ordinary skill in the art. The mobilities of the 28s and 18S ribosomal RNA bands are indicated, based on UV photography of ethidium bromide stained RNA before the transfer.

As can be seen in Pigs. 24A-B, very low levels of VEGF-C and VEGF are expressed by the starved cells as well as cells after 1 hour of stimulation. In contrast, abundant VEGF-B mRNA signal is visible under,these conditions. After a 4 hours of serum stimulation, there is a strong induction of VEGF-C and VEGF mRNAs, COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:19 FAX 61 3 92438333 GRIFFITH HACK -4 IAUSTRALIA 083 0

S

7 9 p which are further increased in the IL-I treated sample.

;Z The effect of IL-1 seems to be abolished in the presence of dexamethasone. A similar pattern of enhancement is O maintained in the 8 hour sample, but a gradual downregulation of all signals occurs for both RNAs in the 24 hour and 48 hour samples. In contrast, VEGF-B mRNA levels remain constant and thus show remarkable stability C- throughout the time period. The results are useful in c guiding efforts to use VEGF-C and its fragments, its antagonists, and anti-VEGF-C antibodies in methods for o treating a variety of disorders.

ci Example 26 Expression and analysis of recombinant murine VEGF-c The mouse VEGF-C cDNA was expressed as a recombinant protein and the secreted protein was analyzed for its receptor binding properties. The binding of mouse VEGF-C to the human VEGFR-3 extracellular domain was studied by using media from Bosc23 cells transfected with mouse VEGF-C cDNA in a retroviral expression vector.

The 1.8 kb mouse VEGF-C cDNA was cloned as an EcoRI fragment into the retroviral expression vector pBabe-puro containing the SV40 early promoter region [Morgenstern et al., Nucl. Acids Res., 18:3587-3595 (1990)], and transfected into the Bosc23 packaging cell line [Pearet et al., Proc. Natl. Acad. Sci, (USA), 90:8392-8396 (1994)] by the calcium-phosphate precipitation method. For comparison, Bosc23 cells also were transfected with the previously- described human VEGF-C construct in the pREP7 expression vector. The transfected cells were cultured for 48 hours prior to metabolic labelling. Cells were changed into DMEM medium devoid of cysteine and methionine, and, after 45 minutes of preincubation and medium change, Pro-mixT L-[(ST in vitro cell labelling mix (Amersham corp.), in the same medium, was added to a final concentration of about 120 PCi/ml. After 6 hours of incubation, the culture medium COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:19 FAX 61 3 92438333 GRIFFITH HACK -IPAUSTRALIA 1@ 084 o -0 vas collected and clarified by centrifugation.

For immunoprecipitation, 1 ml aliquots of the media from metabolically-labelled Bosc23 cells O transfected with empty vector or mouse or human recombinant VEGF-C, respectively, were incubated overnight on ice with 2 pl of rabbit polyclonal antiserum f raised against an N-terminal 17 amino acid oligopeptide y of mature human VEGF-C (HzN-EETIKFAAAHYNTEIL) (SEQ ID No: o 33, residues 104-120). Thereafter, the samples were incubated with protein A sepharose for 40 minutes at 4'C with gentle agitation. The sepharose beads were then *washed twice with immunoprecipitation buffer and four times with 20 mM Tris-HCl, pH 7-4. Samples were boiled in Laemmli buffer and analyzed by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis

(SDS-PAGE).

Inmunoprecipitation of VEGF-C from media of transfected and metabolically-labelled cells revealed bands of approximately 30-32x10 3 M, (a doublet) and 22- 23X10 3 1 in 12.5% SDS-PAGE. These bands were not detected in samples from nontransfected or mocktransfected cells as shown in Fig. 32 lanes marked "vector"). These results show that antibodies raised against human VEGF-C recognize the corresponding mouse ligand.

For receptor binding experiments, 1 ml aliquots of media from metabolically-labelled Bosc23 cells were incubated with VEGFR-3 extracellular domain (see Example covalently coupled to sepharose, for 4 hours at 4'C with gentle mixing. The sepharose beads were washed four times with ice-cold phosphate buffered saline

(PBS),

and the samples were analyzed by gel electrophoresis as described in Joukov et al., EMBO 15:290-298 (1996).

As can be seen from Fig. 32, similar 30-32 x 10 3 M, doublet and 22-23 x 10 3 M, polypeptide bands were obtained in the receptor binding assay as compared to,.the immunoprecipitation assay. Thus, mouse VEGF-C binds to human VEGFR-3. The slightly faster mobility of the mouse COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:20 FAX 61 3 92438333 GRIFFITH HACK -*IPASTRALIA [a 085 o 81 SVEGF-C polypeptides may be caused by the four amino acid residue difference observed in sequence analysis (residues H88-E91, Fig. 31).

o The capacity of mouse recombinant VEGF-C to induce VEGFR-3 autophosphorylation was also investigated.

For the VEGFR-3 receptor stimulation experiments, I) subconfluent NIH 3T3-F1t4 cells, Pajusola et al., Oncogene, 9:3545-3555 (1994), were starved overnight in Sserum-free medium containing 0.2% BSA. In general, the cells were stimulated with the conditioned medium from SVEGF-C vector-transfected cells for 5 minutes, washed C three times with cold PBS containing 200 AM vanadate, and lysed in RIPA buffer for immunoprecipitation analysis.

The lysates were centrifuged for 25 minutes at 16000 x g and the resulting supernatants were incubated for 2 hours on ice with the specific antisera, followed by immunoprecipitation using protein A-sepharose and analysis in 7% SDS-PAGE. Polypeptides were transferred to nitrocellulose and analyzed by immunoblotting using anti-phosphotyrosine (Transduction Laboratories) and anti-receptor antibodies, as described by Pajusola et al., Oncogene, 9:3545-3555 (1994). Filter stripping was carried out at 50'C for 30 minutes in 100 mM 2mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7, with occasional agitation. The results of the experiment are shown in Fig. 33. The results demonstrate that culture medium containing mouse VEGF-C stimulates the autophosphorylation of VEGFR-3 to a similar extent as human baculoviral VEGF-C or the tyrosyl phosphatase inhibitor pervanadate.

VEGFR-2 stimulation was studied in subconfluent porcine aortic endothelial (PAE) cells expressing Kdr (VEGFR-2) (PAE-VEGFR-2) (Waltenberger et al., J. Biol.

chem., 269:26988-26995 (1994)], which were starved overnight in serum-free medium containing 0.2% BSA.

Stimulation was carried out and the lysates prepared as described above. For receptor immunoprecipitation, COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:20 FAX 61 3 92438333 GRIFFITH HACK 4IPAUSTRALIA 00863 o specific antiserum for VEGFR-2 [Waltenberger et al. j.

Biol. Chem., 269:26988-26995 (1994)] was used. The imunoprecipitates were analyzed as described for VEGFR-3 0 in 7% SDS-PAGE followed by Western blotting with antiphosphotyrosine antibodies, stripping of the filter, and re-probing it with anti-vEGFR-2 antibodies (Santa Cruz).

SMouse VEGF-C appeared to be a potent inducer of I VEGFR-3 autophosphorylation, with the 195x10' M, precursor o and proteolytically cleaved 125xo10 M, tyrosine kinase polypeptides of the receptor (Pajusola et al., oncogener o 9:3545-3555 (1994)), being phosphorylated. VEGFR-2 0 stimulation was first tried with unconcentrated medium from cells expressing recombinant. VEGF-C, but immunoblotting analysis did not reveal any receptor autophosphorylation.

To further determine whether mouse recombinant VEGF-C can also induce VEGFR-2 autophosphorylation as observed for human VEGF-C, PAE cells expressing VEGFR-2 were stimulated with tenfold concentrated medium from cultures transfected with mouse VEGF-C expression vector and autophosphorylation was analyzed. For comparison, cells treated with tenfold concentrated medium containing human recombinant VEGF-C (Joukov et al., (1996)), unconcentrated medium from human VECF-C baculovirus infected insect cells, or pervanadate (a tyrosyl phosphatase inhibitor) were used. As can be seen from Fig. 33, in response to human baculoviral VEGF-C as well as pervanadate treatment, VEGFR-2 was prominently phosphorylated, whereas human and mouse recombinant

VEGF-

C gave a weak and barely detectable enhancement of autophosphorylation, respectively. Media from cell cultures transfected with empty vector or VEGF-C cloned in the antisense orientation did not induce autophosphorylation of VEGFR-2. Therefore, mouse VESF-C binds to VEGFR-3 and activates this receptor at a much lower concentration than needed for the activation of VEGFR-2. Nevertheless, the invention comprehends methods COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:20 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA Z087 0 0 83 Sfor using the materials of the invention to take advantage of the interaction of VEGF-C with VEGFR-2, in _addition to the interaction between VEGF-C and VEGFR-3.

ERample 27 VEGF-C E104-S213 fragment expressed in Pichia yeast *n stimulates autophosphorylation of Flt4 (VEGFR-3) and KDR S(VEGFR-2) (N A truncated form of human VEGF-C CDNA was Cq constructed wherein the sequence encoding residues of a putative mature VEGF-C amino terminus H 2 N-E(104)ETIK O (SEQ ID NO: 33, residues 104 et seq.) was fused in-frame to the yeast PH01 signal sequence (Invitrogen Pichia Expression Kit, Catalog #K1710-01), and a stop codon was introduced after amino acid 213 (HzN- RCMS; i.e., after codon 213 of SEQ ID NO: 32). The resultant truncated cDNA construct was then inserted into the Pichia pastoris expression vector pHIL-Sl (Invitrogen).

For the cloning, an internal BglII site in the VEGF-C coding sequence was mutated without change of the encoded polypeptide sequence.

This VEGF-C expression vector was then transfected into Pichia cells and positive clones were identified by screening for the expression of VEGF-C protein in the culture medium by Western blotting. One positive clone was grown in a 50 ml culture, and induced with methanol for various periods of time from 0 to hours. About 10 g1 of medium was analyzed by gel electrophoresis, followed by Western blotting and detection with anti-VEGF-C antiserum, as described above.

As can be seen in Figure 25, an approximately 24 kD polypeptide (note the band spreading due to glycosylation) accumulates in the culture medium of cells transfected with the recombinant VEGP-C construct, but not in the medium of mock-transfected cells or cells transfected with the vector alone.

The medium containing the recombinant VEGF-C protein was concentrated by centricon 30 kD cutoff COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:21 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA [088 -84 ultrafiltration and used to stimulate NIU 3T3 cells expressing Plt4 (VEGFR-3) and porcine aortic endothelial (PAE) cells expressing KDR (VEGFR-2). The stimulated cells were lysed and immunoprecipitated using

VEGFR-

specific.antisera and the immunoprecipitates were analyzed by Western blotting using anti-phosphotyrosina antibodies, chemiluminesence, and fluorography. As a positive control for maximal autophosporylation of the VEGFRs, vanadate (v0 4 treatment of the cells for minutes was used- As can be seen from the results shown in Fig. 26, medium from Pichia cultures secreting the 0 -recombinant VEGF-C polypeptide induces autophosphorylation of both Flt41 polypeptides of 195 D and 125 kD as well as the RDR polypeptide of about 200 kD. Vanadate, on the other hand, induces heavy tyrosyl phosphorylation of the receptor bands in addition to other bands probably coprecipitating with the receptors- These results demonstrate that a VEGFhomologous domain of VEGF-C consisting of amino acid residues 104E 213S (SEQ ID No: 33, residues 104-213) can be recombinantly produced in yeast and is capable of stimulating the autophosphorylation of Flt4 (VEGFR-3) and KDR (VEGFR-2). Recombinant VEGF-C fragments such as the fragment described herein, which are capable of stimulating Flt4 or KDR autophosphorylation are intended as aspects of the invention; methods of using these fragments are also within the scope of the invention.

Example 28 Properties of the differentially processed forms of VEGF-c The following oligonucleotides were used to generate a set of VEGP-C variants: TCTCTTCTGTGCTTGAGTTGAG (SEQ ID NO: 42), used to generate VEGF-C R102s (arginine mutated to serine at position 102 (sEQ ID NO: 33)); (SEQ ID NO: 43), used to generate VEGF-C R102G (arginine mutated to glycine at COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:21 FAX 61 3 92438333 GRIFFITH HACK SIPAUSTRALIA 1089 t"--s position 102 (SEQ ID NO: 33)); GGCGGCGGGCGCCTCGCGAGGACC (SEQ ID NO; 44), used to generate VEGF~C AN (deletion of N-terminal propeptide corresponding to amino acids 32-102 (SEQ ID NO: 33)); CTGGCAGGGAACTGCTAATAATGGAATGAA 3' (SEQ ID NO: used to generate VEGF-C R226,227S (arginine codons i mutated to serines at positions 226 and 227 (SEQ ID NO: o 33)); 5' -GGGCTCCGCGTCCGAGAGGTCGAGTCCGGACTCGTGATGGT o GATGGTGATGGGCGGCGGCGGCGGCGGGCGCCTCGCGAGGACC -3 (SEQ ID c0 NO: 46), used to generate VEGF-C NHis (this construct encodes a polypeptide with a 6xHis tag fused to the Nterminus of the secreted precursor (amino acid 32 of SEQ ID NO: 33)).

Some of the foregoing VEGF-C variant constructs were further modified to obtain additional constructs.

For example, VEGF-C RIO2G in pALTER (Promega) and oligonucleotide 5'-GTATTATAATGTCCTCCACCAAATTTTATAG -3' (SEQ ID NO: 47) were used to generate VEGF-C 4G, which encodes a polypeptide with four point mutations: R102G, AllOG, A111G, and A112G (alanines mutated to glycine at positions 110-112 (SEQ ID NO: 33). These four mutations are adjacent to predicted sites of cleavage of VEGF-C expressed in PC-3 and recombinantly expressed in 293 EBNA cells.

Another construct was created using VEGF-C AN and oligonucleotide

S'-GTTCGCTGCCTGACACTGTGGTAGTGTTGCTGGC

GGCCGCTAGTGATGGTGGTGATGAATAATGAA

CTTGTCTGTAAACATCC

AG (SEQ ID NO: 48) to generate VEGF-C ANACHis. This construct encodes a polypeptide with a deleted N-terminal propeptide (amino acids 32-102); a deleted C-terminal propeptide (amino acids 226-419 of SEQ ID NO: 33); and an added 6kHis tag.at the C-terminus.

All constructs were further digested with HindIII and NotI, subcloned into HindII/NotI digested pREP7 vector, and used to transfect 293 EBNA cells.

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:21 FAX 61 3 92438333 GRIFFITH HACK 4, IPAUSTRALIA la0go o- 86 4c About 48 hours after transfection, the cells were either nmetabolically labelled with Pro_-ix. S described above, ;Z or starved in serum-free medium for 2 days. Media were then Collected and used in subsequent experiments. As O 5 can be seen from Figs. 27A-B, wild type (wt) VEGF-C, VEGF-C NKis and VEGF- ANACHis were expressed to similar levels in 293 ENA cel. At the same time, expression of the VEGF-C 4G polypeptide was considerably lower, PPossibly due to the changed conformation and decreased stability of the translated product. However, all the above VEGF-C variants were secreted from the cells O (mr e F 2 7 A nd 2 7 Bell S(compare Figs. 27A and 27B). The conditioned media from the transfected and starved cells were concentrated fold and used to assess their ability to stimulate tyrosine phosphorylation of Flt4 (VEGFR-3) expressed in NIH 3T3 cells and KDR (VEGFR-2) expressed in PAE cells.

Figs. 28A-B show that wild type (wt) VEGF-C, as well as all three mutant polypeptides, stimulate tyrosine phosphorylation of VEGFR-3. The most prominent stimulation is by the short mature VEGF-C ANACHis. This mutant, as ell as VEGF-C NHis, also stimulated tyrosine phosphorylation of VEGFR-2. Thus, despite the fact that a major component of secreted recombinant VEGF-C is a dimer of 32/29 kD, the active part of VEGF-C responsible for its binding to VEGFR-3 and VEGFR-2 is localized between amino acids 102 and 226 (SEQ ID NO: 33) of the VEGF-C precursor. Analysis and comparison of binding properties and biological activities of these

VEGP-C

proteins and variants, using assays such as those described herein, will provide data concerning the.

significance of the observed major 32/29 kD and 21-23 kD VEGF-C processed forms. The data indicate that constructs encoding amino acid residues 103-225 of the VEGF-C precursor (SEQ ID NO: 33) generate a recombinant ligand that is functional for both VEGFR-3 and VEGFR-2.

The data from this and preceding examples demonstrate that numerous fragments of the VEGF-C COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:22 FAX 61 3 92438333 GRIFFITH HACK 4 IAUSTRALIA 091 0 87polypeptide retain biological activity. A naturally occurring VEGF-- polypeptide spanning amino acids 103-226 (or 103-227) of SEQ ID NO: 33, produced by a natural O processing cleavage defining the C-terminus, has been shown to be active. Example 27 demonstrates that a fragment with residues 104-213 of SEQ ID NO: 33 retains Sbiological activity.

t In addition, data from Example 21 demonstrates O that a VEGF-C polypeptide having its amino terminus at position 112 of SEQ ID NO: 33 retains activity.

Additional experiments have shown that a fragment lacking 0 residues 1-112 of SEQ ID NO: 33 retains biological activity.

In a related experiment, a stop codon was substituted for the lysine at position 214 of SEQ ID NO: 33 (SEQ ID NO: 32, nucleotides 991-993). The resulting recombinant polypeptide still was capable of inducing Flt4 autophosphorylation, indicating that a polypeptide spanning amino acid residues 113-213 of SEQ ID NO: 33 is biologically active.

Sequence comparisons of members of the VEGF family of polypeptides provides an indication that still smaller fragments of the polypeptide depicted in SEQ ID NO: 33 will retain biological activity. In particular, eight highly conserved cysteine residues of the VEGF family of polypeptides define a region from residues 131 211 of SEQ ID NO: 33 (see Figure 31) of evolutionary signficance; therefore, a polypeptide spanning from about residue 131 to about residue 211 is expected to retain VEGF-C biological activity In fact, a polypeptide which retains the conserved motif RCXXCC a polypeptide comprising from about residue 161 to about residue 211 of SEQ ID NO: 33 is postulated to retain VEGF-C biological activity. To maintain native conformation of thes fragments, it may be preferred to retain about 1-2 additional amino acids at the carboxy-terminus and 1-2 or more amino acids at the amino terminus.

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:22 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA Z092s U--H 0 88 l eBeyond the preceding considerations evidence ex s that maller fragments and/or fragment variants which lack the conserved cysteines nonetheless will retain VEGF-C biological activity. Conseqently, the materals and methods of the invention include all VEGF-C fragments and variants that retain at least one iological activity of VEGF-C, regardless of the presence or absece of members of the conserved set of cysteine residues.

0 Example 29 o Expression of human vEGF-c under the human X14 keratin Cl promoter in t-rnasgenic mice induces abundant growth of 6 lymphatic vessels in the skin i sThe Flt4 receptor tyrosine kinase is relatively specifically expressed in the endothelia of lymphatic vessels. Raipainen et al., Proc. Natl. Acad Sci. (USA), 92: 3566-3570 (1995). Furthermore, the VEGF-C growth factor stimulates the F1t4 receptor, showing less activity towards the KDR receptor of blood vessels (ukov et al., ZMBw 15: 290-298 (1996); See Example 26).

Experiments were conducted in transgenic mice to analyze the specific effects of VEGF-C overexpression in tissues. The human K14 keratin promoter is active in the basal cells of stratified squamous epithelia (Vassar et al., Proc. Natl- Acad. Sci. (USA), 86:1563-1567 (1989)-) and was used as the expression control element in the recombinant VEGF-C transgene. The Vector containing the Kl4 keratin promoter is described in Vassar et al., Genes Dev., 5:714-727 (1991) and Nelson et al., J. Cell Biol. 97:244-251 (1983).

The recombinant VEGF-C transgene was constructed using the human full length VEGF-C cDNA (GenBank Ace. No. X94216). This sequence was excied 3S from a pCI-neo vector (Promega) with XhoI/Notl, and the resulting 2027 base pair fragment containing the open reading frame and stop codon (nucleotides 352-1611 of SEQ COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:22 FAX 61 3 92438333 GRIFFITH HACK 4, IPAUSTRALIA [093 0 -89 ID NO: 32) was isolated. The isolated fragment was then subjected to an end-filling reaction using the Klenow fragment of DNA polymerase. The blunted fragment was Sthen ligated to a similarly opened BamHI restriction site in the K4 vector. The resulting construct contained the EcoRI site derived from the polylinker of the pCl-neo vector. This EcoRI site was removed using standard techniques (a Klenow-mediatedfill-in reaction following Spartial digestion of the recombinant intermediate with EcoRI) to facilitate the subsequent excision of the DNA 0 fragment to be injected into fertilized mouse oocytes.

C The resulting clone, designated K14-VEGF-C, is illustrated in Fig. The EcoRI-HindIxI fragment from clone E14 VEGF- C containing the K14 promoter, VEGF-C cDNA, and K14 polyadenylation signal was isolated and injected into fertilized cocytes of the FVB-NIH mouse strain. The injected zygotes were transplanted to oviducts of pseudopregnant C57BL/6 x DBA/2J hybrid mice. The resulting founder mice were analyzed for the presence of the transgene by polymerase chain reaction of tail DNA using the primers: 5'-CATGTACGAACCGCCAG-3' (SEQ ID NO: 49) and 5'-AATGACCAGAGAGAGGCGAG-3' (SEQ ID NO: 50). In addition, the tail DNAs were subjected to EcoRV digestion and subsequent Southern analysis using the EcoRI-HindIII fragment injected into the mice. Out of 8 pups analyzed at 3 weeks of age, 2 were positive, having approximately 40-50 copies and 4-6 copies of the transgene in their respective genomes.

The mouse with the high copy number transgene was small, developed more slowly than its litter mates and had difficulty eating suckling). Further examination showed a swollen, red snout and poor fur.

Although fed with a special liquid diet, it suffered from edema of the upper respiratory and digestive tracts after feeding and had breathing difficulties. This mouse died eight weeks after birth and was immediately processed for COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:22 FAX 61 3 92438333 G I F~ A K- P U T A I 9 GRIFFITH HACK 4 IPAUSTRALIA [a 094 CA histology gon~ o h~bridizatiastochemistrY. n _1 hompriinHtiologca exninatic~n showed that in comari 0 ~to the8 skin Of littenlate<; the dorsal dersj tsu -MfR4vpF.ctaxgenc -mice was atrophic and COflflctive tisewas replaced by large lacunae devoid of red cells, but lined with a thin tfldotheliallyr( it roq 5 j Pigs.29A-;. Teldistended vessel-.llke structures reebldthose seen i ua resenuhuman lYxfl~ang j 0 mas. The number of skin adnexal Organs and hair follicles weerdc.

CA In the nou~j regj~ an increased n lumber of vessels wa~s een Thee-freVEGF-C overexpress io Vessel structre in the underlying skin, inlulding large vssellacunae. The endothelial cells surrounding these lacunae Conltained abundant y1t4 SRNA in in situ hybridization (see Exramples 23 and 30 for thol 3 The vessel morphology -indiates: that meF timuolates.

the growth of vessels havingr fea te orE- simlates vessels' The Other XQl4-yp.. trns j ous m had a Similar Skin histopatholageicmoseha The foregoing in vivo data indicates utilities for both VEC

PY~

1 eptides and POlypeptide variants havin 9 VEGF--C, biological activity, and (1i) anti-vEG..c antibodies and i1EGr-c antagonists that inhibit VE7GP-c acivt~(e-g., by binding yawc o interfering with VEcP-c/receptgor interactions. For example, tedt Indicates a therapeutic utilitY for VECP-c thlyepdtiae in Patients wherein growtb of lymhatc tssepay es hede s rb e r e re in P ients following breast ca-ncer or the r su eymwerec mphat jc tissue has been removed and whee l mph~j 0 drainage has therefore been compiom issa, resulting in swelling; or in Patients Suffering from elephantiazs, The data indicates a therapeutic utility for anti -vw..c antibody substances and VEGp-c antagonist, for conditions 8 wherein growth-i,.1bition of lymphatic tissue may be desirable treataett 'of COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:23 FAX 61 3 92438333 GRIFFITH HACK 4, IPAUSTRALIA g o- 91- Y lymphangiomas). Accordingly, methods of administering VEGF-C and VEGF-C variants and antagonists are contemplated as methods and materials of the invention Example Expression of VEGF-C and Plt4 in the Developing Mouse l Embryos from a 16-day post-coitus pregnant mouse were prepared and fixed in 4% paraformaldehyde S(PFA), embedded in paraffin, and sectioned at 6 Am. The sections were placed on silanated microscope slides and C treated with xylene, rehydrated, fixed for 20 minutes in 4% PFA, treated with proteinase K (7mg/ml; Merck, Darmstadt, Germany) for 5 minutes at room temperature, again fixed in 4% PFA and treated with acetic anhydride, dehydrated in solutions with increasing ethanol concentrations, dried and used for in situ hybridization.

In situ hybridization of sections was performed as described (Vastrik et al., j. Cell Biol., 128:1197-1208 (1995)). A mouse VEGF-C antisense

RNA

probe was generated from linearized pBluescript II SK+ plasmid (Stratagene Inc.), containing a fragment corresponding to nucleotides 499-979 of mouse VEGF-C cDNA, where the noncoding region and the'BR3P repeat were removed by Exonuclease III treatment. The fragment had been cloned into the EcoRI and HindIII sites of pBluescript II SK+. Radiolabeled RNA was synthesized using T7 RNA Polymerase and ["S)-UTP (Amershan, Little Chalfont, UK). About two million cpm of the VEGF-C probe was applied per slide. After an overnight hybridization, the slides were washed first in 2x SSC and 20-30 mM DDT for 1 hour at 50*C. Treatment continued with a high stringency wash, 4x SSC and 20 mM DTT and 50% deionized formamide for 30 minutes at 65'C followed by RNase-A treatment (20 pg/ml) for 30 minutes at 37C. The high stringency wash was repeated for 45 minutes. Finally, the slides were dehydrated and dried for 30 minutes at COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:23 FAX 61 3 92438333 GRIFFITH HACK -IPAUSTRALIA a096 0- 92 C -room temperature. The slides were dipped into photography emulsion and exposed for 4 weeks. Slid were developed using Kodak D-16 developer, counterstained with hematoXylin and mounted-with Permount o 5 (Fisherchemical).

For in situ hybridizations of Flt4 sequences, a mouse Flt4 CDNA fragment covering bp 1-192 of the p ublihed sequence (Finnert y et al., Oncogene, 8;2293- S2298 (1993)) was used, and the above-described protocol was followed, with the following exceptions.

Approximately one million cpm of the Flt4 probe were o applied to each slide. The stringent washes following hybridization were performed in lx SsC and 30 mM DTT for 105 minutes.

The figure shows photomicrographs of the hybridized sections in dark field microscopy (Figs. 36A- C) and light field microscopy (Fig. 36D). Magnifications used for photography were 4x for Figs. 36A-B and 10x for Figs. 36C-D. The transverse sections shown are from the cephalic region and the area shown for VEGF-C and FLT4 are about 14 sections apart, Flt4 being more cranially located in the embryo. In Fig- 36A (Flt4 probe), the developing nasopharyngeal cavity is in the midline in the upper, posterior part; in the anterior part of Fig. 36A is the snout with emerging fibrissal follicles and, in the midline, the forming nasal cavity. On both sides, the retinal pigment gives a false positive signal in dark field microscopy. The most prominently Flt4-hybridizing structures appear to correspond to the developing lymphatic and venous endothelium. Note that a plexus-like endothelial vascular structure surrounds the developing nasopharyngeal mucous membrane. In Fig. 36B, the most prominent signal is obtained from the posterior part of the developing nasal conchae, which in higher magnification (Figs. 36C-D) show the epithelium surrounding loose connective tissue/forming cartilage.

This structure gives a strong in situ hybridization COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:23 FAX 61 3 92438333 GRIFFITH HACK )IPAUSTRALIA IR1097 S93 signal for VEGF-C. Also in Fig. 36B, more weakly hybridizing areas can be seen around the snout, although this signal is much more homogeneous in appearance.

S Thus, the expression of VEGF-C is strikingly high in the developing nasal conchae The conchae are surrounded with a rich vascular Splexus, important in nasal physiology as a source for the Smucus produced by the epithelial cells and for warming inhaled air. It is suggested that VEGF-C is important in Ci 10 the formation of the concheal venous plexus at the mucous membranes, and that it may also regulate the permeability c of the vessels needed for the secretion of nasal mucus.

Possibly, VEGF-C and its derivatives, and antagonists, could be used in the regulation of the turgor of the conchal tissue and mucous membranes and therefore the diameter of the upper respiratory tract, as well as the quantity and quality of mucus produced. These factors are of great clinical significance in inflammatory (including allergic) and infectious diseases of the upper respiratory tract. Accordingly, the invention contemplates the use of the materials of the invention, including VEGF-C, Flt4, and their derivatives, in methods of diagnosing and treating inflammatory and infectious conditions affecting the upper respiratory tract, including nasal structures.

Example 31 Charaoterisation of the exon-intron organization of the human VEGP-C gene Two genomic DNA clones covering exons 1, 2, and 3 of the human VEGF-C gene were isolated from a human genomic DNA library using VEGF-C CDNA fragments as probes. In particular, a human genomic library in bacteriophage EMBL-3 lambda (Clontech) was screened using a PCR-generated fragment corresponding to nucleotides 629-746 of the human VEGF-C cDNA (SEQ ID NO: 32). One positive clone, designated "lambda was identified, and the insert was subcloned as a 14 kb Xhol fragment COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:24 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA S098 o 94into the pBSK I vector (Stratagene). The genomic library also was screened with a labeled 130 bp NotI-acI fragment from the 5'-noncoding region of the VEGF-C cDNA (the NotI site is in the polylinker of the cloning Vector; the Sacl site corresponds to nucleotides 92-97 of SEQ ID NO: 32). Two positive clones, designated "lambda and "lambda were obtained. Restriction mapping analysis showed that clone lambda 3 contai ri s exs 2 and 0 3, while clone lambda 5 contains exon 1 and the putative c 10 promoter region.

Three genomic fragments containing exons 4, 6 and 7 were sub c loned from a genomic VEGF-C P1 plasmid clone- In particular, purified DNA from a genomic P1 plasmid clone 7660 (Paavonen et al., Circulation, 93: 1079-1082 (1996)) was used. EcoRI fragments of the P1 insert DNA were ligated into pBSK IX vector. Subclones of clone 7660 which contained human VEGF-C cDNA homologous sequences were identified by colony hybridization, using the full-length VEGF-C cDNA as a probe. Three different genomic fragments were identified and isolated, which contained the remaining exons 4-7.

To determine the genomic organization, the clones were mapped using restriction endonuclease cleavage. Also, the coding regions and exon-intron junctions were partially sequenced. The result of this analysis is depicted in Figures 11 and 17. The sequences of all intron-exon boundaries (Fig. 17, SEQ ID NOS: 57- 68) conformed to the consensus splicing signals (Mount, Nucl. Acids Res., 10: 459-472 (1982)). The length of the intron between exon-5 and 6 was determined directly by nucleotide sequencing and found to be 301 bp. The length of the intron between exons 2 and 3 was determined by restriction mapping and Southern hybridization and was found to be about 1.6 kb. Each of the other intronS was over 10 kb in length.

A similar analysis was performed for the murine genomic VEGF-C gene. The sequences of murine

VEGF-C

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:24 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA ~s 95 gintron-exon boundaries are depicted in Figure 17 and SEQ ID NOs: 69-80.

The restriction mapping and sequencing data Sindicated that the signal sequence and the first residues of the N-terminal propeptide are encoded by exon 1. The second exon encodes the carboxy-terminal portion of the N-terminal propeptide and the amino terminus of the VEGF homology domain. The most conserved sequences of the o VEGF homology domain are distributed in exons 3 (containing 6 conserved cysteine residues) and 4 O (containing 2 cys residues). The remaining exons encode C cysteine-rich motifs of the type C-6X-C-10X-CRC (eXons and 7) and a fivefold repeated motif of type C-6X-B-3X-C-C-C, which is typical of a silk protein.

To further characterize the VEGF-C gene promoter, the lambda 5 clone was further analyzed.

Restriction mapping of this clone using a combination of single- and double-digestions and Southern hybridizations indicated that it includes: an approximately 5 kb region upstream of the putative initiator ATG codon, (2) exon 1, and part of intron I of the VEGF-C gene.

A 3.7 kb Xba I fragment of clone lambda containing exon 1 and 5' and 3' flanking sequences, was subcloned and further analyzed. As reported previously, a major VEGF-C mRNA band migrates at a position of about 2.4 kb. Calculating from the VEGF-C coding sequence of 1257 bp and a 391 bp 3' noncoding sequence plus a polyA sequence of about 50-200 bp, the iRNA start site should be located about 550-700 bp upstream of the translation initiation codon.

To further characterize the promoter of the human VEGF-C gene, a genomic clone encompassing about 1.4 kb upstream of the translation initiation site was isolated, and the 5' noncoding cDNA sequence and putative promoter region were sequenced. The sequence obtained is set forth in SEQ ID NO: 54. similar to what has been observed with the VEGF gene, the VEGF-C promoter is rich COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:24 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA Z100 in G and C residues and lacks consensus TATA and CCAAT sieuencs.

5 Instead, it has numerous putative binding inites or Spl, a ubiquitous nuclear protein that can initate transcription of TATAl ess genes See Pugh an Tjian, 'Genes and Dev., 5:105_119 (191). In additiond Sequencs pstre of the VEGF- translation start site Swere found to contain frequent consensus binding sites for the AP-2 factor. This suggests that the CCAMTP-dependent protein kinase and protein kinase C, as ctivators Of AP-2 transcription factor (Curran and Franza, Cell, 55:395-37 (1988)], mediate VEGF-C Stranscriptional regulation.

al h The VEGF-C gene is abundantly expressed in adult human tissues, such as heart, placenta, ovary and small intestine, and is induced by a variety of factors.

Indeed, several potential binding sites for regulators of tissue-specific gene expression, like NFkB and GATA, are located in the distal part of the VEGF-C promoter. For example, NFkB is known to regulate the expression of tissue factor in endothelial cells. Also, transcription factors of the GATA family are thought to regulate cell-type specific gene expression.

Unlike VEGF, the VEGF-C gene does not contain a binding site for the hypoxia-indBuible factor, HIF-1 (Levy et al., Biol. Chem., 270: 13333-13340 (1995)).

This finding suggests that if the VEGF-C mRNA is regulated by hypoxia, the mechanism would be based mainly on the regulation of IURNA stability. In this regard, numerous studies have shown that the major control point for the hypoxic induction of the VEGF gene is the regulation of the steady-state level of mRNA. See Levy et al., J. Biol. Chem., 271: 2746-2753 (1996). The relative rate of VEGF mRNA stability and decay is considered to be determined by the presence of specific sequence motifs in its 3' untranslated region

(UTR),

which have been demonstrated to regulate RRNA stability (Chen and Shyu, Mol. Cell 1101., 14: 8471-8482 (1994)).

The 3'-UTR of the VEGF-C gene also contains a putative COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:25 FAX 61 3 92438333 GRIFFITH HACK 4IPAUSTRALIA Z101 S- 97- Smotif of this type (TTATTT), at positions 1873-1878 of SSEQ ID NO: 32.

SExample 32 Identification of a VEGP-C splice variant As reported in Example 16, a major 2.4 kb VEGFt C mRNA and smaller amounts of a 2.0 kb mRNA are g observable. To clarify the origin of these RNAs, several 0 additional VEGF-C cDNAs were isolated and characterized.

A human fibrosarcoma cDNA library from HT1080 cells in the lambda gtll vector (Clontech, product #HL1048b) was screened using a 153 bp human VEGF-C cDNA fragment as a probe as described in Example 10. See also Joukov et al., EMBO 15:290-298 (1996). Nine positive clones were picked and analyzed by PCR amplification using oligonucleotides 5'-CACGGCTTATGCAAGCAAAG-3' (SEQ ID NO; and 5'1AACACAGTTTTCCATAATAG-3- (SEQ ID o0: 56) These oligonucleotides were selected to amplify the portion of the VEGF-C cDNA corresponding to nucleotides 495-1661 of SEQ ID NO: 32. PCR was performed using an annealing temperature of 55 C and 25 cycles.

The resultant PCR products were electrophoresed on agarose gels. Five clones out of the nine analyzed generated PCR fragments of the expected length of 1147 base pairs, whereas one was slightly shorter. The shorter fragment and one of the fragments of expected length were cloned into the pCRTMII vector (Invitrogen) and analyzed by sequencing. The sequence revealed that the shorter PCR fragment had a deletion of 153 base pairs, corresponding to nucleotides 904 to 1055 of SEQ ID NO: 32. These deleted bases correspond to exon 4 of the human and mouse VEGF-C genes, schematically depicted in Fig. 17. Deletion of exon 4 results in a frameshift, which in turn results in a c-terminal truncation of the full-length VEGF-C precursor, with fifteen amino acid residues translated from exon 5 in a different frame than the frame used to express the full-length protein. Thus, COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:25 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 102 S- 98 c the C-terminal amino acid sequence of the resulting truncated polypeptide would be Leu (181)-Ser-Lys-Thr.

SVal-Ser-Gly-Ser-Glu-Gln-Asp-Leu-Pro-His-Glu-Leu-His-Val Glu(199) (SEQ ID NO: 81). The VEGF-C variant encoded b this splice variant would not contain the C-terminal cleavage site of the VEGF-C precursor. Thus, a putative alternatively spliced RNA form lacking conserved exon 4 was identified in HT-1080 fibrosarcoma cells and this C form is predicted to encode a protein of 199 amino acid 0 residues, which could be an antagonist of VEGF-C.

0 Example 33 VEGF-C is similarly processed in different cell cultures in vitro To study whether VEGF-C is similarly processed in different cell types, 293 EBNA cells,

COS-

1 cells and HT-1080 cells were transfected with wild type human

VEGF-

C oDNA and labelled with Pro-Mixm as described in Example 22. The condit i oned media from the cultures were collected and subjected to immunoprecipitation using antiserum 882 (described in Example 21, recogniiing a peptide corresponding to amino acids 104-120 of SEQ ID NO: 33). The immunopreoipitated polypeptides were separated via SDS-PAGE, and detected via autoradiography. The major 2 form of secreted recombinant VEGF-C observed from all cell lines tested is a 29/32 kD doublet. These two polypeptides are bound to each other by disulfide bonds, as described in Example 22. A less prominent band of approximately 21 kD also was detected in the culture media.

Additionally, a non-processed VEGF-C precursor of 63 kDa was observed. This form was more prominent in the COS-1 cells, suggesting that proteolytic processing-of

VEGF-C

in COS cells is less efficient than in 293 EBNA cells.

Endogenous VEGF-C (in non-transfected cells) was not detectable under these experimental conditions in the HT-1080 cells, but was readily detected in the conditioned medium of the PC-3 cells. Analysis of the subunit COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:25 FAX 61 3 92438333 GRIFFITH HACK 4 IAUSTRALIA litm -99 polypeptide sizes and ratios in PC-3 cells and 293 EBNA cells revealed strikingly similar results: the most prominent form was a doublet of 29/32 kDa and a less prominent form the 21 kD polypeptide. The 21 kD form produced by 293 EBNA cells was not recognized by the 882 antibody in the Western blot, although it is recognized when the same antibody is used for immunoprecipitation (see Sdata in previous examples). As reported in Example 21, o cleavage of the 32 kD form in 293 EBNA cells occurs between amino acid residues 111 and 112 (SEQ-ID NO: 33), O downstream of the cleavage site in PC-3 cells (between Sresidues 102 and 103). Therefore, the 21 kD form produced Sin 293 EBNA cells does not contain the complete N-terminal peptide used to generate antiserum 882.

In a related experiment, PC-3 cells were cultured in serum-free medium for varying periods of time (1 8 days) prior to isolation of the conditioned medium. The conditioned medium was concentrated using a Centricon device (Amicon, Beverly, USA) and subjected to Western blotting analysis using antiserum 882. After one day of culturing, a prominent 32 kD band was detected- Increasing amounts of a 21-23 kD form were detected in the conditioned media from 4 day and 8 day cultures. The diffuse nature of this polypeptide band, which is simply called the 23 kD polypeptide in example 5 and several subsequent examples is most likely due to a heterogenous and variable amount of glycosylation. These results indicate that, initially, the cells secrete a 32 kD polypeptide, which is further processed or cleaved in the medium to yield the 21-23 kD form. The microheterogeneity of this polypeptide band would then arise from the variable glycosylation degree and, from microheterogenelty of the Processing cleavage sites, such as obtained for the amino terminus in PC-3 and 293 EBNA cell cultures. The carboxyl terminal cleavage site could also vary, examples of possible cleavage sites would be between residues 225-226, 226-227 and 227-228 as well as between residues 216-217.

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:26 FAX 61 3 92438333 GRIFFITH HACK IFASTRALIA 1104 O 100 7C Taken together, these data suggest the possibility that secreted cellular protease(s) are responsible for the ;Z generation of the 21-23 kD form of VEGF-C from the 32 kD Spolypeptide. Such proteases could be used in vitro to O 5 cleave VEGF-C precursor proteins in solution during the production of VEGF-C, or used in cell culture and in vivo to release biologically active

VEGF-C.

SExample 34 Differential binding of VEGF-C forms by the extracellular domains of VEGFR-3 and VEGFR-2 SIn two parallel experiments, 293 EBNA cells were transfected with a construct encoding recombinant wild type VEGF-C or a construct encoding VEGF-C DNDCHis (Example 28) and about 48 hours after transfectlon metabolically labelled with Pro-MixT as described in previous examples. The media were collected from mocktransfected and transfected cells and used for receptor binding analyses- Receptor binding was carried out in binding buffer (PBS, 0.5% BSA, 0.02% Tween 20, 1 microgram/ml heparin) containing approximately 0.2 microgram of either a fusion protein comprising a VEGFR-3 extracellular domain fused to an immunoglobulin sequence (VEGFR-3-Ig) or a fusion protein comprising VEGFR-2 extracellular domain fused to an alkaline phosphatase sequence

(VEGF-

R-2-AP; Cao et al., j. Biol. Chem. 271:3154-62 (1996)).

As a control, similar aliquots of the 293 EBNA conditioned media were mixed with 2 pl of anti-VEGF-C antiserum (VEGF-C

IP).

After incubation for 2 hours at room temperature, anti-VEGF-C antibodies and VEGFR-3-Ig protein were adsorbed to protein A-sepharose (PAS) and VEGFR-2-AP Was Immunoprecipitated using anti-AP monoclonal antibodies (Medix Biotech, Genzyme Diagnostics, San Carlos, CA, USA) and protein G-sepharose. Complexes containing

VEGF-C

bound to VEGFR-3-Ig or VEGFR-2-AP were washed three times COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:26 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0 101- 0q in binding buffer, twice in 20 mM Tris-HCl (pH 7.4) and VEGF-C immunoprecipitates were washed three times in RIPA ;Z buffer and twice in 20 mM tris-HCI (pH 7.4) and analyzed via SDS-PAGE under reducing and nonreducing conditions.

As a control, the same media were precipitated with anti- AP and protein G-sepharose (PGS) or with PAS to control for possible nonspecific adsorption.

SThese experiments revealed that VEGFR-3 bound gC to both the 32/29 kD and 21-23 kD forms of recombinant 0 10 VEGF-C, whereas VEGFR-2 bound preferentially to the 21-23, kD component from the conditioned media. In addition, Ssmall amounts of 63 kD and 52 kD VEGF-C forms were observed binding with VEGFR-3. Further analysis under nonreducing conditions indicates that a great proportion of the 21-23 kD VEGF-C bound to either receptor does not contain interchain disulfide bonds. These findings reinforce the results that VEGF-C binds VEGFR-2. This data suggests a utility for recombinant forms of VEGF-C which are active towards VEGFR-3 only or which are active towards both VEGFR-3 and VEGFR-2. On the other hand, these results, together with the results in Example 28, do not eliminate the possibility that the 32/29 kD dimer binds VEGFR-3 but does not activate it. The failure of the 32/29 kD dimer to activate VEGFR-3 could explain the finding that conditioned medium from the N-His VEGF-C transfected cells induced a less prominent tyrosine phosphorylation of VEGFR-3 than medium from VEGF-C DNDCHis transfected cells, even though expression of the former polypeptide was much higher (see Figs. 27 and 28). Stable VEGF-C polypeptide variants that bind to a VEGF-C receptor but fail to activate the receptor are useful as VEGF-C antagonists.

COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:26 FAX 61 3 92438333 GRIFFITH HACK -IPAUSTIRALIA linioe -102 SDeposit of Biological Materials: Plasmid FLT4-L has been deposited with the American Type Culture Collection (ATCC 12301 Parklawn Dr., Rockville MD 20952 (USA), pursuant to the provisions of the Budapest Treaty, and has been assigned a deposit date of 24 July 1995 and ATCC accession number 97231.

Ci While thelpresent invention has been described in C terms of specific, embodiments, it is understood that variations and modifications will occur to those in the O 10 art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

N:MaTourne\C8a\PatenMWe 20O nu6e22 '57zAUsi 227AU Speciicmdoi Q07-2..dc 9/0r07 COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01

Claims (4)

1. A uiie n Slatd polypeptide which is o 5 capable of binding to F2Lt4 receptor tyrosine kinese and that is not an antibody. A rnn-humaan mammaliLan -polyp;pktide aooaraing to -clai 1. o Cl

3. A. human polypepttade according to claim ,1. A polypeptide according to- claim 3 having an appren-t molecular woeight of about 32 ltD asE assessed by SDS-PAGH under reducing conditions. A Dolynpeptida',,acO4rdinu to- claim :3 that is subutantsaxay tree or other human polypaptides.

6. A purified and isolated polypep-tide according to claim 1, said polypepthida being encoded by plasmid PFLT4-L, depoeitedi as ATCC Accession Number

97231. 7. A jolypeptideacdcording to claim I having an amino acid sequence oomprising a portion of SEQ ID NO: 33. 8. A Poirpeptide accord ing to claim 1 comprising *an aino aoid sequence -set forth in SEQ ID NO; 33 from. about: residue 161 of SEQ ID NOf; 33. to about residue 211 Of SEC TD NO: 33.- 9. A, polypeptidet_ according to claim 1 comprising amino acid sequence set forth- in SEQ ID NO: 3.3 from* about rsalddue 131 oZ BUQ ID NO: 33 to about residue 211 of SEQ ID NO: 33. A polypeptida according to claim 1 comprising ani aminoa acid sequence set forth in SEQ ID NO: 33 from re- Midue 113 tjj SRQ in No! 33 1'o! resiWdUe 213 Qf SRO In NO! 33- COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:35 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA [1140 136 S11- A polypeptide according to claim 1 comprising an amino acid sequence set-fsrth- 0 in SEQ ID NO: 33 from residue 113 of SEQ ID NO: 33 to residue 227 of SEQ ID NO: 33. S12- A polypepdde according to claim 1 comprising:amino acids 103 to 217 of SEQ ID NO: 33. s 13. A polypeptide according to claim I comprising amino acids 103 to 225 of SEQ SID NO: 33. 14. A polypeptide according to claim 1 comprising amino acids 103 to 227 of SEQ SID NO: 33. In 15. A polypeptide according to claim I comprising amino acids 32 to 227 of SEQ N 16 ID NO: 33. 16. A polypeptide according to any one of claims 1-15, wherein said polypeptide is Scapable of stimulating tyrosine phosphorylation of Flt4 receptor tyrosine kinase in a host cell o expressing said Flt4 receptor tyrosine kinase. cl 17. A polypeptide according to claim I having the amino acid sequence of residues 1 to 419 of SEQ ID NO: 33. 18. A purified and isolated polypeptide which is capable of binding to Flt4 receptor tyrosine kinase, substantially as hereinbefore described with reference to any one of the Examples. 19. A polypeptide according to any one of claims 1-18 further comprising a detectable label. A purified protein comprising a first polypeptide linked to a second polypeptide, wherein at least one of said first polypeptide and said second polypeptide is a polypeptide according to any one of claims 1-18, and wherein said protein is capable of binding to Flt4 receptor tyrosine kinase. 25 21. A purified protein according to claim 20 wherein said first polypeptide is covalently linked to said second polypeptide. 22. A purified protein according to claim 20 wherein each of said first polypeptide N, and said second polypeplide is a polypeptide according to any one of claims 1-18, 23. A purified and isolated nucleic acid comprising a nucleotide sequence encoding so a polypeptide according to any one of claims 1-18. 24. A nucleic acid according to claim 23 comprising a nueleotide sequence encoding a polypeptide consisting of amino acids 113 to 213 of SEQ ID NO: 33. A nucleic acid according to claim 23 comprising a nucleotide sequence encoding a polypeptide consisting of amino acids 103 to 217 of SEQ ID NO: 33. .26. A nucleic acid according to claim 23 having the nucleotide sequence of nucleotides 352 to 1608 of SEQ ID NO: 32. 27. A nucleic acid according to claim -23 comprising a VEGF-C encoding insert of plasmid pFLT4-L, deposited as ATCC Accession Number 97231. 28. A vector comprising a nucleic acid according to any one of claims 23-27. [n:libc]03237:MEF COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:36 FAX 61 3 92438333 .GRIFFITH HACK IPAUSTRALIA []141 137 O 29. A host cell transformed or transfecled with a nucleic acid according to any one 0 of claims 23-27. An antibody which is specifically reactive with a polypeptide according to any one of claims 1-18. S 5 31. An antibody according to claim 30 which is a monocolonal antibody. O 32. A pharmaceutical composition comprising a polypeptide according to any one of claims 1-18 in a pharmaceutically acceptable diluent, adjuvant, excipicnt or carrier. 33. A method of making a polypeptide capable of specifically binding to Flt4 receptor tyrosine kinase, said method comprising the steps of: C' 10 expressing a nucleic acid according to any one of claims 23-27 in a host 0 cell; and purifying a polypeptide capable of specifically binding to Fit4 receptor Styrosine kinase from said host cell or from a growth medium of said host cell. Cl -34. A polypeptide capable of specifically binding to Flt4 receptor tyrosine kinase, said polypeptide produced by the method according to.claim 33. A murine polypeptide according to claim 1. 36. A polypeptide according to claim 35, said polypeptide comprising-a portion of the amino acid sequence set forth in SEQ ID NO: 41, said portion being capable of specifically binding.to an Flt4 receptor tyrosine kinase. 37. A purified and isolated nucleic acid encoding the polypcptide according to claim or 36. 38. A purified and isolated nucleic acid having at least about 570 nucleotides, said nucleic acid specifically hybridising to a human gene encoding VEOF-C. 39. A nucleic acid according to claim 38 which hybridises to a human gene encoding VEGF-C, under hybridisation conditions wherein said nucleic acid fails to hybridise to a human gene encoding VEGF or VEGF-B, and wherein said nucleic acid comprises a continuous nucleotide sequence of at least twenty nucleotides from a nucleotide sequence selected from the group consisting of: SEQ ID NO: 32, and so a nucleotide sequence complementary to SEQ ID NO: 32. A method for detecting endothelial cells in a biological tissue comprising the steps of: exposing a biological tissue comprising endothelial cells to a polypeptide according to any one of claims 1-19, under conditions wherein said p-olypeptide binds to as endothelial cells; and detecting said polypeptide bound to endothelial cells in said biological tissue, thereby detecting said endothelial cells. 41. The method according to claim 40, further comprising the step of washing said biological tissue, said washing step being performed after said exposing step and before said detecting step. [n:\lib]03237:MEF COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:36 FAX 61 3 92438333 GRIFFITH HACK -*IPAUSTRALIA IR1142 S138 S42. A method for detecting endothelial cells in a biological tissue, substantially as 1 hereinbefore described with reference to any one of the Examples. 43. A method of modulating the growth of mammalian endothelial cells comprising the steps of: Sexposing mammalian endothelial cells to a polypeptide according to any one of claims 1-18 or 34 in an amount effective to modulate the growth of mammalian endothelial Scells. n 44. A purified and isolated polypeptide which is capable of binding to Kdr S(VEGFR-2), said polypeptide having an amino acid sequence comprising a portion of SEQ ID NO: 33. A purified nucleic acid comprising a promoter for VEGF-C. 1 46. A nucleic acid according to claim 45 comprising a portion of SEQ ID NO: 54, wherein said portion is capable of promoting expression of a protein encoding gene operatively linked thereto under conditions wherein VEGF-C is expressed in native host is cells. 47. The polypeptide according to any one of claims 1 to 18 or 34 when used in the modulation of growth of mammalian endothelial cells. 48. Use of a polypeptide according to any one of claims 1 to 18 or 34 in the preparation of a medicament for modulating the growth of mammalian endothelial cells. 49. A medicament prepared according to claim 48. A pharmaceutical composition comprising an antibody according to either of claims 30 or 31 in a pharmaceutically acceptable diluent, adjuvant, excipient, or carrier. 51. A method for the treatment of a condition requiring modulation of the growth of mammalian endothelial cells, said treatment comprising exposing said endothelial cells to a polypeptide according to any one of claims 1 to 18 or 34 in an amount effective to modulate the growth of said endothelial cells. 52. The polypeptide according to any one of claims 1 to 18 or 34 when used in a method for the treatment of a condition requiring modulation of the growth of mammalian endothelial cells- 53. Use of a polypeptide according to any one of claims 1 to 18 or 34 in the preparation of a medicament for treatment of a condition requiring modulation of the growth of mammalian endothelial cells. 54. A medicament when prepared according to claim 53. A method for the treatment of a condition requiring modulation of the growth of mammalian endothelial cells, said treatment comprising exposing said endothelial cells to wIvgr MrnoAA i Aa-air- COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:36 FAX 61 3 92438333 GRIFFITH HACK IFAUSTRALIA 143 139 O San antibody according to either of claims 30 or 31 in an amount effective to modulate the growth of said endothelial cells. 56. The antibody according to either of claims 30 or 31 when used in a method for the treatment of a condition requiring modulation of the growth of mammalian endothelial 0 s cells. 57. Use of an antibody according to either of claims 30 or 31 in the preparation of a flt medicament for treatment of a condition requiring modulation of the growth of mammalian C^ endothelial cells. o 58. A medicament when prepared according to claim 57. 1 o0 59. The method according to claim 51 or claim 55 wherein said condition is an O endothelial cell disorder. The method according to claim 59 wherein said endothelial cell disorder is selected from the group consisting of physical loss of lymphatic vessels, lymphatic vessel occlusion, and lymphangiomas. is 61. The polypeptide according to claim 52 wherein said condition is an endothelial cell disorder. 62. The polypeptide according to claim 61 wherein said endothelial cell disorder is selected from the group consisting of physical loss of lymphatic vessels, lymphatic vessel occlusion, and lymphangiomas. 63. The antibody according to claim 56 wherein said condition is an endothelial cell disorder. 64. The antibody according to claim 63 wherein said endothelial cell disorder is selected from the group consisting of physical loss of lymphatic vessels, lymphatic vessel occlusion, and lymphangiomas. 65. The use according to claim 53 or claim 57 wherein said condition is an endothelial cell disorder. 66. The use according to claim 65 wherein said endothelial cell disorder is selected from the group consisting of physical loss of lymphatic vessels, lymphatic vessel occlusion, and lymphangiomas. 67. A purified and isolated nucleic acid encoding a polypeptide which is capable of binding to Flt4 receptor tyrosine kinase, substantially as hereinbefore described with reference to any one of the examples. 68. A host cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes a polypeptide which is capable of binding to Flt4 receptor rn.1rmininAdA .Ann-4 Tl COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:37 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA [144 140 Styrosine kinase, substantially as hereinbefore described with reference to any one of the examples. 69. A method of making a polypeptide which is capable of binding to Flt4 receptor tyrosine kinase, substantially as hereinbefore described with reference to any one of the o s examples. A polypeptide which is capable of binding to Flt4 receptor tyrosine kinase when made according to the method of claim 69. n 71. A purified and isolated nucleic acid comprising a nucleotide sequence that 0 encodes a polypeptide capable of binding Flt4 receptor tyrosine kinase,-wherein said nucleotide sequence is selected from the group consisting of: 0 a nucleotide sequence which is capable of hybridising with a nucleic acid according to any one of claims 23 to 27 under the following hybridisation conditions: hybridisation at 42°C for 20 hours in a solution containing formamide, 5x SSPE, 5x Denhardt's solution, 0.1% SDS and 0.1mg/ml denatured salmon sperm DNA; and (ii) washing the filter twice for thirty minutes at room temperature and twice for thirty minutes at 65 0 C with a wash solution containing lx SSC, and 0.1% SDS; and wherein said polypeptide includes a domain defined by eight cysteine residues that are conserved in human vascular endothelial growth factor (VEGF), human platelet derived growth factor A (PDGF-A), and human platelet derived growth factor B (PDGF-B), wherein said polypeptide lacks any domain that has one or more cysteine motifs of a Balbiani ring 3 protein (BR3P); and a nucleotide sequence which, because of the degeneracy of the genetic code, does not hybridise with the sequence of any of claims 23 to 27 but which encodes a polypeptide comprising the amino, acid sequence shown in SEQ ID NO: 33 or a portion thereof effective to permit binding to Flt4. 72. A DNA construct comprising a nucleic acid according to any one of claims 23 to 27 or 71, 73. A DNA construct comprising a nucleotide sequence that encodes a polypeptide which is capable of binding Flt4 receptor tyrosine kinase, substantially as hereinbefore described with reference to any one of the examples. 74. A vector comprising the DNA construct of either claim 72 or claim 73. fD-lT Tk!inmt1 i AA 'f COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:37 FAX 61 3 92438333 GRIFFITH HACK 4IPA'USTRALIA [a 145 141 O A vector comprising a nucleotide sequence that encodes a polypeptide capable of binding Flt4 receptor tyrosine kinase, substantially as hereinbefore described with reference to any one of the examples. 76. A host cell transformed or transfected with a DNA construct according to claim os 72 or claim 73. 77. A host cell transformed or transfected with a vector according to any one of claims 28, 74 or 'l 78. A polypeptide capable of binding to Flt4 receptor tyrosine kinase when O produced by the host cell of any one of claims 29, 76 or 77. 0 COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:37 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 1146 0 142 0 SThe claims defining the invention are as follows: I. A purified and isolated polypeptide comprising an amino acid sequence encoded by plasmid pFLT4-L, deposited as ATCC Accession Number 97231, wherein the polypeptide binds to the extracellular domain of Fl4 receptor tyrosine kinase (Flt4). 2. A purified and isolated polypeptide comprising an amino acid sequence encoded by plasmid pFLT4-L, deposited as ATCC Accession Number 97231, wherein said polypeptide lacks the carboxyl terminal portion of the amino acid sequence encoded 0 by plasmid pFLT4-L that contains cysteine motifs of a Balbiani ring 3 protein (BR3P). 3. A purified and isolated polypeptide that binds to the extracellular domain of human Flt4 receptor tyrosine kinase, said polypeptide comprising an amino acid sequence that includes a contiguous portion of the amino acid sequence in SEQ ID NO:33 effective to permit said binding, wherein said polypeptide lacks any portion of SEQ ID NO:33 that has one or more cysteine motifs of a Balbiani ring 3 protein (BR3P). Is 4. A polypeptide according to claim 3, wherein said contiguous portion includes eight cysteine residues that are conserved in human vascular endothelial growth factor (VEGF), human platelet derived growth factor A (PDGF-A), and human platelet derived growth factor B (PDGF-B). A purified and isolated polypeptide that binds to the extracellular domain of human Flt4 receptor tyrosine kinase, said polypeptide comprising a portion of the amino acid sequence in SEQ ID NO:33 effective to permit said binding, said polypeptide lacking at least carboxy-terminal residues of SEQ ID NO:33 beyond residue 227. 6. A purified polypeptide that binds to the extracellular domain of human Flt4 receptor tyrosine kinase, said polypeptide produced by a method comprising the steps of: expressing a nucleic acid in a host cell, wherein said nucleic acid comprises a nucleotide sequence encoding a portion of the amino acid sequence in SEQ ID NO:33 effective to permit such binding; and purifying a polypeptide that binds to the extracellular domain of human FIt4 from said host cell or from a growth medium of said host cell, wherein said polypeptide lacks at least the carboxy-terminal portion of SEQ ID NO:33 that is characterized by cysteine motifs of a Balbiani ring 3 protein. 7. A purified and isolated polypeptide according to any one of claims 3-6 wherein said portion of the amino acid sequence in SEQ ID NO:33 includes residues 161 to 211 of SEQ ID NO:33. fLL-\AYLri\rHz7.710iRs .a--nr COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:38 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA I147 o 143 8. A purified and isolated polypeptide according to any one of claims 3-6 wherein said portion of the amino acid sequence in SEQ ID NO:33 includes residues 131 to 211 of SEQ.1D NO;33. 9. A purified and isolated polypeptide according to any one of claims 3-6, s wherein said portion of the amino acid sequence in SEQ ID NO:33 includes residues 113 Sto 213 of SEQ ID NO:33. Cl 10. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 includes residues 113 Sto 227 of SEQ ID NO:33. 0 to 11. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 includes amino acids 103 to 217 of SEQ ID NO:33. 12. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 includes amino acids is 103 to 225 of SEQ ID NO:33. 13. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 includes amino acids 32 to 211 of SEQ UD NO:33. 14. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 includes amino acids 32 to 227 of SEQ ID NO:33. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 is a continuous portion having as its amino terminal residue an amino acid between residues 30 and 162 of SEQ ID NO:33 and having as its carboxy terminal residue an amino acid between residues 210 and 228 of SEQ ID NO:33. 16. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 is a continuous portion having as its amino terminal residue an amino acid between residues 102 and 132 of SEQ ID NO:33 and having as its carboxy terminal residue an amino acid between residues 210 and 228 of SEQ ID NO:33. 17. A purified and isolated polypeptide according to any one of claims 3-6, wherein said portion of the amino acid sequence in SEQ ID NO:33 is a continuous portion having, as its amino terminal residue, residue 103 of SEQ ID NO:33, and having, COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:38 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 01148 o 144 P as its carboxy terminal residue an amino acid between residues 216 and 228 of SEQ ID NO:33. 18. A purified and isolated polypeptide that binds to the extracellular domain of Flt4 receptor tyrosine kinase (Flt4), wherein the polypeptide comprises a portion of SEQ SID NO:33 effective to permit such binding, and wherein the polypeptide has an apparent IC molecular weight of approximately 23 kD as assessed by SDS-PAGE under reducing C, conditions. 0 19. A purified and isolated polypeptide according to any one of claims 3-18, wherein the polypeptide has an amino acid sequence consisting of a portion of the amino 0 10 acid sequence in SEQ ID NO:33. A purified and isolated polypeptide comprising a human polypeptide that 3 binds to the extracellular domain of Flt4 receptor tyrosine kinase and has an apparent molecular weight of approximately 23 kD as assessed by SDS-PAGE under reducing conditions, wherein amino terminal amino acids 2 through 18 of said human polypeptide have an amino acid sequence corresponding to amino acids 2 through 18 set forth in SEQ ID NO:13. 21. A purified and isolated polypeptide that binds to the extracellular domain of Fit4 receptor tyrosine kinase, wherein said polypeptide has an apparent molecular weight of approximately 23 kD as assessed by SDS-PAGE under reducing conditions and is purifyable from conditioned media from a PC-3 prostatic adenocarcinoma cell line, said cell line having ATCC CRL No. 1435, using an affinity purification procedure wherein .the affinity purification matrix comprises a polypeptide comprising the extracellular domain of Flt4 receptor tyrosine kinase. 22. A purified and isolated polypeptide that binds to the extracellular domain of human Flt4 receptor tyrosine kinase (FIt4EC), wherein said polypeptide comprises an amino acid sequence encoded by a DNA which hybridizes to a non-coding strand complementary to nucleotides 352 to 1611 of SEQ ID NO:32 under the following hybridization conditions: hybridization at 42"C in a hybridization solution comprising 50% formamide, 5 X SSC, 20 mM Na*PO4, pH 6.8; and washing in 0.2 X SSC at and wherein said polypeptide lacks any cysteine motifs of a Balbiani ring 3 protein (BR3P). 23. A purified and isolated mammalian polypeptide that binds to the extracellular domain of human Flt4 receptor tyrosine kinase (Flt4EC), rIArAVT rnT n-c-n I COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:38 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 149 o 145 Ssaid polypeptide including a contiguous portion of a mammalian Flt4 ligand c- precursor polypeptide that is sufficient to bind human FIt4EC, 0 wherein said mammalian Flt4 ligand precursor polypeptide comprises an amino acid sequence that is encoded by a DNA which hybridizes to a non-coding strand s complementary to nucleotides 352 to 1611 of SEQ ID NO: 32 under the following hybridization conditions: hybridization at 42C in a hybridization solution comprising Ci 50% formamide, 5 X SSC, 20 mM Na*P0 4 pH.6.8; and washing in 0.2 X SSC at 55 0 C, O C wherein said contiguous portion includes eight cysteine residues that are o conserved in human vascular endothelial growth factor (VEGF), human platelet derived 0 10 growth factors A and B (PDGF-A, PDGF-B), human placenta growth factor (PIGF-1), and human vascular endothelial growth factor B (VEGF-B), and wherein said polypeptide lacks any portion of the mammalian Fit4 ligand precursor polypeptide that has one or more cysteine motifs of a Balbiani ring 3 protein (BR3P). 24. A purified and isolated polypeptide according to any one of claims 2-12, 16- 17, and 22-23 having an apparent molecular weight of about 23 kD as assessed by SDS PAGE under reducing conditions. A purified and isolated polypeptide according to any one of claims 2-15 and 22-23 having an apparent molecular weight of about 32 kD as assessed by SDS PAGE under reducing conditions. 26. A purified and isolated polypeptide according to any one of claims 1-25, said polypeptide having an amino acid sequence consisting of a portion of the amino acid sequence set forth in SEQ ID NO:33. 27; A non-human mammalian polypeptide according to claim 22 or 23. 2s 28, A human polypeptide according to claim 22 or 23. 29. A polypeptide according to any one of claims 1-28, wherein said polypeptide is capable of stimulating tyrosine phosphorylation of Fit4 in a host cell expressing said Flt4. A purified and isolated polypeptide which is capable oL binding the extracellular domain of Kdr receptor tyrosine kinase (VEGFR-2), said polypeptide having an amino acid sequence comprising a portion of SEQ ID NO:33 effective to permit such binding. 31. A polypeptide according to any one of claims 1-30 further comprising a detectable label. r.A*v A TiT mrfnqcea n- COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:39 FAX 61 3 92438333 GRIFFITH HACK -)IPAUSTRALIA laiu 146 S32. A composition comprising a polypeptide according to any one of claims 1-31 ;Z in a pharmaceutically acceptable diluent, adjuvant, excipient, or carrier. 33. A purified protein comprising a first polypeptide linked to a second polypeptide, wherein at least one of said first polypeptide and said second polypeptide is a s polypeptide according to any one of claims 1-31, and wherein said protein is capable of Sbinding to Flt4 receptor tyrosine kinase C, 34. A purified protein according to claim 33, wherein said first polypeptide is 0 covalently linked to said second polypeptide. A purified protein comprising a first polypeptide linked to a second S o polypeptide, wherein each of said first polypeptide and said second polypeptide is a polypeptide according to any one of claims 1-31. 36. A pharmaceutical composition comprising a protein according to any one of claims 33-35 in a pharmaceutically-acccptable diluent, adjuvant, excipient, or carrier. 37. A purified and isolated nucleic acid comprising a nucleotide sequence encoding a polypeptide according to any one of claims 1-31. 38. A nucleic acid according to. claim 37 having the nucleotide sequence of nucleotides 352 to 1608 of SEQ ID NO:32. 39. A nucleic acid according to claim 37 comprising a VEGF-C encoding insert of plasmid pFLT4-L, deposited as ATCC Accession Number 97231. 40. A purified and isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide that binds to human Flt4 receptor tyrosine kinase, said polypeptide having an amino acid sequence comprising a portion of the amino acid sequence shown in SEQ ID NO:33 effective to permit such binding, said nucleic acid lacking a nucleotide sequence that encodes the portion of the amino acid sequence shown in SEQ ID NO:33 that has cysteine motifs of a Balbiani ring 3 protein. 41. A purified and isolated nucleic acid according to claim 40 wherein said polypeptide stimulates tyrosine phosphorylation of human Flt4. 42. A nucleic acid according to claim 40, wherein said polypeptide has an apparent molecular weight of about 23 kD as assessed by SDS polyacrylamide gel electrophoresis under reducing conditions. 43. A nucleic acid according to any one of claims 40-42, wherein said polypeptide comprises an amino-terminal amino acid sequence set forth in SEQ ID NO:13. f:\DAYIJLIBM2Z10osSg rRir.,rr COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:39 FAX 61 3 92438333 GRIFFITH HACK e IPAUSTRALIA 1151 S147 S44. A purified and isolated nucleic acid according to any one of claims 40-42, wherein amino terminal amino acids 2 through 18 of said polypeptide have an amino acid .sequence identical to amino acids 2 through 18 set forth in SEQ ID NO:13. A purified and isolated nucleic acid according to any one of claims 40-44, s wherein said polypeptide comprises approximately 120 amino acids. S46. A purified and isolated nucleic acid according to any one of claims 40-44, C, wherein said polypeptide comprises amino acids 103 to 222 of SEQ ID NO:33. 0 47. A nucleic acid according to claim 40 or 41, wherein said polypeptide has an Sapparent molecular weight of about 32 kDa as assessed by SDS polyacrylamide gel g0o electrophoresis under reducing conditions. 48. A nucleic acid according to claim 40 or 41, wherein said portion of the amino acid sequence shown in SEQ ID NO:33 is a continuous portion that includes eight cysteines of SEQ ID NO:33 that are conserved in human vascular endothelial growth factor (VEGF), human platelet derived growth factor A (PDGF-A), and human platelet derived growth factor B (PDGF-B), and excludes the carboxyl terminal portion of SEQ ID NO:33 that contains cysteine motifs of a Balbiani ring 3 protein. 49. A nucleic acid according to claim 48 wherein said continuous portion has amino acid 103 of SEQ ID NO:33 as its amino terminus. A nucleic acid according to claim 40 or 41, wherein said portion of the amino acid sequence shown in SEQ ID NO:33 is a continuous portion having amino acid 103 of SEQ ID NO:33 as its amino terminal residue, and having as its carboxy terminal residue an amino acid between residues 221 and 228 of SEQ ID NO:33. 51. A purified and isolated nucleic acid encoding a polypeptide that binds the extracellular domain of human Flt4 receptor t&rosine kinase and stimulates tyrosine phosphorylation of Flt4 receptor tyrosine kinase, said polypeptide having an amino acid sequence consisting of a continuous portion of the sequence shown in SEQ ID NO:33, said continuous portion commencing at residue, number 103 of SEQ ID NO:33 and lacking at least carboxy terminal residues of SEQ ID NO:33 beyond residue 227. 52. A purified and isolated nucleic acid comprising a nucleotide -sequence that 3o encodes a polypeptide that binds human Flt4 receptor tyrosine kinase, said polypeptide having an amino acid sequence comprising a continuous portion of the amino acid sequence shown in SEQ ID NO:33 effective to permit such binding, said nucleic acid lacking a nuclootide sequence that encodes the carboxy-terminal portion of the amino acid sequence shown in SEQ ID NO:33 beyond residue 227. rl-\XTAYl JRw i77rnc A-r-nrr COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:39 FAX 61 3 92438333 GRIFFITH HACK -4 IPAUSTRALIA 152 o 148 53. A purified and isolated nucleic acid according to claim 52, wherein said Z, encoded polypeptide stimulates tyrosine phosphorylation of human Fit4_ 54. A nucleic acid according to claim 51 or 52, wherein said nucleic acid lacks a nucleotide sequence that encodes amino acids 32-102 of SEQ ID NO:33. s 55. A purified and isolated nucleic acid according to claim 51 or 52, wherein said n nucleic acid lacks a nucleotide sequence that encodes the amino terminal portion of the C, amino acid sequence shown in SEQ ID NO:33 that precedes residue 103. C 56. A nucleic acid according to any one of claims 37-55, wherein the nucleic acid o further comprises an expression control sequence operatively linked to the encoding sequence. 57. An expression construct comprising the nucleic acid according to any one of claims 37-55 operatively linked to an expression control sequence, said expression construct lacking a nucleotide sequence that encodes the carboxy-terminal portion of the amino acid sequence shown in SEQ ID NO:33 beyond residue 227. 58. A vector comprising a nucleic acid according to any one of claims 37-55, wherein said vector lacks a nucleotide sequence that encodes the portion of the amino acid sequence shown in SEQ ID NO:33 that has cysteine motifs of a Balbiani ring 3 protein. 59. A host cell transformed or transfected with a nucleic acid according to any one of claims 37-56. A host cell transformed or transfected with an expression construct or vector according to claim 57 or 58. 61. A host cell transformed or transfected with a polynucleotide, wherein said polynucleotide includes a strand that hybridizes to a DNA comprising the 2s non-coding strand complementary to SEQ ID NO:32, under the following hybridization conditions: hybridization at 42"C for 20 hours in a solution containing formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS and 0.1 mg/ml denatured salmon sperm DNA; and o 3 washing the filter twice for thirty minutes at room temperature and twice for thirty minutes at 65°C with a wash solution containing 1 x SSC, and 0.1% SDS; and wherein said host cell expresses a polypeptide encoded by said polynucleotide, rI-\fA VY T m7T7ncwB COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:40 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0153 S149 Swherein said polypeptide includes a domain defined by eight cysteine residues that are conserved in human-vascular endothelial growth factor (VEGF), human platelet Sderived growth factor A (PDGF-A), and human platelet derived growth factor B (PDGF-B), wherein said plolypeptide lacks any domain that has one or more cysteine tr motifs of a Balbiani ring 3 protein (BR3P), and wherein said polypeptide binds to the extracellular domain of human Flt4 receptor tyrosine kinase. o 62. A host cell transformed or transfected with a polynucleotide comprising a C 1to nucleotide sequence that encodes a polypeptide that is capable of binding to the extracellular domain of human Flt4 receptor tyrosine kinase, wherein said polynucleotide includes a strand that hybridizes to a DNA comprising the non-coding strand complementary to SEQ ID NO:32, under the following hybridization conditions: hybridization at 42*C for 20 hours in a solution containing formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS and 0.1 mg/ml denatured salmon sperm DNA; and washing the filter twice for thirty minutes at room temperature and twice for thirty minutes at 65°C with a wash solution containing 1 x SSC. and 0.1% SDS; and wherein said host cell expresses and secretes a polypeptide encoded by said polynucleotide, and wherein said polypeptide binds the extracellular domain of human Flt4 receptor tyrosine kinase and has a molecular weight of about 23 kD or about 32 kD as assessed by SDS-PAGE under reducing conditions. 63. A host cell according to claim 61 or 62 that expresses a naturally occurring Flt4 ligand protein encoded by said polynucleotide. 64. A host cell according to claim 61 or 62 that expresses a human Flt4 ligand protein encoded by said polynucleotide. 65. A host cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:33, wherein said host cell expresses a polypeptide encoded by said polynucleotide, said polypeptide including a contiguous portion of SEQ ID NO:33 that is sufficient to bind to the extracellular domain of human Flt4 receptor tyrosine kinase (Flt4EC), COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:40 FAX 61 3 92438333 GRIFFITH HACK -*IPAUSTRALIA U154 o 150 ci g wherein said contiguous portion includes eight cysteine residues that are I, conserved in human vascular endothelial growth factor (VEGF), human platelet derived growth factor A (PDGF-A), and human platelet derived growth factor B (PDGF-B), wherein said polypeptide lacks.any portion of SEQ ID NO:33 that has one or s more cysteine motifs of a Balbiani ring 3 portein (BR3P), and Vt) wherein said polypeptide binds to Flt4EC. C 66. A host cell comprising a polynucleotide that includes the insert of plasmid 1 pFLT4-L, deposited as ATCC accession No. 97231, wherein said host cell expresses and o secretes a polypeptide encoded by said insert, o, to wherein said secreted polypeptide binds to human Flt4 receptor tyrosine kinase and includes a domain defined by eight cysteine residues that are conserved in human vascular endothelial growth factor (VEGF), human platelet derived growth factor A (PDGF-A), and human platelet derived growth factor B (PDGF-B), and wherein said secreted polypeptide lacks any domain that has one or more cysteine motifs of a Balbiani ring 3 protein (BR3P). 67. A host cell according to claim 66, wherein said host cell expresses said polynucleotide and produces a human protein that is capable of binding to the extracellular domain of human Flt4 receptor tyrosine kinase, said protein having a molecular weight of about 23 kD as assessed by SDS-PAGE under reducing conditions. 68, A host cell according to claim 67, wherein said host cell expresses said polynucleotide and produces a human protein that is capable of binding to the extracellular domain of human Flt4 receptor tyrosine kinase, said protein having a molecular weight of about 32 kD assessed by SDS-PAGE under reducing conditions. 69. A host cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:33, wherein said host cell expresses a polypeptide encoded by said polynucleotide, said polypeptide including a contiguous portion of SEQ ID NO:33 that is sufficient to bind to the extracellular domain of human Flt4 receptor tyrosine Idnase (Flt4EC), wherein said contiguous portion includes eight cysteine residues that are conserved in human vascular endothelial growth factor (VEGF), human platelet derived growth factor A (PDGF-A), and human platelet derived growth factor B (PDGF-B), wherein said polypeptide lacks any portion of SEQ ID NO:33 that precedes position 103 and lacks anyportion of SEQ ID NO:33 that has one or more cysteine motifs of a Balbiani ring 3 protein (BR3P), and I:\DAYTJ\ .I1;~'SAR dorm.-rr COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:40 FAX 61 3 92438333 GRIFFITH HACK 4IPAUSTRALIA 1a155 S151 §wherein said polypeptide has a molecular weight of about 23 kD as assessed C, by SDS PAGE under reducing conditions and binds to Flt4EC. A host cell according to any one of claims 61-69, wherein said polynucleotide is an expression vector, said expression vector including an expression control sequence s operatively linked to sequence that encodes said polypeptide. tn 71. A eukaryotic host cell according to any one of claims 61-70 that secretes said Spolypeptide. 72. A method of making a polypeptide that binds to the extracellular domain of SFlt4 receptor tyrosine kinase, said method comprising the steps of: growing a host cell transformed or transfected with a nucleic acid according to any one of claims 37-56 under conditions in which the cell expresses a polypeptide encoded by the nucleic acid; and purifying the polypeptide from said host cell or from a growth medium of said host cell, wherein the polypeptide binds to the extracellular domain of Flt4 receptor tyrosine kinase. 73. A method for producing a polypeptide that is capable of binding the extracellular domain of human Flt4 receptor tyrosine kinase and stimulating tyrosine phosphorylation of Flt4 receptor tyrosine kinase, comprising the steps of: growing a host cell according to any one of claims 59-71 under conditions which permit expression in said host cell of a polypeptide encoded by said polynucleotide; and isolating said polypeptide from the host cell or the growth medium of the host cell, wherein said polypeptide binds to the extracellular domain of human Flt4 receptor tyrosine kinase and stimulates phosphorylation of Flt4 receptor tyrosine kinase. 74. A method according to claim 72 or 73, wherein said host cell is a mammalian host cell that secretes said polypeptide and wherein said isolating step comprises isolating said polypeptide from said growth medium. A method for producing a polypeptide that binds to the extracellular domain (EC) of human Flt4 receptor tyrosine kinase (Flt4), comprising steps of: growing a host cell comprising a polynucleotide that comprises a nucleotide sequence that encodes the amino acid sequence set forth in SEQ ID NO:33, under conditions in which the host cell expresses and secretes a polypeptide encoded by the polynucleotide; and COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:41 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA Q156 O 152 Sisolating a polypeptide that binds Flt4 EC from the growth medium of the host c- cell, said polypeptide having a molecular weight of approximately 23 kD as assessed by SSDS-PAGE under reducing conditions and having an amino acid sequence comprising a portion of SEQ ID NO:33 effective to bind Flt4 EC. 76. A method according to claim 75 wherein said polynucleotide comprises an t expression vector that comprises a nucleotide sequence that encodes the amino acid set forth in SEQ ID NO:33. C 77. A method according to claim 75 wherein said host cell comprises a PC-3 o prostatic adenocarcinoma cell (ATCC CRL1435). i to0 78. A method according to claim 75 wherein said polynucleotide comprises the insert of plasmid pFLT4-L, deposited as ATCC Accession No. 97231. 79. A purified polypeptide that binds to the extracellular domain of-Flt4 receptor tyrosine kinase, said polypeptide produced by a method according to any one of claims 72-78. Is 80. A polypeptide according to any one of claims 1-31 or 79, wherein said polypeptide further includes a peptide tag to facilitate purification of the polypeptide. 81. A polypeptide according to claim 80, wherein said tag comprises a polyhistidine amino acid sequence. 82. A polypeptide according to claim 22 or 23 that is a marine polypeptide. 83. A purified polypeptide that binds Flt4 receptor tyrosine kinase, said polypeptide comprising the amino acid sequence set forth in SEQ ID NO:41 or a portion thereof effective to permit such binding. 84. A purified and isolated murine Flt4 ligand precursor polypeptide comprising the amino acid sequence set forth in SEQ ID NO:41. 85. A composition comprising a polypeptide according to any one of claims 79- 84, and further comprising a pharmaceutically acceptable diluent, adjuvant, excipient, or carrier 86. A purified and isolated nucleic acid comprising a nucleotide sequence encoding the polypeptide according to claim 82, 83 or 84. 87. A purified polypeptide capable of binding to the extracellular domain of human Flt4 receptor tyrosine kinase, said polypeptide produced by a method comprising the steps of: rI\nAVI IR\r m77inccB, COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:41 FAX 61 3 92438333 GRIFFITH iACK IPAUSTRALIA 1157 o 153 expressing a nucleic acid in a host cell, said nucleic acid comprising a c- nucleotide sequence encoding the amino acid sequence in SEQ ID NO:41 or a portion thereof effective to permit such binding; and purifying a polypeptide that binds to the extracellular domain of human Flt4 receptor tyrosine kinase from said host cell or from a growth medium of said host cell, wherein said polypeptide lacks at least the carboxy-terminal portion of SEQ ID NO:41 that is characterized by cysteine motifs of a Balbiani ring 3 protein. c 88. A composition comprising polyclonal antibodies raised against a polypeptide 0 according to any one of claims 1-31 and 79-84. p t0 89. A purified antibody that binds to a peptide consisting of the amino acid sequence set forth in SEQ ID NO:39. An antibody according to claim 89 which is a monoclonal antibody. 91. A polyclonal antiserum produced by a process comprising the steps of: immunizing a mammal with a composition comprising a polypeptide according to any is one of claims 1-31 and 79-84; and obtaining antiserum from said mammal after said immunizing step, said antiserum containing antibodies that bind to said polypeptide. 92. Polyclonal antibodies purified from an antiserum according to claim 91, said polyclonal antibodies including antibodies that bind to said polypeptide. 93. A method for detecting endothelial cells in a biological tissue sample comprising the steps of: exposing a biological tissue sample comprising endothelial cells to a polypeptide according to any one of claims 1-31 and 79-84, under conditions wherein said polypeptide binds to endothelial cells; and detecting said polypeptide bound to endothelial cells in said biological tissue, thereby detecting said endothelial cells. 94. The method according to claim 93, further comprising the step of washing_ said biological tissue, said washing step being performed after said exposing step and before said detecting step. 95. A method of modulating the growth of mammalian endothelial cells, comprising the step of: contacting mammalian endothelial cells with a polypeptide according to any one of claims 1-31 and 79-84, in an amount effective to modulate the growth of the mammalian endothelial cells. COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:41 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA ~158 o154 S96. Use of a polypeptide according to any one of claims 1-31 and 79-84 in the preparation of a medicament for modulating the growth of mammalian endothelial cells. 97. A method of modulating the activity of human Flt4 receptor tyrosine kinase comprising administering to a person in need of modulation of Flt4 receptor tyrosine Skinase activity a composition according to claim 32 or V) 98. A method of modulating the activity of human Flt4 receptor tyrosine kinase g, comprising contacting cells that express human Flt4 receptor tyrosine kinase with a C' polypeptide according to any one of claims 1-31 and 79-84. S99. Use of a polypeptide according to any one of claims 1-31 and 79-84 in the S 10 preparation of a medicament for modulating the activity of Flt4 receptor tyrosine kinase. 100. A method of modulating the growth of lymphatic endothelia, comprising steps of: identifying a patient in need of modulation of the growth of lymphatic endothelia; and administering to the patient a composition comprising a polypeptide in an amount effective to modulate the growth of lymphatic endothelial cells, wherein said polypeptide is a polypeptide according to any one of claims 1-31 and 79-84. 101. A method according to claim 100, wherein the identifying step comprises selecting a patient having lymphatic vessel loss or damage due to surgical intervention, wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia. 102. A method according to claim 101, wherein the polypeptide is administered in 2 an amount effective to stimulate regrowth of lymphatic vessels. 103. A method according to claim 100, wherein the identifying step comprises identifying a patient having or at risk for developing edema, wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia. 104. A method according to claim 100, wherein the identifying step comprises identifying a patient having lymphatic vessel aplasia, iI-\nAVr Ilr IDnlrhoo COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:42 FAX 61 3 92438333 GRIFFITH HACK 4IPAUSTRALIA Q159 o 155 Swherein the polypeptide binds and stimulates phosphorylation of Flt4 Sexpressed in endothelial cells, and Swherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia. 105. A method according to claim 100, wherein the identifying step comprises Sselecting an organ transplant patient, Ci wherein the polypeptide binds and stimulates phosphorylation of Flt4 C' expressed in endothelial cells, and o wherein the polypeptide is administered in an amount effective to stimulate C oi growth of lymphatic endothelia. 106. A method according to claim 100, wherein the identifying step comprises identifying a patient having reduced lymphatic vessel function due to lymphatic vessel blockage, wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia. 107. A method according to claim 100, wherein the identifying step comprises identifying a patient having lymphatic vessel occlusion, wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia, 108. A method according to claim 100, wherein the identifying step comprises identifying a patient having elephantiasis, wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia. 109. A method according to claim 100, wherein the identifying step comprises identifying a patient having a lymphangioma, wherein the polypeptide binds and inhibits phosphorylation of Fit4 expressed in endothelial cells. COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:42 FAX 61 3 92438333 GRIFFITH HACK 4 IAUSTRALIA [aloo 8 156 S110. A method according to claim 100, wherein the administering step comprises administering a composition that comprises the polypeptide and a diluent, adjuvant, o excipient or carrier. 111. The use of a polypeptide according to any one of claims 1-31 and 79-84 in the manufacture of a medicament for modulating the growth of lymphatic endothelia. ^t 112. The use of a polypeptide according to any one of claims 1-31 and 79-84 in the manufacture of a medicament for treatment of.a disease or condition selected from the 1 group consisting of lymphatic vessel loss or damage due to surgical intervention, edema, o lymphatic vessel aplasia, lymphatic vessel occlusion, and elephantiasis. 0 io 113. A method of modulating the activity of Flt4 receptor tyrosine kinase (Flt4) in Flt4-expressing cells, comprising steps of: providing a nucleic acid according to any one of claims 37-56; transforming or transfecting a cell with the nucleic acid such that the cell expresses and secretes a polypeptide encoded by said nucleic acid, wherein said is secreted polypeptide binds the extracellular domain of human Flt4 and has a molecular weight of about 23 kD as assessed by SDS-PAGE under reducing conditions; and 'contacting Flt4-expressing cells with the secreted 23 kD polypeptide. 114. Use of a nucleic acid according to any one of claims 37-56 in the manufacture of a medicament for the modulation of the growth of lymphatic endothelia. 115. A purified nucleic acid comprising a vertebrate VEGF-C promoter nucleotide sequence. 116. A purified and isolated nucleic acid comprising a portion of SEQ ID NO:54, wherein said portion is capable of promoting expression of a protein encoding gene operatively linked thereto, 117. A purified and isolated mammalian nucleic acid which hybridizes to a nucleic acid complementary to SEQ ID NO:54 under the following hybridization conditions: hybridization at 42 0 C in a hybridization solution comprising 50% formanide, 5 X SSC, mM Na@PO 4 pH 6.8; and washing in 0.2 x SSC at wherein said nucleic acid is capable of promoting expression vf a protein encoding gene operatively linked thereto. 118. A polypeptide according to any one of claims 1 to 30, substantially as hereinbefore described with reference to any one of the examples. rf r.lfnr l 1,t l m l"r temn j COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:42 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0 161 o 157 S119. A method of producing a polypeptide according to any one of claims 1 to ;Z said method substantially as hereinbefore described with reference to any one of the -examples. 120. A polypeptide produced according to the method of claim 119. 121. A pharmaceutical composition comprising a polypeptide according to clahnim th 118 or 120 together with a pharmaceutically acceptable diluent, adjuvant, excipient or In Cl carrier. 0 C- 122. A purified and. isolated nucleic acid sequence according to any one of claims o 37 to 56, said nucleic acid sequence substantially as hereinbefore described with reference 0 10 to any one of the examples. 123. An expression construct comprising a nucleic acid sequence according to claim 122. 124. A host cell transformed or transfected with a nucleic acid sequence according to claim 122 or an expression construct according to claim 123- is 125- A method for detecting endothelial cells in a biological tissue sample comprising the steps of: exposing a biological tissue sample comprising endothelial cells to a polypeptide according to claim 118 or 120, under conditions wherein said polypeptide binds to endothelial cells; and detecting said polypeptide bound to endothelial cells in said biological tissue, thereby detecting said endothelial cells. 126. A polypeptide according to any one of claimrs 1 to 31, 79 to 84, 118 and 120 when used for detecting endothelial cells in a biological tissue sample. 127. A method of modulating the growth of mammalian endothelial cells, comprising the step of: contacting mammalian endothelial cells with a polypeptide according to claim 118 or 120, in an amount effective to modulate the growth of the mammalian endothelial cells. 128. A polypcptide according to any one of claims 1 to 31, 79 to 84,. 118 and 120 when used for modulating the growth of mammalian cells. 129. Use of a polypeptide according to claim 118 or 120 in the preparation of a medicament for modulating the growth of mammalian endothelial cells. SF.\r fTv*T f Imrfl cn s COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:43 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 01162 o 158 S130. A method of modulating the activity of human Flt4 receptor tyrosine kinase ;Z comprising contacting cells that express human Flt4 receptor tyrosine kinase with a polypeptide according to claim 118 to 120. 131. A polypeptide according to any one of claims 1 to 31, 79 to 84, 118 and 120 when used for modulating the activity of human Flt4 receptor tyrosine kinase. S132. Use of a polypeptide according to claim 118 or 120 in the preparation of a Ci medicament for modulating the activity of Ft4 receptor tyrosine kinase. C 133. A method of modulating the growth of lymphatic endothelia, comprising steps Sof: S to identifying a patient in need of modulation of the growth of lymphatic endothelia; and administering to the patient a composition comprising a polypeptide in an amount effective to modulate the growth of lymphatic endothelial cells, wherein said polypeptide is a polypeptide according to claim 118 or 120. is 134 A polypeptide according to any one of claims 1 to 31, 79 to 84, 118 and 120 when used for modulating the growth of lymphatic endothelia, 135. Use of a polypeptide according to claim 118 or 120 in the preparation of a medicament for modulating the growth of lymphatic endothelia. 136. A polypeptide according to any one of claims 1 to 31, 79 to 84, 118 and 120 when used for treatment of a disease or condition selected from the group consisting of lymphatic vessel loss or damage due to surgical intervention, edema, lymphatic vessel aplasia, lymphatic vessel occlusion, and elephantiasis. 137. Use of a polypeptide according to claim 118 or 120 in the manufacture of a medicament for treatment of a disease or condition selected from the group consisting of lymphatic vessel loss or damage due to surgical intervention, edema, lymphatic vessel aplasia, lymphatic vessel occlusion, and elephantiasis. 138. A method of modulating the activity of Flt4 receptor tyrosine kinase (Flt4) in Flt4-expressing cells, comprising steps of: providing a nucleic acid according to claim 122; transforming or transfecting a cell with the nucleic acid such that the cell expresses and secretes a polypeptide encoded by said nucleic acid, wherein said secreted polypcptide binds the extracellular domain of human Flt4 and has a molecular weight of about 23 kD as assessed by SDS-PAGE under reducing conditions; and contacting Flt4-expressing cells with the secreted 23 kD polypeptide. rInAY V TR\r I177n5RR Adr-mrr COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:43 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 163 o 159 139. A nucleic acid according to any one of claims 37 to 56 and 122, when used Sfor modulating the activity of Flt4 receptor tyrosine kinase (Fit4) in FIt4-expressing cells. 140. Use of a nucleic acid according to claim 122 in the manufacture of a medicament for the modulation of the growth of lymphatic endothelia. 141. A purified and isolated polypeptide according to any one of claims 11, 12, n 17 and 18, wherein said polypeptide is capable of binding the extracellular domain of Kdr receptor tyrosine kinase (VEGFR-2). C 142. A purified and isolated nucleic acid sequence comprising a nucleotide Ssequence that encodes a polypeptide according to claim 141. 143. A host cell transformed or transfected with a nucleic acid sequence according to claim 142- 144. A pharmaceutical composition comprising a polypeptide according to claim. 141 together with a pharmnnaceutically-acceptable diluent, adjuvant, excipient, or carrier. 145. Use of a polypeptide according to claim 141 in the manufacture of a medicament for modulating the growth of mammalian endothelial cells. 146. A method of modulating the growth of mammalian endothelial cells comprising the step of: contacting mammalian endothelial cells with a polypeptide according to claim 141, in an amount effective to modulate the growth of the mammalian endothelial cells. 147. A polypeptide according to claim 141 when used for modulating the growth of mammalian endothelial cells 148. A purified protein according to claim 33, wherein said second polypeptide has an amino acid sequence corresponding to amino acid residues 228 to 419 of SEQ ID NO:33. 149. A purified protein according to claim 33 or 148, wherein said first polypeptide is a polypeptide according to claim 14 or 150. A purified protein according to any one of claims 33, 1.48 or 149, wherein_ said protein is a heterodimer. 151. A protein according to any one of claims 33 and 148 to 150rwherein said protein is a tetramer. 152. A pharmaceutical composition comprising a protein according to any one of claims 33 and 148 or 151 together with a pharmaceutically-acceptable diluent, adjuvant, excipient, or carrier. In-tAvr mn Isv177incten A.- 4 COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:43 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA Q1164 S160 153. Use of a protein according to any one of claims 33 and 148 or 151 in the manufacture of a medicament for modulating the growth of mammalian endothelial cells. 154. A method of modulating the growth of mammalian endothelial cells 0 comprising the step of: s contacting mammalian endothelial cells with a protein according to any one of claims 33 and 148 or 151, in an amount effective to modulate the growth of the mammalian endothelial cells. O 155. A protein according to any one of claims 33 and 148 or 151 when used for modulating the growth of mammalian endothelial cells. O O [LOAYLB\UIBZZ]055S8.doc.rT COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:43 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA la185 -161- o The claims defining the invention are as follows: c S1. An antibody that specifically binds to a o polypeptide that binds Flt4 receptor tyrosine kinase (Flt4), wherein the polypeptide has an amino acid sequence consisting of a portion of SEQ ID NO: 33 effective to l permit such binding, and wherein the antibody inhibits the Sbinding between the polypeptide and Flt4. 2. An antibody that specifically binds to a polypeptide that binds VEGFR-2, wherein the polypeptide has an amino acid sequence consisting of a portion of SEQ ID NO: 33 effective to permit such binding, and wherein the antibody inhibits binding between the polypeptide and VEGFR-2. 3. An antibody according to claim 1 or 2, wherein the polypeptide has an apparent molecular weight of approximately 23 kD as assessed by SDS-PAGE under reducing conditions. 4. An antibody that specifically binds with a polypeptide ligand of Flt4 receptor tyrosine kinase (Flt4), wherein the polypeptide ligand comprises a polypeptide encoded by the cDNA insert of plasmid pFlt4-L, having ATCC Accession No. 97231; wherein the polypeptide has a molecular weight of about 23 kD as assessed by SDS- PAGE under reducing conditions, and wherein the antibody inhibits the binding between the polypeptide and Flt4. An antibody that specifically binds with a polypeptide ligand of VEGFR-2, wherein the polypeptide ligand comprises a polypeptide encoded by the cDNA insert of plasmid pFlt4-L, having ATCC Accession No, 97231; wherein the polypeptide has an apparent molecular weight N:\Melbournetsiractarl\62OOOA S57AU\SpcisPW62257.AU Speifiation 2007,6-.d COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:44 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0166 162 o of approximately 23 kD as assessed by SDS-PAGE under reducing conditions, and wherein the antibody inhibits Sbinding between the polypeptide and VEGFR-2. 6. An antibody according to claim 1 or 4, wherein the polypeptide binds VEGFR-2, and wherein the- antibody inhibits binding between the polypeptide and VEGFR-2. 7. An antibody according to any one of claims 1-6, wherein the polypeptide binds and stimulates phosphorylation of Plt4, and wherein the antibody inhibits 0C the polypeptide from stimulating phosphorylation of Plt4. 8. An antibody according to any one of claims 1-7, wherein the polypeptide binds and stimulates phosphorylation of VEGFR-2, and wherein the antibody inhibits the polypeptide from stimulating phosphorylation of VEGFR-2. 9. An antibody according to any one of claims 1-8, wherein amino-terminal amino acids 2 through 18 of said polypeptide correspond to amino acids 2 through 18 set forth of SEQ ID NO: 13. A molecule that comprises an antigen- binding fragment of an antibody according to any one of claims 1-9, wherein the molecule specifically binds the polypeptide. 11. An antibody substance selected from the group consisting of: an antibody that specifically binds a VEGF-C polypeptide that consists of amino acids 103 to 227 of SEQ ID NO: 33, and N eliboNursnCsclmsPaml6200-629999\ P2257 AUSlICiAP62257 AU Spccificauian 200f--l.do COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:44 FAX 61 3 92438333 GRIFFITH HACK 4 IPAUSTRALIA 0167 163 0 o a polypeptide comprising a fragment of ci that specifically binds to said VEGF-C polypeptide; ;Z wherein the antibody substance inhibits the VEGF-C polypeptide from stimulating phosphorylation of VEGFR-2; and wherein the antibody substance inhibits the VEGF-C polypeptide from stimulating phosphorylation of f VEGFR-3. ci S12- A composition comprising an antibody, ci antibody substance, or molecule according to any one of claims 1-11 in a pharmaceutically acceptable carrier. ci 13. A use of the antibody, antibody substance, or molecule according to any one of claims 1-11 in the manufacture of a medicament for inhibiting ligand binding to Flt4, wherein the ligand comprises the amino acid sequence set forth as SEQ ID NO: 33 or a fragment thereof effective to bind Flt4, and wherein the antibody is present in the medicament in an amount effective to inhibit Flt4 phosphorylation- 14. A use of an antibody, antibody substance, or molecule according to any one of claims 1-11 in the manufacture of a medicament for inhibiting endothelial cell proliferation, wherein said antibody, antibody substance, or molecule is present in the medicament in an amount effective to inhibit activation of Plt4 by ligand in a patient, thereby inhibiting endothelial cell proliferation. A use of an antibody, antibody substance, or molecule according to any one of claims 1-11 in the manufacture of a medicament for treatment of a disease or condition selected from the group consisting of lymphatic obstruction, lymphatic vessel edema, lymphatic vessel N:M~omt~\iintf~)^i)W~~y AUi3vcaVPi317AU Sptcifimbn ax7-I-1dilt COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:44 FAX 61 3 92438333 GRIFFITH HACK -4IPAUSTRALIA Z168 -164 o aplasia, lymphatic vessel occlusion, Milroy's Disease and ci elephantiasis. 16. A use of an antibody, antibody substance, or molecule according to any one of claims 1-11 in the manufacture of a medicament for controlling cancer metastases. In tIfl 17. A method of inhibiting ligand binding to ci oFlt 4, wherein the ligand comprises the amino acid ci sequence set forth as SEQ ID NO: 33 or a fragment thereof to bind Flt4, by administering an antibody, antibody Clq substance or molecule according to any one of claims 1-11 in an amount effective to inhibit activation of Flt4 by ligand. 18. A method of inhibiting endothelial cell proliferation, by inhibiting activation of Flt4 by ligand by inhibiting ligand binding to Flt4 according to the method of claim 17. 19. A method of treating a disease or condition selected from the group consisting of lymphatic obstruction, lymphatic vessel edema, lymphatic vessel aplasia, lymphatic vessel occlusion, Milroy's Disease and elephantiasis, comprising administering to a patient in need thereof an effective amount of an antibody, antibody substance or molecule according to any one of claims 1-11. 20. A method of controlling cancer metastases comprising administering to a patient in need thereof an antibody, antibody substance or molecule according to any one of claims 1 to 11. 21. An antibody according to claim 1, a molecule according to claim 10, an antibody substance according to claim 11, a composition according to claim COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01 01/06 2007 17:45 FAX 61 3 92438333 GRIFFITH HACK IPAUSTRALIA 0169e 165 12, a use according to any one of claims 13 to 16 or a method according to any one of claims 17 to substantially as herein before described, with reference to the examples, and, or figures. N %M botnncCz swC=c\1icutW2O-Z3l6fl57 A~fSpccTW7fl5.AU Specikcauin O7-to1 de COMS ID No: SBMI-07622503 Received by IP Australia: Time 17:53 Date 2007-06-01